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The volume-regulated anion channel (VRAC) is a crucial part of the regulatory vol-
ume decrease in vertebrate cells with various other proposed roles as, for example,
in apoptosis, differentiation, and auto/paracrine signaling. Their modular architec-
ture with differing biophysics and potential functions, as well as the lack of specific
inhibitors, led to VRAC’s activation mechanism being elusive until today. Further-
more, current methods to study VRACs fail to account for the diversity of these
channels.
In this thesis, the movement of fluorophores at the C-termini of the VRAC form-
ing protein family LRRC8 upon activation was proven by Fo¨rster-resonance energy
transfer (FRET) microscopy. Patch-clamp fluorometry validated that FRET vari-
ations reflect channel gating. FRET microscopy of fluorescently labeled LRRC8
proteins was, therefore, exploited as a new optical sensor for VRAC activity.
The optical sensor revealed isotonic activation of VRAC by the diacylglycerol
analog phorbol-12-myristate-13-acetate (PMA), an effect abolished by the whole-
cell configuration. VRACs trapped on endomembranes by the reverse dimerization
system cannot be activated by decreased intracellular ionic strength. Furthermore,
are VRACs rendered active under isotonic conditions by inhibition of the diacyl-
glycerol kinase (DAGK) by dioctanoylglycol. Activation of VRAC by hypotonicity
was impaired by the PKD inhibitor CRT 0066101.
Concludingly, ionic strength is not the critical regulator of VRAC activity in liv-
ing cells. Instead, they are activated by diacylglycerol mediated PKD recruitment.
Electrophysiological approaches might obscure the effects of drugs and protein ma-
nipulations, as seen for PMA. The here established FRET-based optical sensor opens





Der Volumen regulierte Anionenkanal (VRAC) spielt eine zentrale Rolle im Prozess
der regulierten Volumenverringerung von Wirbeltierzellen nebst anderen vermuteten
Rollen in Prozessen wie der Apoptose, Differenzierung und der auto/parakrinen
Sekretion. Sowohl der modulare Aufbau, der zu unterschiedlichen biophysikalischen
Eigenschaften und vermutlich Funktionen fu¨hrt, als auch das Fehlen spezifischer
Inhibitoren hat dazu gefu¨hrt, dass der Aktivierungsmechanismus von VRAC bis
heute ungekla¨rt ist.
In dieser Arbeit beweise ich mithilfe von Fo¨rster Resonanz Energie Transfer
(FRET) Mikroskopie, dass sich fluoreszente Proteine, die an den C-Terminus der
VRAC formenden LRRC8 Proteinfamilie fusioniert sind, bei der Aktivierung des
Kanals bewegen. Mithilfe von patch-clamp Fluorometrie konnte ich zeigen, dass
FRET A¨nderungen tatsa¨chlich das O¨ffnen und Schließen des Kanals wiederspiegeln.
Ich habe daher FRET-Mikroskopie von fluoreszierenden LRRC8 Fusionsproteinen
als optisches Werkzeug genutzt, um die Aktivierung von VRACs zu detektieren.
Mit diesem Werkzeug konnte ich die Aktivierung von VRAC unter isotonen Bedin-
gungen durch das Diacylglycerol Analogon Phorbol-12-myristat-13-acetat (PMA)
nachweisen und gleichzeitig zeigen das die whole-cell Konfiguration diesen Effekt
unterdru¨ckt. VRACs die in Endomembranen lokalisiert sind ko¨nnen nicht durch
intrazellula¨r reduzierte Ionensta¨rke aktiviert werden. Desweitern, bleiben bereits
aktivierte Kana¨le auch unter isotonen Bedingungen aktiv, wenn das Enzym Dia-
cylglycerolkinase (DAGK) durch Dioctanoylglycol (DOG) inhibiert wird. Die Ak-
tivierung von VRAC durch Hypotonizita¨t konnte auch durch den PKD Inhibitor
CRT 0066101 eingeschra¨nkt werden.
Ich folgere daraus, dass die intrazellula¨re Ionensta¨rke nicht maßgeblich an der Ak-
tivierung von VRAC beteiligt ist. Stattdessen werden die Kana¨le durch Diacylglyc-
erol rekrutierte PKDs aktiviert. Wie am Beispiel von PMA gezeigt werden konnte,
ko¨nnen elektrophysiologische Methoden die Effekte von applizierten Chemikalien
oder Manipulationen auf Proteinebene verschleiern. Das neue, hier etablierte optis-
che Werkzeug ero¨ffnet neue Mo¨glichkeiten um VRAC auf eine nicht-invasive, Un-




1.1 Cellular ion homeostasis- A story of swelling and
shrinking
Cells, as the smallest unit of life, are a confined space of defined composition striving
at all times to maintain their intrinsic properties in a defined range. A plethora of
mechanisms underlie the homeostasis keeping cells and their properties in balance
with their environment. Among those properties of cells is their volume, dictated
by the concentration interplay of ions and osmolytes intra- and extracellularly. To
maintain their volume, cells need mechanisms to counteract imbalances of osmolytes
leading to either swelling or shrinkage. This thesis deals with a critical player of the
process of regulatory volume decrease (RVD) following swelling of cells: the volume-
regulated anion channel (VRAC). To understand VRAC’s role in RVD, the principles
of ion and volume homeostasis shall be introduced in the first section of this thesis,
before I focus on VRACs themselves and the struggle of their investigation.
Metazoan cells are encapsulated by a semipermeable membrane, which is highly
permeable to water compared to the main inorganic osmolytes of a cell being K+,
Na+ and Cl−. Water will, therefore, flow along its osmotic gradient created by
concentration differences of intra- and extracellular osmolytes, in or out of the cell.
Whereas the intrinsic permeability of cellular membranes for these inorganic os-
molytes is small, they can pass the membrane through ion transporting proteins.
There are three groups of them: pumps, transporters, and channels. While pumps
and transporters actively transport ions even against their electrochemical gradient,
by either using metabolic energy or the gradient of a different osmolyte, channels
form pores in the plasma membrane. Osmolytes can diffuse through those pores as
soon as the channel is in an open conformation. Apart from the named inorganic
osmolytes that can pass the membrane, cells contain a significant amount of non-
permeable charged proteins and other osmolytes as sugars, DNA, etc. This high
content of intracellular non-permeable osmolytes would lead, together with extra-
cellular osmolytes entering the cell down their concentration gradient to reach zero
chemical potential, to an influx of water to “dilute” the cytosol to extracellular lev-
els. Cells cannot achieve these levels due to the named non-permeable species. The
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steady-state equilibrium of diffusible and non-diffusible species is described by the
Gibbs-Donnan equilibrium. At this equilibrium, the osmolyte content of cells would
be higher than that of the extracellular space (caused by the impermeable colloids),
creating an osmotic pressure. This pressure is defined as the force needed to stop
water from entering a compartment with a higher concentration of osmolytes. Plant,
bacterial, and yeast cells have a rigid cell wall that can withstand exactly this osmotic
pressure, protecting them from harmful water influx and bursting. Animal cells lack
this protective cell wall and would, therefore, swell until membrane rupture with-
out further cellular intervention [1]. To counteract the osmotic pressure caused by
intracellular non-permeable species, the Na+-K+-ATPase extrudes under consump-
tion of energy three molecules of Na+ for the intake of two molecules of K+. So,
cells sacrifice metabolic energy to render Na+ an extracellular non-permeable species
counterbalancing the intracellular organic ones. This, as “pump and leak” denoted
concept, stabilizes cell volume in the presence of the non-permeable osmolyte con-
tent [2, 3]. Apart from thereby diminished Na+ concentrations, intracellular levels
of Cl− are reduced as well compared to the extracellular space, which again creates
“osmotic space” for the cellular organic osmolytes [1].
As a consequence of an established osmotically neutral equilibrium, metazoan cells
accumulate negative charge intracellularly, creating a potential difference between
the cytosol and the extracellular space (the membrane potential). Eukaryotic cells
have resting membrane potentials between -40 to -95 mV. Ions are thereby affected
by two forces: their chemical potential, depending on the intra- and extracellular
concentration of that ion and their electrical potential depending on the repulsion of
equally and attraction of oppositely charged species. The net force that will either
lead to ions flowing out or into a cell can be estimated with the Nernst equation,
calculating the Nernst potential. At this equilibrium potential, the respective ion
would have no net exchange anymore. Exemplary concentrations of K+, Na+, and
Cl− measured in HeLa cells [4] were (in mM) 170, 32 and 43 with extracellular
concentrations of the same ions of 5.5, 152, and 129 mM. Thus, the chemical gradient
would lead to an influx of Na+, and Cl− and efflux of K+. Due to the electrical
potential, though, an opening of respective channels would lead to the efflux of Cl−.
As well would K+ leave the cell, while Na+ would enter it. Apart from K+, Na+
and Cl−, cells contain significant amounts of uncharged organic osmolytes as well
that are used for volume regulation, such as taurine, myo-inositol, betaine, sorbitol,
and myo-inositol [5]. Since they do not carry any charge, their direction of flow
is dictated only by their concentration gradient, being usually highly concentrated
intracellularly compared to the extracellular fluid.
The described osmolyte balance renders animal cells capable of reacting to volume
and osmolyte perturbations in several ways. The osmolarity of the extracellular fluid
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is tightly regulated and varies only in a narrow window (reviewed in [6]). Extracel-
lular changes of osmolarity are, therefore, usually limited to cells of the intestines
and kidney. Intestinal epithelial, blood and kidney medullar cells can be exposed to
solutions with highly varying osmolarities. These cells need mechanisms to counter-
act swelling induced by extracellular hypotonicity by RVD and shrinkage induced
by extracellular hypertonicity by regulatory-volume increase (RVI). Cells embedded
in a tightly regulated tissue rather experience osmotic perturbations by intracellular
changes created by transepithelial transport, and catabolic or anabolic processing
of macromolecules (reviewed in [7]). An increase in intracellular osmolarity by, e.g.,
break-down of polysaccharides leads to water influx and cell swelling. Returning to
basal volume is accomplished by RVD through the efflux of K+, Cl−, and organic
osmolytes with obliged water following the osmolytes for both extracellularly hypo-
tonic and intracellularly hypertonic induced swelling. To increase the permeability
of these osmolytes, a plethora of different channels and transporters is embedded in
the plasma membrane that can be opened to allow their conduction [8]. A hypoth-
esis for an elegant sorting mechanism for which species (ions or organic osmolytes)
are allowed to flow out of the cell to restore the volume is linked to the ionic strength
of the cytoplasm (discussed in [9]). The ionic strength of a solution is the sum of the
solved ions in it and is kept stable by cells to retain, e.g., the functionality of proteins,
and the membrane potential. Swelling induced by hypotonicity of the surrounding
medium leads to water influx into the cells, diluting the cytoplasm and lowering
the ionic strength of it. An opening of ion channels would, therefore, be counter-
productive in two different ways: firstly the driving force for the respective ion to
leave the cell would be lowered already by the decreased concentration after swelling,
and their efflux would even further decrease the already lowered ionic strength. To
achieve RVD without further loss of ions, the efflux of organic osmolytes would be
more advantageous for the overall cell fitness. Vice versa would it be beneficial to
activate channels and transporters for inorganic osmolytes if cells swell isosmotically
(for example, by increased uptake of salts). This was shown for a swelling activated
KCl-cotransporter in dog red blood cells, which showed an increased volume sensi-
tivity with increased ionic strength [10]. Similarly, in trout red blood cells RVD was
either accomplished by the efflux of amino acids when intracellular ionic strength
was low or by KCl efflux if the ionic strength was high [11, 12].
There are several different channels and transporters known to be involved in
RVD. Many of them are expressed simultaneously in the same cell, and some are
exclusive to certain cell types. The electroneutral efflux of inorganic osmolytes,
being K+ and Cl− for volume regulation, is either directly coupled by, e.g., KCl-
cotransporters or indirectly by seperate K+ channels and Cl− channels. There are
four KCl-cotransporters encoded in eukaryotic genomes: the solute-carrier family 12
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A (SCL12A) with members 4-7, also known as KCC1-4. Their expression profiles
differ, with KCC2 being specific to neurons and constitutively activated to use the
driving force of K+ to lower the concentration of Cl− in neurons below the Nernst
equilibrium of Cl− [13, 14]. KCCs are known to play important roles in steady-state
volume-regulation and RVD [15]. As a major property for this task, all isoforms are
known to be activated by cell swelling [16–20]. In mouse erythrocytes, it was even
shown that KCCs are responsible for the majority of RVD in these cells [21]. Besides
the electroneutral cotransport by one transporter, cells lower their volume by parallel
activation of individual K+ and Cl− channels. Known K+ channels are the calcium-
activated K+ channels containing the small, intermediate, and bid conductance K+
channels (SK, IK, and BK) or, .e.g, the two-pore domain channels TRAAK,TREK,
and TASK2 (reviewed in [8, 22]). For electroneutrality, efflux of either K+ or Cl−
necessitates the respective other ions to leave the cell as well. Therefore, there
must be several accompanying Cl−-channels. One group is the calcium-activated
Cl−-channel group, containing the bestrophin and TMEM16 family (reviewed in
[23, 24]). It needs to be noted that their activation by swelling is also dependent
on Ca2+ levels, which is not changed upon swelling in all cell types (reviewed in
[8]). Another group is the long-time enigmatic “group” of volume-regulated anion
channels.
1.2 The volume-regulated anion channel VRAC
In 1988 two groups described for the first time chloride currents with VRAC char-
acteristics involved in volume regulation [25, 26]. In the following years, compa-
rable currents were detected in basically every vertebrate cell line under investi-
gation. VRAC seems to be ubiquitously expressed throughout a single organism,
and throughout the whole vertebrate subphylum [27, 28]. The unknown molecular
identity of the channel responsible for these currents led to nonuniformeous nomen-
clatures and unknown functions for the mysterious VRAC. Today it is known that
descriptions of channels called volume-sensitive outwardly rectifying anion channel
(VSOR), volume-sensitive organic osmolyte/anion channel (VSOAC), and volume-
activated anion channel (VAAC) were indeed all of VRACs, explainable by its mod-
ular nature described in section 1.2.2. In 2014, two groups found independently the
leucine-rich repeat-containing protein family 8 (LRRC8) to form VRACs, starting a
new era with now known protein targets to decipher the mystery of VRAC [29, 30].
In all the years between 1988 and 2014, various groups worked on the identification
and characterization of VRAC, leading to a defined biophysical characterization of
VRACs but unclear physiological functions and regulatory mechanisms.
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1.2.1 VRAC’s role in regulatory volume decrease and beyond
As described above, cells can decrease their volume by efflux of Cl−. The first
identified function of VRACs was precisely that: the release of chloride upon cell
swelling to induce RVD. Knock-out and knock-down approaches after identification
of the LRRC8 protein family forming VRACs could verify that RVD is impaired
without functional VRACs in several cell types from different organisms [28–33].
Besides their ability to conduct Cl−, VRACs are known to conduct organic osmolytes
as taurine and glutamate as well. Nevertheless, there was a controversy about the
physiological role of VRACs for taurine release upon RVD (reviewed in [8]). With the
discovery of the LRRC8 protein family, this controversy was ended by experiments
not suffering from unclear VRAC diversity and unspecific pharmacology. Mediation
of taurine and other organic osmolyte efflux through VRAC could be clearly shown
for neuronal [34] and non-neuronal cells [30, 35]. VRAC is, therefore, not a pure
anion channel, as it was suspected to be for a long time. The diversity of conducted
species and VRACs themselves (see section 1.2.2) renders these channels capable of
more physiological functions than RVD.
Channels and transporters involved in RVD usually have more physiological roles
than RVD. This is true for VRACs as well, with proposed involvement in physiolog-
ical processes like apoptosis, migration, proliferation, auto- and paracrine signaling,
to name a few (reviewed in [36]). As for many aspects concerning VRACs, there
exists ambiguous data for these roles. The three mechanisms by which VRACs could
fulfill their proposed tasks are shown in figure 1.1 (reviewed in [36]).
Programmed cell death is often accompanied by a reduction of cell volume; the
apoptotic volume decrease (AVD) [37, 38]. Having a pivotal role in RVD, VRACs
were thought to be involved in AVD as well (reviewed in [39]). Indeed, several
groups could show the involvement of VRACs in AVD, e.g., in colonic epithelial
cells, myocardial cells, and chondrocytes [40–42]. Besides, VRAC currents can be
evoked isosmotically with known apoptosis inducers, as staurosporine, FAS ligand,
and cisplatin [43, 44]. The importance of cell-type dependency when analyzing
VRACs, in general, reveals itself in their (missing) activation by staurosporine.
Whereas apoptosis in HCT116 cells could be reduced by knock-out of the obligatory
LRRC8A subunit, HeLa cells did not show this reduction by knock-down of the
same subunit [43, 45]. As is the role of AVD in general, the involvement of VRACs
in apoptosis is not fully understood yet.
Volume regulation is not only necessary as a reaction to altered osmolarity but is
also part of physiological processes as proliferation [46]. VRACs were suspected to be
involved in cell cycle progression and proliferation due to unspecific pharmacological
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Figure 1.1: Mechanisms underlying VRACs physiological functions
Schematic presentation of the three mechanisms of VRACs to fulfill their physiologicals
tasks. Modified from [36]. (a) Release of Cl− and other organic osmolytes to reduce cell
volume by obliged water efflux. (b) Release of Cl− leads to changes of the membrane
potential (Ψ) which alter the nernst potentials of other ions and the activity of other ion
channels. (c) Release of organic osmolytes that act as extracellular signaling molecules.
acid (NPPB), 4-[(2-Butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1H-inden-5-
yl)oxy]butanoic acid (DCPIB), and quinine were all shown to affect several targets
apart from VRACs, weakening the conclusion of their involvement [50–52]. Indeed,
all existing data based on depletion of LRRC8 proteins show no role of VRAC for
proliferation. Neither do knock-out cell lines show impaired proliferation nor did
knock-down ones [29, 30, 45, 53]. It is safe to assume, that VRACs do not play a
pivotal role in proliferation, eliminating one often-cited role of these channels. Of
course, either a species or tissue-specific involvement cannot be excluded yet, but
having protein depletion tools at hand enables future experiments to finally answer
this question.
Another often mentioned potential role for VRACs is in cell migration [54]. The
hypothesis for the involvement of ion channels in cellular migration is their asymmet-
rical opening at the leading and trailing edge of a migrating cell, reducing the volume
at the trailing edge for an amoeba-like movement. It was shown that glioblastoma
cell line’s and HCT116 cell’s migration could be impaired by either application of
VRAC inhibitors or knock-down of LRRC8A [55, 56]. Nevertheless, our lab could
not reproduce the impairing effect of VRAC inhibition, knock-out, and knock-down
on migration in all these cell lines [53]. As for proliferation, the role of VRAC in
cell migration is, thereby, at least questionable.
A fascinating field is the potential role of VRACs in auto- and paracrine signaling.
Conducting excitatory amino acids (EAA) as glutamate and aspartate, VRAC was
thought to play a role in EAA signaling in the brain (reviewed in [57, 58]). In-
deed, the physiological role of VRACs in astrocyte-neuron communication could be
confirmed [34, 59, 60]. Glutamate signaling is important for neuronal excitability,
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plasticity, and ultimately learning processes in the central nervous system. Being
usually released in vesicles by neurons, astrocytes are believed to be involved in glu-
tamate secretion as well (reviewed in [61]). Nevertheless, there is an intense debate
over the molecular mechanism behind the proposed glutamate release by astrocytes
(reviewed in [62]). Having VRAC confirmed to be the entity for EAA release not
only in cultured astrocytes but even in an astrocyte-specific LRRC8A knock-out
mouse (showing learning and memory deficits) clearly shows VRACs importance
beyond RVD [59, 60].
VRACs importance is further underlined by the severity of the phenotype of
Lrrc8a−/− knock-out mice [63]. Knock-out of LRRC8A leads to increased pre- and
postnatal mortality, with born pubs dying latest at the age of 100 days. Born mice
show severe growth retardation, defective organ development comprising kidney
and muscle abnormalities, and impaired T-cell function. Interestingly there is a
spontaneous mouse mutant known, that shows the same (but milder) phenotype,
namely e´buoriffe´ (ebo) [64]. Only recently the cause for the ebo phenotype was
found to be a depletion in Lrrc8a truncating the leucine-rich repeat-domain [65].
The infertility of ebo/ebo mice is indeed due to the abolished conducting ability of
VRACs, as a germline-specific knock-out of LRRC8A was shown to lead to male
infertility as well in mice by impaired spermatogenesis [31].
Another tissue-specific role for VRACs was found in glucose sensing and insulin
secretion. Swelling is a known result of glucose uptake and metabolization by pancre-
atic β-cells [66]. Indeed, anion currents with VRAC characteristics were measured in
β-cells stimulated with glucose and roles beyond RVD of these currents proposed be-
fore the identification of the LRRC8 family (reviewed in [67]). Recently two groups
verified VRACs involvement in glucose sensing and insulin secretion in LRRC8A
knock-out mouse models [33, 68]. The electrogenic release of Cl− by VRACs upon
glucose uptake depolarizes the membrane potential. This opens voltage-gated Ca2+
channels and leads to an influx of Ca2+ into β-cells, which ultimately leads to insulin
release. Even though both studies disagree on the severity of LRRC8A depletion on
insulin secretion, they do agree in a general role of VRACs for membrane depolar-
ization and insulin secretion.
1.2.2 The modular architecture of VRAC(s?) formed by the
LRRC8 protein family
For a long time, it was not understood how a single channel, if it only was one, could
potentially fulfill such diverse tasks and conduct different species as VRAC was sus-
pected of doing. With the identification of the leucine-rich repeat-containing protein
family 8 (LRRC8) to be forming VRACs finally a possible answer to the question of
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diversity was found [29, 30]. The LRRC8 family comprises five members, LRRC8A-
E. LRRC8A is the obligatory subunit needed for channel formation. Knock-out of
LRRC8A, with all four other genes still functional, leads to the same loss of chlo-
ride current upon cell swelling as knocking out all five LRRC8 genes. Without the
A subunit, overexpressed LRRC8B-E are stuck in the endoplasmic reticulum (ER)
[30]. To form functional and conducting VRACs, at least LRRC8A and one other
family member is needed. Recently, four groups solved the cryo-EM structure of
LRRC8A homomers [69–72]. As impressively precisely predicted by Abascal and
Zardoya in 2012, VRACs form hexamers [73]. VRACs share, therefore, topology
and channel structure with pannexins, connexins, and innexins.
The five paralogs are formed by around 800 amino acids, with a moderate sequence
similarity of on average 45.92 % [73]. They comprise four transmembrane domains,
with the C- and N-terminus located intracellularly. Nearly half of the amino acids
of LRRC8 proteins form the intracellular, C-terminal leucine-rich repeat domain
(LRRD). These domains comprise up to 17 leucine-rich repeats, that are known
protein-protein interaction motifs. Until now, no direct interaction partners of the
LRRDs of VRAC subunits are known, but it is conceivable that protein interaction
motifs in a channel fulfill regulatory tasks.
The topology of a single LRRC8 protein and the structure of a LRRC8A homomer
are shown in figure 1.2. The four transmembrane helices of every subunit (TMH1-
4) are connected by two extracellular loops (EL1 and 2), and an intracellular loop
(IL1) between TMH2 and 3. Intracellular loop 2 (IL2) is connecting TMH4 with
the LRRD (Figure 1.2A). The LRRD of a subunit has the, for that domain type,
typical horseshoe shape, with the concave side of every LRRD facing the pore axis.
Interestingly there are some discrepancies concerning the overall channel symmetry
in the four solved structures (discussed in [74]). Three structures show a six-fold
rotational symmetry (C6) for all regions except the LRRD [69, 71, 72] and one a
three-fold symmetry (C3) [70]. As a possible reason for the C3 symmetry was dis-
cussed that the detergents used to reconstitute the channels are bigger than plasma
membrane lipids, forcing themselves in fitting pockets and rearranging the channel
to this symmetry [72]. The symmetry of the LRRDs is less clear compared to the
other regions. Two groups propose a C3 symmetry, leading to a trimer of dimer for-
mation, with two neighboring subunits having tight interaction interfaces between
their LRRDs and wider interfaces to the next pairs (example of C3 arranged LRRDs
shown in figure 1.2B) [69, 71]. The other two structures hint towards a disordered,
heterogeneous LRRD arrangement [70, 72].
An LRRC8A homohexamer can be divided into four regions: the extracellular do-
main (ECD), the transmembrane domain (TMD), the intracellular domain (ICD),



































Figure 1.2: Structure of VRACs
(A) Topology of a single LRRC8 protein (left) and schematic representation of the struc-
ture of a single subunit within a hexamer (right). Folded structure resembles the light blue
subunit shown in B (B) Solved cryo-EM structure of an LRRC8A hexamer (PDB:5ZSU
[70]). Shown is the channel viewed parallel to the plasma membrane (left) and from the
intracellular side (right). Individual subunits are differntly coloured. Two subunits in the
left structure were removed for better visualization. Figure modified from [74].
charged residues. The domain architecture forming the pore starts with the first
resolved stretch of EL1 of all subunits. El1 of the subunits are slanted towards the
pore axis and form the narrowest, resolved part of the osmolyte permeation path-
way in all structures. R103 protrudes into the pore and is believed to be responsible
for the charge selectivity towards anions of VRAC heteromers [69]. In the TMD,
the extracellular space facing part of TMH1 and the intracellular space facing part
of TMH2 further form the pore. Whereas, TMH3 and TMH4 face the lipid envi-
ronment of the plasma membrane. Membrane lipids were shown to directly interact
with several ion channels, modifying their function and regulating their activity [75].
If such an interaction is influencing VRACs as well, it will, therefore, probably be
by the interaction of lipids with TMH3 and 4. Unfortunately, the N-terminus is
not resolved in all four structures. The structurally closely related connexins and
innexins were shown to have an N-terminal coil (NTC) protruding into the central
channel axis, creating a constriction with selectivity instances and size restriction
tasks [76, 77]. Even though the possible NTCs of LRRC8A hexamers were not
resolved, mutagenesis studies with the first 15 amino acids of LRRC8 proteins re-
vealed their importance for general conductance, ion permeability, and inactivation
gating [78]. Thus, it is likely that VRACs, as do connexins and innexins, have an
NTC that is folded into the permeation pathway of the channel. Past the potential
NTC, the lowest part of the pore is finally formed by a meshwork of helices of IL2.
The involvement of the LRRDs in pore formation is unclear due to their unsure
localization in the solved structures.
Knock-out of three of the five LRRC8 genes and overexpression of LRRC8A and
another subunit leads to functional VRACs that conduct ions [30]. These het-
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eromers show different biophysics and conduct different species (see section 1.2.3).
Combinations of two subunits, therefore, gives rise to several different VRACs. In
living cells, the situation is probably even more complicated since it was shown
by co-immunoprecipitation and TIRF based bleaching experiments, that functional
VRACs could contain more than two different subunits [79, 80]. Mapping of the con-
servation scores for the respective residues between the five paralogs on the solved
structure of LRRC8A homomers hints towards the domains and amino acids that
are responsible for the biophysical differences of heteromers [70]. Pore architec-
ture forming domains, namely ECD, TMH1 and 2, and ICD, are highly conserved
between the different family members, implying that these structures are equally
arranged in different VRAC heteromers. Variability of VRACs, thereby, arises from
diversified regions, being TMH3 and 4, non-pore forming parts of the ECD, the
LRRDs, specific residues in the NTC and the constriction forming residues at the
permeation pathway entrance (R103 in LRRC8A).
1.2.3 Biophysical characterization of VRACs - a matter of
subunit composition
Decades of research on VRACs without knowing their molecular identity led to a
detailed electrophysiological and biophysical fingerprint to discriminate them from
other channels. Under basal conditions, VRAC currents are not detectable but
start seconds after an activating stimulus, such as hypotonicity, and develop over
minutes to reach their maximum. A hallmark of VRAC currents is the deactivation
at positive potentials above 40 mV, that discerns them from other Cl− channels
as, e.g., the already mentioned bestrophins, which show no deactivation at positive
potentials [81]. Even though being a characteristic property of VRACs, the varying
degree of inactivation between different cell lines was unexplainable for a long time
(reviewed in [48, 82]). The reason for these variations in inactivation is again the
subunit dependence of this property [30]. VRACs formed by LRRC8A and another
subunit show significantly different inactivation kinetics at positive potentials, with,
e.g., LRRC8E inactivating very fast compared to LRRC8C [30]. Since there seems to
be a different expression profile of LRRC8 proteins in tissues and cell lines, detected
variations of inactivation are probably due to different subunit compositions in that
cell line under investigation [83, 84].
Whereas VRACs do not display significant cation permeability, their permeability
towards anion corresponds to Eisenmann’s sequence I for weak field strength: I− >
Br− > Cl− > F− (reviewed in [48]). Estimates of the permeability of VRACs
towards taurine compared to Cl− (Ptaurine/PCl) yielded permeation ratios of 0.15-
0.4 [85–88]. These studies were done in different cells from different organisms
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and lacked, due to the LRRC8 protein family being not identified yet, controls
of subunit expression in the investigated cell lines. Today it is known, that the
subunit composition of VRACs leads to different conducting preferences as well.
LRRC8D is the main subunit needed for taurine efflux upon cell swelling [43]. This
underlines the importance of taurine for RVD in general, and specifically, the subunit
dependence for VRAC activity and function, since Cl− currents in LRRC8D−/− cells
were unaltered to WT cells, whereas their RVD was impaired [43]. Interestingly,
the preference of LRRC8D for taurine is linked to taurine baring no net charge at
physiological pH [59]. Raised extracellular pH levels lead to more anionic taurine
molecules, which were conducted by other subunit compositions lacking LRRC8D
[59]. Besides taurine, LRRC8D was shown to be essential for the conduction of
myo-inositol, gamma-aminobutyric acid (GABA), glycine, and lysine [35, 80]. The
permeation of ATP was increased for VRACs formed by either LRRC8E or C [80].
All LRRC8 subunits can conduct Cl−, besides the other named osmolytes. Only for
LRRC8B, no other conducted species apart from Cl− could be identified yet.
Another hallmark of VRAC’s electrophysiological fingerprint is its mild outward
rectification. Per definition, current is the net outside movement of positive charge.
For an anion channel, this means that high outward current reflects an inward flux
of Cl−, whereas, an inward current is the outward flux of Cl−. By being outwardly
rectifying, VRACs conduct, therefore, more chloride at positive potentials (into
cells), than at negative potentials (out of cells). As for many other aspects of
VRACs, this property is again subunit dependent. Reconstituted combinations of
LRRC8A with another LRRC8 protein revealed that complexes containing LRRC8D
have a stronger outward rectification then complexes of LRRC8C or E [79].
1.3 Techniques to study VRACs
1.3.1 Electrophysiology- The gold standard
Electrophysiology assesses the flow of ions through biological membranes by using
electrodes in cells or at their plasma membrane [89]. Over the last century, the
methods around electrophysiology developed to a sophisticated toolset for various
applications. Indeed, electrophysiological measurements are the most used method
to study VRACs yet. In general, there are two different ways of measuring the
electrical behavior of a cell: either by holding the voltage of the plasma membrane
constant (voltage-clamp) and measuring the occurring flow of charged species or
by holding the current of a cell constant (current-clamp) to measure the mem-
brane potential. Assessment of the membrane potential is a typical application in
neuro-science, where action potentials of neurons are measured. Investigation of
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ion channels in mostly non-neuronal cells is usually done by voltage-clamp, where
the flow of ions can be readily measured since injected currents to hold the voltage
constant directly reflect flux of charged species through the plasma membrane after
a short capacitive loading of the plasma membrane (reviewed in [90]). There are
four different configurations in which voltage-clamp experiments can be performed:
whole-cell, inside-out, outside-out, and cell-attached configuration (reviewed in [91]).
To perform a voltage-clamp experiment, a glass tip, containing an electrode, is
brought into physical contact with the plasma membrane of a cell. The lipids of
the membrane attach to the glass surface, forming a tight seal that, hopefully, elec-
trically shields the pipette interior from the extracellular solution with a resistance
of several giga ohms. The name for this seal is derived from this high resistance
and is called giga-seal. Having established a giga-seal leads to the easiest mode for
electrophysiological experiments, the cell-attached configuration. Channels that are
in the enclosed membrane patch in the pipette tip can be measured in their cellu-
lar environment this way, physically and electrically isolated from other channels.
Electrophysiological measurements of patches of the plasma membrane are, there-
fore, used for either single-channel or at least measurements of a small subset of
channels. These patch-clamping techniques for small numbers of channels comprise
the inside-out, outside-out, and cell-attached configuration. Cell-attached measure-
ments suffer from hardly controllable voltage levels, so only a few groups managed
to detect VRAC currents in this configuration [79, 80, 92, 93].
The other methods potentially assessing single-channel events are the outside-out
and the inside-out configuration. Those are established after successful cell-attached
mode, by either withdrawing the pipette tip slowly from the plasma membrane,
excising a patch of it with the cytosolic side facing the bath solution (inside-out)
or by rupturing the plasma membrane before withdrawal of the pipette tip for the
membrane patch residing at the tip to form a vesicle with the cytosolic side facing the
pipette internal solution (outside-out). This way, single channels can be investigated
outside of their cellular context. Furthermore, it creates the possibility to directly
bring either the intracellular or the extracellular side of a channel into contact with
defined drugs or signaling molecules, only measuring the specific channels in the
membrane patch. To my knowledge, there is no publication yet showing single-
channel currents of VRACs in inside-out patches. In pre-swollen cells, though, single-
channel currents of VRACs have been measured using the outside-out configuration
[94, 95]. In membrane patches of Xenopus oocytes, outside-out currents of VRACs
could be measured without pre-swelling of the oocytes by exploiting the increased
basal activity of C-terminally tagged LRRC8 subunits [80].
The by far most used configuration to study VRACs and their underlying sig-
naling is the whole-cell configuration. To establish the whole-cell configuration, the
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membrane patch in the pipette of a cell-attached configuration is ruptured by the
application of abrupt suction. Rupture of the plasma membrane grants direct access
to the cytosol, dialyzing it against the pipette solution. Thereby, the ionic composi-
tion of the cytosol can be controlled and adjusted according to the question at hand.
In the whole-cell configuration the currents of all channels activated at that moment
are recorded, in comparison to the small subset or even single-channels of the other
configurations. A variation of the whole-cell configuration, to avoid dilution of pro-
teins and signaling molecules, is the perforated-patch configuration [96]. To achieve
perforation of the plasma membrane, pore-forming antibiotics are included in the
pipette solution. Small ions as K+, Na+, and Cl− can pass these pores, allowing
control of their intracellular concentration, whereas bigger molecules as proteins or,
e.g., ATP are retained in the cytosol. While the whole-cell configuration is used
in virtually every publication dealing with the electrophysiology of VRACs, only a
subset of them utilized the perforated-patch configuration [68, 97–99].
Electrophysiology revealed valuable information about the biophysics of VRACs
and their regulation. As for every method, it has its limits and drawbacks as well that
need to be considered. Investigation of VRACs in excised membrane patches (inside-
out and outside-out configuration) allows detailed characterization of VRAC’s bio-
physics, but always in the absence of the cellular signaling context. Theoretically,
the addition of potential binding partners, or modifying enzymes to the bath or
pipette solution could be used to identify those involved in VRAC activation. How-
ever, it is unsure whether they can fulfill their role in activation isolated from the
cytosol and their direct identification without other upstream pathways is rather
unlikely. In the cell-attached configuration, the cellular context is still available for
the patch embedded channels. As mentioned, a successful measurement of VRAC
currents in this configuration is hard to accomplish. Furthermore, the channels in
the isolated patch seem to be influenced by their isolation, since currents in the cell-
attached configuration can only be measured on pre-swollen cells, not on patches of
cells that are swollen post patching [92]. Thereby, the effect of manipulations of the
cellular signaling pathways can not be monitored directly. When using the whole-cell
configuration, the formulation of the pipette solution, against which the cytosol is
dialyzed, needs to be carefully adjusted to the channel type under investigation. For
example, in most experiments dealing with VRACs, the pipette solution contains
Cs+ to block K+ channels which might pollute the recorded currents. Recently, it
was proposed that the addition of Cs+ impairs isolation of anionic currents by Han
and coworkers1 [100]. Besides, the volume of the pipette solution is huge compared
1The paper of Han et al. is highly controversial. They state that the hypotonicity induced chloride
currents in astrocytes are due to the Tweety-homolog family and not due to the LRRC8 family.
Judging the implications and correctness of this finding is beyond the scope of this thesis.
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to the cytosol, thereby the efflux of osmolytes through channels is nullified by the
same osmolytes diffusing back into the cell through the ruptured membrane from the
pipette solution. RVD is, therefore, heavily impaired, reflected in a highly increased
volume gain of patched cells to unpatched cells in a hypotonic solution. Together
with the blocked K+ channels, the whole-cell configuration creates an artificial en-
vironment with unpredictable influences on cellular signaling events underlying the
regulation of VRACs. The perforated-patch configuration can at least minimize the
mentioned dilution effects of the whole-cell configuration but is seldom used.
A basic premise of electrophysiological measurements is that the osmolytes passing
the channels under investigation are either positively or negatively charged. As
introduced above (see section 1.2.3), VRACs can conduct uncharged osmolytes like
taurine. At physiological pH of 7.4, taurine is uncharged and can, therefore, not
be detected as current. It is generally possible to measure taurine as current by
increasing the pH of the extracellular solution to a pH of 8 [85]. Those measurements
were more valuable for investigation if taurine is released through the same channel
as Cl−, but are of limited value for analysis of cellular signaling since the pH change
itself might influence it. So electrophysiological experiments can only detect the flow
of charged species, even though it might be of functional importance that VRACs
conduct uncharged species as well in the explored case. Detection of fluxes of specific
osmolytes can, nevertheless, be accomplished by a different method.
1.3.2 Determination of osmolyte concentrations
An elegant approach to determine the efflux of a specific osmolyte is the loading
of cells with radiotracer variants of that osmolyte and following measurement of
radioactivity in the supernatant after stimuli application. Usually, either 3H or
14C labeled osmolytes, as D-3[H]aspartate or 14[C]taurine, are used [30, 34, 35,
101]. Incubation of cells with labeled osmolytes for several hours leads to their
uptake by cellular transport systems (reviewed in [102]). After their uptake, the
release of labeled osmolytes can be measured, e.g., after hypotonic treatment, by
scintillation counting and compared between different conditions. The detection
efficiencies for 3H exceed nowadays 68 % and for 14C 98 %, rendering radiotracer
efflux measurements very sensitive and enables detection of very small concentrations
of osmolytes [103]. Radiotracer studies were useful to directly show that VRACs do
conduct specific osmolytes [30, 104].
The content of amino acids of a cell (or their supernatant) can be measured in-
dependently of exogenously applied radiotracers with, e.g., high-performance liquid
chromatography (HPLC) based seperation and detection. For intracellular amino
acid content determination, cells incubated with and without hypotonic medium are
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lysed, and the protein content denatured, leaving soluble amino acids for measure-
ment. Using this technique, reduced levels of several amino acids and mainly taurine
could be shown in cultured astrocytes challenged with hypotonicity [105]. Analysis
of the supernatant of swollen cells can also yield information about osmolyte efflux.
Again, an HPLC technique with sufficient sensitivity can be used to detect increases
of extracellular amino acid contents [106]. Furthermore, readily buyable assay kits
for glutamate level measurements were used to show VRAC dependent increased
extracellular glutamate concentration after hypotonicity [35].
The assay used to identify the LRRC8 protein family to form VRACs exploits the
quenching of a fluorophore by I− influx into cells by channel opening [29, 30]. To
perform this assay, a halide sensitive YFP mutant [107] is either stably [29, 30, 43] or
transiently expressed in cells [108]. As described above, VRACs conducts halides in
general and I− to a bigger extent than Cl−. Upon opening of VRACs, extracellular
I− can, therefore, enter the cells and quench the fluorescence of the halide-sensitive
YFP. The intensity of YFP is then detected as an indicator of VRAC activity.
Nevertheless, these methods can not be used as a general tool to detect VRAC
activity. Radiotracer approaches can only detect the osmolytes that were loaded
to the cells before. VRACs are capable of conducting several osmolytes, and the
regulation of which is released upon specific stimuli is still unknown. Furthermore,
there are several transporters and channels for the species that VRAC can conduct
as well, so tedious controls to determine which channel is responsible for the mea-
sured concentration change are needed. To validate, e.g., that results of the YFP
quenching assay are due to the opening of VRACs, knock-down or knock-out mod-
els are required. Pharmacological manipulations, though, can only result in hints
toward VRAC, for the named unspecificity.
1.3.3 Cell volume measurements
Since one of the roles of VRACs is the RVD after swelling, measurement of the cell
volume is a seemingly straight forward approach to detect their action. Surprisingly,
the exact determination of cell volume can be difficult, and various methods exist for
cell volume measurements (reviewed in [109]). The gold standard of exact volume
measurements is the electronic conductance (better known as coulter sizing) method
that has been used for investigation of VRACs role in RVD [29, 110]. Here, two
compartments, each containing an electrode, are separated by a small aperture.
Cells in suspension pass through this aperture and increase, thereby, the resistance
of the electrical circuit. The cell volume is a function of the voltage spike generated
by this high resistance. Being very reliable, the only drawback of this method is the
need for an according coulter sizer device.
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Many groups used a calcein based method to determine volume changes semi-
quantitatively [30, 111, 112]. Crowe et al. established calcein as a volume probe by
merely exploiting the fact that the intensity of a fluorophore in a restricted plane of
a cell is dependent on its concentration [113]. This approach was further refined to
use the self-quenching of calcein at higher concentrations to obtain quick and low-
noise measurements of cell water content [114]. However, the need for intracellular
concentrations high enough for self-quenching to occur can lead to inconsistencies
between cells and loading conditions and are, therefore, less accurate as coulter
sizing. Volume estimations with calcein are usually semi-quantitatively, but most
VRAC studies investigated the relative volume change between cells and did not
rely on absolute volume values.
The least accurate method used to determine relative volume changes upon VRACs
action is the so-called optical sectioning [115, 116]. Differential interference contrast
(DIC) images of detached, therefore round, cells were used to measure the diame-
ter of the cross-section and to calculate the cross-sectional area. The ratio of the
cross-sectional area at two different time points is then used as an approximation for
relative volume changes. To assure high accuracy of the determined cross-sectional
area, the same plane of a cell needs to be measured every time. Acquisition of z-
stacks for every time point is a rather slow process, not feasible for most applications,
whereas selection of the plane by the experimenter inherits a human selection bias.
It is possible to calculate the volume for adherent cells as well with the sectioning
method, but this approach is rather cumbersome and time-consuming (discussed in
[109]).
Taken together, cell volume measurements can be useful to assess the influence
of VRACs on RVD, but for the redundancy of the RVD processes in cells the exact
mechanism of VRAC’s action need to be verified with other methods as well.
1.3.4 VRAC heterogeneity as a challenge
As introduced in section 1.2.3, LRRC8 subunit composition dictates channel prop-
erties, creating several problems concerning the established methods to investigate
VRACs. In the decades before the identification of the LRRC8 protein family to
form VRACs, all investigations were done with endogenous, mixed subunit popula-
tions. Not only do the expression levels vary between different tissues and potentially
species, but it is also still unknown how channels composed of more than two dif-
ferent subunits combine the properties of their single members. Therefore, old data
suffers from uncertainty if investigated effects were due to VRACs in general (caused
by unspecific drugs) and if so, due to which composition. Knowledge of the channel
composition is of importance to avoid contradictory findings. A striking example is
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the opposite effect of oxidation on different subunits [117].
Having knock-out and knock-down approaches available, it is possible today to
directly compare, e.g., electrophysiological results in the presence and absence of
single or multiple LRRC8 proteins. Being undoubted of value, these approaches are
inflexible and can not account for the potential interplay of differently composed
VRACs over time (especially considering the invasiveness of electrophysiology).
1.4 The data maze of VRAC activation and
regulation
Most of the work regarding the activation of VRACs presented here was done with-
out knowing the molecular nature of VRACs. Therefore, misconceptions and con-
tradictions had to occur due to the missing knowledge of the modular complexity
behind these channels. Furthermore, it seems likely that a group of channels with
tasks as diverse as VRACs are controlled by several different pathways, that might
be dependent on tissue and even cell cycle state of a single cell. Following statements
concerning VRAC regulation are, therefore, not as general as the formulation might
implicate and shall give an overview of potential pathways worth of revisiting with
new tools.
As their name suggests, VRACs are volume regulated and, therefore, activated
in swollen cells. Since they can not directly sense changes of cellular volume, other
parameters that are altered upon swelling and activate VRACs have to exist (re-
viewed in [118]). A controversial activation path involves the ionic strength of a
cell. Cells swell due to a water influx, which dilutes the cytosolic ion content, re-
ducing the ionic strength inside of a swollen cell. Several publications state that
ionic strength directly activates VRACs in living cells [119, 120]. This notion is
convincingly supported by the fact that single VRACs in lipid bilayer droplets are
activated by reduced ionic strength but not by lowered osmolarity [79]. However,
other studies could show that an isosmotic swelling, with constant ionic strength,
by injecting fluids into cells leads to activation of VRACs as well [115, 121, 122].
The activating role of ionic strength for VRACs is, therefore, elusive yet.
Intracellular ATP levels were shown to regulate VRACs activation by hypotonicity
induced swelling [123–126]. Interestingly, the substitution of intracellular ATP by
non-hydrolyzable analogs did not prevent channel activation, leading many groups
to conclude that phosphorylation events are not a crucial part in the underlying
signaling of VRAC activation [86, 116, 123, 125]. Subsequent studies found that
even though substitution by non-hydrolyzable ATP derivates does not impair VRAC
activation, the kinase activity of protein tyrosine kinases (PTK) is critical for it [127].
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This led to the conclusion that dialysis of cytosolic ATP and replacement with non-
hydrolyzable derivates is not extensive enough to suppress all phosphorylation events
in a cell. The theory of insufficient ATP depletion is supported by the low levels
of ATP required for phosphorylation compared to needed concentrations for ATP-
binding dependent processes (reviewed in [128]).
In compliance with the ambiguous role of phosphorylation events concluded from
ATP experiments, the involvement of kinases and phosphatases is obscure. Phar-
macological hints exist for a role of PTKs in dog cardiac myocytes, rat astrocytes,
and bovine endothelial cells [129–131]. Surprisingly, inhibition of the counter en-
zyme family of protein tyrosine phosphatases (PTP) impaired VRAC activation in
bovine chromaffin cells, and mouse fibroblasts [132, 133]. An equivalently confus-
ing data situation is found for the regulation of VRACs by the protein kinase C
(PKC) family. PKCs were found to be important for VRAC activation in astro-
cytes by pharmacological, and PKC depletion by small interfering RNA (siRNA)
and mutation approaches [134, 135]. Other inhibitor-based studies identified either
an activating or deactivating role of PKCs in various other cells [136–140].
Apart from the contradictory findings mentioned above, several other seemingly
unrelated regulatory signaling molecules and messengers have been ascribed to
VRAC’s activation mechanism. Those include purinergic signaling, sphingosine-1-
phosphate (S1P), phosphatidylinositol-3,4,5-triphosphate (PIP3), calcium concen-
tration, G-proteins, G-protein-coupled receptors (GPCR), reactive oxygen species
(ROS), and tumor necrosis factor-α (TNFα) (reviewed in [8, 9, 36]). For the sake
of understandability, they shall not be discussed here in-depth, but rather complete
the picture of the confusing data maze around the regulation of VRACs.
1.5 Assessing ion channel activity with fluorescence
microscopy
Advances in the field of fluorescence microscopy have pushed the borders of resolu-
tion and sensitivity achievable today. Using super-resolution microscopy and tech-
niques as Fo¨rster-resonance energy transfer (FRET), the underlying mechanisms
of several ion channels could be investigated in fascinating new ways (reviewed in
[141]). An example is the usage of FRET to determine the molecular events behind
the slow-gating of the Cl− channel ClC-0 [142]. The process of opening and closing
of channels is referred to as gating, whereas ClC-0 is known to have two different
modes of gating (slow and fast, reviewed in [143]). The molecular events behind
the slow gating mode were elusive until FRET experiments could show a rearrange-
ment of the C-termini of ClC-0 subunits to be involved [142]. Another example of
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fluorescence microscopy being used to study the activity of channels is the AMPA
receptor (AMPAR) [144]. Again exploiting FRET microscopy, it was shown that
intracellular domains rearrange upon extracellular ligand binding.
Optical methods have several advantages compared to classical approaches to
study VRACs. By knowing which subunits are labeled, optical experiments do not
suffer from uncertainty which LRRC8 proteins are responsible for seen effects. Fur-
thermore, it would offer spatio-temporal information about the channels and would
be less invasive than electrophysiological approaches. Since the imaging of cells is
a gentle measurement approach, longtime experiments of cells expressing fluores-
cently labeled LRRC8 proteins can be performed. Especially FRET microscopy is
a versatile tool since sub-resolution information about the relative localization of




2 Aim of this work
Volume-regulated anion channels (VRACs) are a diverse class of channels conduct-
ing various osmolytes, including Cl−, taurine and glutamate. Besides their crucial
role for regulatory volume decrease, they have proposed roles in physiological pro-
cesses like apoptosis, differentiation, insulin secretion, and auto/paracrine signaling.
VRACs are composed of at least LRRC8A and another member of the LRRC8
family, leading to the characteristics of VRACs being dictated by their subunit
composition.
A critical step in the preparation of this thesis was the realization of the imper-
fection of existing data concerning VRAC regulation. I do want to emphasize that
most of the work was performed without knowing the molecular nature of VRACs
and relied on unspecific inhibitors. Furthermore, have the existing methods for in-
vestigations of VRACs the drawbacks of being invasive (as in electrophysiological
approaches) and the requirement for cumbersome pharmacological and protein de-
pletion manipulations to distinguish effects caused by specific subunit compositions
from either other plasma membrane channels or differently composed VRACs.
Therefore, I aim in this thesis to establish a new microscopy-based tool for inves-
tigations of VRACs. The new optical tool should be less invasive then electrophysi-
ology, offer time-resolved information about channel activity, and pay respect to the
different subunit compositions of these channels. With this optical tool, I aim to
characterize the elusive activation mechanism of specifically composed VRACs by





3.1 Establishing a FRET sensor for optical monitoring
of VRAC activity
3.1.1 Validation and characterization of FRET between LRRC8
subunits
FRET occurs between fluorophores that are in close proximity to each other and
have the correct orientation. The Fo¨rster radius describes the distance between two
fluorophores at which they transfer non-radiatively their energy with an efficieny of
50 % and depends on various factors and is different for given sets of FRET pairs,
being 5 nm for the classic FRET pair of cyan-fluorescent protein/yellow-fluorescent
protein (CFP/YFP). Many variables can be changed to successfully create fusion
proteins with the fluorophores positioned for FRET, namely the exact position of
the fluorophore in the protein sequence and the length, and rigidity of the linker
sequence between the native protein and the tag. Tags at the N-terminus of LRRC8
subunits were shown to render VRACs inactive [30]. Therefore, I chose to insert
either CFP or YFP tags at the extreme C-terminus with a short 12 amino acid long
linker. LRRC8A tagged with either CFP or YFP (A-CFP, A-YFP) is expressed
and transported to the plasma membrane in HeLa cells (Figure 3.1). LRRC8E
tagged with CFP or YFP (E-CFP, E-YFP) is stuck in the ER when expressed alone
(data not shown), but colocalizes with LRRC8A at the plasma membrane when
co-expressed (Figure 3.1) [30].
To test if the fluorophores are positioned in a way for FRET to occur, I utilized
acceptor photobleaching (APB). If CFP is close enough to YFP and correctly ori-
ented, a specific percentage of CFP molecules will transfer their excitation energy
radiation less to YFP. The CFP emission is thereby quenched by this percentage
and can be unquenched by bleaching of YFP. So, FRET can be calculated by the
increase of CFP emission after bleaching of YFP compared to the emission before
bleaching. Usually APB is performed on confocal microscopes with fixed specimen.
A small area of YFP is then bleached with its respective laser line and the CFP





Figure 3.1: Expression and localization of FP labeled LRRC8A and E
Plasma membrane localization of fluorescently labeled LRRC8 subunits in HeLa cells 24
h after transfection with either A-CFP/A-YFP (top) or A-CFP/E-YFP (bottom). Scale
bar= 20 µm
performed on widefield microscopes with living cells as well, with certain limitations
to the accuracy of determined FRET (dFRET) values. Especially for samples with
small FRET efficiencies, there is a need for careful control experiments, including
seperate negative controls and negative controls in the same experiment. I bleached
only a small portion of a field of view (FOV) by closing the field diaphragm to the
size of one or two cells (Figure 3.2A). Thereby I can directly compare the increase
in CFP intensity of bleached to unbleached cells as an intrinsic negative control.
Indeed complexes formed by A-CFP/A-YFP show a significant increase of CFP in-
tensity after bleaching of YFP compared to unbleached control cells (Figure 3.2B).
This increase strongly hints towards the occurrence of FRET between the fluorescent
proteins fused to the LRRDs of LRRC8A.
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Figure 3.2: Acceptor photobleaching of CFP and YFP labeled VRACs
(A) Example images of an APB experiment with HeLa cells expressing A-CFP/A-YFP.
Shown are the CFP channel (top row) and the YFP channel (bottom row), before (left
panels) and after (right panels) bleaching. The region bleached with closed field diaphragm
is indicated by white circles. Colored circles (next to the respective cell) added for iden-
tification in graphs shown in B. Scale bar, 20 µm. (B) Quantification of exemplary APB
experiment shown in A. Individual cells are represented by the color code in A. Top graph
represents the percentual CFP intensity change compared to t=0 of the respective cell.
Bottom graph represents the percentual YFP intensity during the APB experiment. (C)
Quantification of all APB experiments. Data points (diamonds) represent the percentual
CFP intensity change of indicated subunit compositions. For each subunit pair, the CFP




Homomers formed by LRRC8A alone might have the interesting potential to dis-
cover mechanisms intrinsic to all VRACs since this is the obligatory subunit needed,
but they are believed to be of no biological relevance. Functional VRACs are rather
formed by LRRC8A and at least one other member of the LRRC8 family. I, there-
fore, performed APB with complexes of A-CFP/E-YFP and A-YFP/E-CFP, which
again both showed an increase in CFP intensity after bleaching as seen for A-CFP/A-
YFP complexes (Figure 3.2C). Co-expression of A-CFP and the unrelated plasma
membrane protein CD4 tagged with YFP did not lead to an increase in CFP after
APB. Theoretically the FRET efficiency in dependence on the fraction of interacting
donors can be recovered from the change in CFP intensity according to
dFRET = IDD/IDDAB
Whereas, IDD is the CFP intensity before bleaching and IDDAB the CFP intensity
after bleaching. According to ABP experiments, A-CFP/E-YFP complexes have a
mean dFRET of 14.4 ± 10.1 %, whereas switching the fluorescent proteins leads to
a mean dFRET of 31.3 ± 12.3 % for A-YFP/E-CFP. The efficiency for A-CFP/A-
YFP homomers is higher as well with 29.6 ± 7.3 %. Comparison of the dFRET
values hints to a situation with a large fraction of non-interacting donors for A-
CFP/E-YFP. This is consistent with the likely stoichiometry of VRACs formed by
overexpressed A and E subunits, which was shown in Xenopus oocytes to be depen-
dent on sheer abundance of subunits: Comparing the intensities of overexpressed
A-CFP and A-YFP with E-CFP and E-YFP it is obvious that LRRC8A is more
strongly expressed. This expression ratio leads to a shift in the distribution of
likely channel compositions towards more A subunits per channel and even channels
solely formed by A. In the case of A-CFP/E-YFP, not all donors can interact with
an acceptor, decreasing the observable dFRET since those donors cannot show an
increased intensity after ABP. The acceptor E-YFP is thereby the limiting factor
for FRET, a notion supported by the higher dFRET seen for the A-YFP/E-CFP
combination.
ABP is a reliable but destructive process, preventing the observation of FRET over
time. To do so, one can utilize the most commonly used sensitized-emission FRET
(seFRET) technique. Here FRET efficiency is recovered from the sensitized acceptor
signal upon excitation of the donor. This is achieved with emission and excitation
filters which as specifically as possible excite only donor molecules and let only the
emission of the acceptor pass. The following nomenclature is used for the different
channels used for seFRET experiments: the donor channel detects donor emission
after donor excitation (IDD), the acceptor channel detects acceptor emission after
acceptor excitation (IAA), and the FRET channel detects acceptor emission after
26
Results
LRRC8A-CFP / LRRC8E-YFP 
A






Figure 3.3: Measurement of FRET between LRRC8 subunits by seFRET
(A) Wide-field images of HeLa cells expressing A-CFP/E-YFP. Shown are the three chan-
nels needed for cFRET calculation: donor (IDD), acceptor (IAA), and FRET(IDA). (B)
The cFRET map calculated from the three channels shown in A with pixFRET plugin for
ImageJ. Calibration bar left of cFRET map represents cFRET values and their respective
color code in the LUT.
donor exciation (IDA). Technical limitations and the broad excitation and emission
spectra of fluorophores prohibit the detection of sensitized emission to be specificly
pure FRET signals. IDA contains as well signals from cross-excitation of acceptors
in the donor channel and bleed-through of donor emission into the acceptor chan-
nel. To account for these errors seFRET experiments need correction factors for the
given set up which can be recovered from samples expressing only donors or accep-
tors. To calculate seFRET from a sample with acceptors and donors, one detects
three channels: IDD, IAA, and IDA (Figure 3.3A). With the beforehand determined
correction factors the erroneous contributions of the cross-talk to the IDA can be
subtracted. The cFRET, purged of cross-talk, is now still dependent on fluorophore
concentrations and cannot be compared to cFRET values generated on a different
platform since filter sets and camera sensitivities influence it as well. There are
several possible normalization variants to minimize these problems, namely normal-
izing to total acceptor concentration (aFRET), total donor concentration (dFRET)
or the arithmetic or geometrical mean of both. For many applications one can gain
information by the comparison of aFRET and dFRET, since a difference here shows
the stoichiometry of the interaction. Higher aFRET values imply non-interacting
donors and vice versa. The focus of this thesis is on VRACs formed by LRRC8A
and -E due to their biological relevance compared to VRACs formed only by A.
With YFP being brighter and having a higher quantum yield than CFP, I chose to
work mainly with A-CFP/E-YFP to have the brighter fluorescent protein on the
lesser expressed subunit. Having recorded IDD, IAA, and IDA one can calculate a
cFRET map, by removing cross-talk and normalize to one of the above-mentioned
values for every pixel of the image (Figure 3.3B).





































































































































Figure 3.4: Comparison of normalization methods reveals aFRET to be supe-
rior
Distribution of different cFRET values depending on normalization in relation to CFP,
YFP intensity and CFP/YFP ratio. Data points were acquired from 84 different HeLa
cells expressing A-CFP/E-YFP, for which unFRET,aFRET, and dFRET maps were cal-
culated and mean values of identical ROIs measured. CFP and YFP intensities of the
same cells were measured in the same ROIs as used for FRET measurement.
YFP at varying ratios to compare unnormalized cFRET (unFRET), aFRET and
dFRET (Figure 3.4). The expected dependency of FRET on the relative abundance
of the subunits can be seen for unFRET levels of cells in relation to their expression
profiles. With more E-YFP expressed, unFRET is linearly increasing, verifying it
to be the limiting factor. A-CFP as the donor, on the other hand, is in such an
excess, that even unFRET is not affected by changing expression levels. If the ratio
of A-CFP to E-YFP becomes greater than one, unFRET is exponentially getting
smaller. The seen linear dependency on E-YFP abundance vanishes by normalizing
to the acceptor concentration, rendering aFRET independent of absolute abundance
of either A-CFP or E-YFP and their ratio in an individual cell. Normalizing to the
donor shows that dFRET suffers from clear concentration dependency with dFRET
decreasing with increasing absolute A-CFP abundance and a clear exponential de-
crease with increasing ratio of A-CFP to E-YFP. Without searching for specific
expression ratios, I could see higher A-CFP levels in most cells. This is reflected in
aFRET being higher with a mean efficiency of 48.4 ± 14.5 % compared to dFRET
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with 15.7 ± 12.6 %. This verifies the observation of APB experiments that LRRC8A
is in excess and dFRET is very small due to non-interacting donors for A-CFP.
Taken together, FRET can be measured between C-terminally labelled LRRC8
subunits and aFRET is the beneficial normalization method for A-CFP/E-YFP ex-
periments, with it being independent on expression ratios and approximating abso-
lute cFRET values best due a high probability of all acceptors (E-YFP) interacting
with donors and no free acceptors, since LRRC8E is not able to form homomers
that reach the plasma membrane. For clarity aFRET and cFRET will be used
synonymously throughout this thesis.
3.1.2 FRET changes upon activation of VRAC and can be used
as optical activity sensor
After establishing seFRET measurements of fluorescently labeled VRAC subunits
I next asked whether this can be used to monitor VRAC activity in living cells.
HeLa cells expressing A-CFP/E-YFP show a decrease in cFRET when the bath so-
lution of the cells was switched from isotonic (340 mOsm) to hypotonic buffer (250
mOsm; Figure 3.5A,E). The same effect was observed in NRK (data not shown) and
HEK293 cells (Figure 3.5E). Reduction of cFRET was reversible and repeatable.
The absolute cFRET values differ highly between individual cells. Interestingly,
when normalized to their respective cFRET in isotonic buffer, the percentual reduc-
tion was robustly by 5 to 10 % (Figure 3.5E). VRAC homomers formed by LRRC8A
are usually considered to be conducting no measurable currents (reviewed in [74]).
Nevertheless, I could detect the same reduction of cFRET upon hypotonicity in
HeLa cells expressing A-CFP/A-YFP (Figure 3.5B,E). Interestingly, there seem to
be two distinct populations of cFRET reduction for LRRC8A homomers, but the
used sample size here is too small for a clear statement. FRET occurs between
molecules that are correctly oriented and in close proximity to each other, which
creates the risk for overexpressed proteins to statistically enter the Fo¨rster radius
of each other by simple diffusion. Membrane proteins do suffer even more from this
crowding effect due to the limited space of the 2D plasma membrane compared to

















































































































Figure 3.5: VRAC activation by hypotonicity is reflected by cFRET changes
(A, B, C, D) Top panels: cFRET maps of cells expressing FRET constructs in isotonic
and hypotonic buffer. Calibration bar left of cFRET map represents cFRET values and
their respective color code in the look-up table (LUT). Bottom graph: cFRET normal-
ized to isotonic conditions of the cell shown in top panels over time in different buffers.
(A) HeLa cell expressing A-CFP/E-YFP. (B) HeLa cell expressing A-CFP/A-YFP. (C)
HEK293 cell expressing GluA2-6Y-10C. (D) Hela cell expressing CFP-18AA-YFP. (E)
Quantification of normalized cFRET of cells expressing A-CFP/E-YFP (n = 9 dishes
with 47 HeLa cells; n = 8 with 29 HEK293 cells), A-CFP/A-YFP (n = 8, 24 HeLa cells),
glutamate receptor GluA2-6Y-10C (n = 4, 13 HEK293 cells) and CFP-18AA-YFP (n =
4, 11 HeLa cells). Data represent mean of last five time points in hypotonic buffer of
individual cells (magenta diamonds), and mean of all cells ± s.e.m. Baseline cFRET in
isotonic buffer indicated by green dashed line. Statistics: *p<0.05; ***p<0.0005; n.s., not
significant, Student’s t-test comparing isotonic to hypotonic.
FRET signals arising from crowding would, therefore, be susceptible to volume
changes by either reducing the chance of fluorophores entering each other’s Fo¨rster
radii in swollen cells or increasing it in shrunken. I utilized two negative controls to
rule out the contribution of crowding on the detected decrease of cFRET upon cell
swelling caused by hypotonicity. Neither GluA2-6Y-10C, an intra-receptor FRET
sensor of the AMPAR subunit GluA2 localized at the plasma membrane [144], nor
the cytosolic fusion construct CFP-18AA-YFP [145] showed reduced cFRET when
expressing cells were challenged with hypotonicity (Figure 3.5C,D,E). Especially
the GluA2-6Y-10C construct is comparable to VRACs by being a plasma mem-
brane protein forming homotetramers, which could, therefore, suffer from the same
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crowding effects as VRACs, that would change by cell volume changes. To further
validate that the observed FRET change is due to channel gating I performed patch-
clamp fluorometry together with Yuchen Hao from the AG Plested, FMP Berlin.
All beforehand shown experiments were performed on HeLa and HEK293 cells with



















































Figure 3.6: FRET changes reflect channel gating
(A) Representation of a patch-clamp fluorometry experiment. Images of a HEK 5xKO cell
transfected with A-CFP/E-YFP. Voltage step protocol for assessing VRAC current over
time shown on top right. Bottom row: IDD, IAA,IDA, and cFRET maps of the cell shown in
bright field picture (top).Calibration bar left of cFRET map represents cFRET values and
their respective color code in the look-up table (LUT). (B) Simultaneous measurements
of whole-cell current at -80 mV (open circles) and normalized cFRET values (solid circles)
during buffer exchange experiment with A-CFP/E-YFP-expressing HEK 5xKO cells. Data
represent mean of 4 cells ± s.d. Above, representative current traces from voltage-step
protocols at the indicated time points (a, b, c).
Hence channels might be formed with mixtures of fluorescently labeled subunits
and endogenous unlabeled ones. This mixture does not interfere with monitoring
VRAC activity by FRET since all signals of the sensitized emission can only arise
from channels with at least a donor and an acceptor molecule. For whole-cell voltage-
clamp measurements it would mean that there is no way to discriminate currents of
expressed subunits and endogenous VRACs. We, therefore, used HEK cells deficient
of all 5 LRRC8 genes (5x KO). These were transfected with A-CFP/E-YFP and
patch-clamped after 24 to 48 h for simultaneous recording of current and FRET
responses to hypotonicity in the same cell (Figure 3.6A). As is described for untagged
VRACs [30], we detected currents developing over a timescale of minutes, which were
outwardly rectifying and inactivating at positive potentials (Figure 3.6B). Current
and cFRET correlated very well and changed concurrently upon osmolarity changes,
with a slow opening and a faster closing process. Concludingly, the reduction of





















































Figure 3.7: FRET changes with channel activity irrespective of expression ra-
tio
(A) Relationship between the relative cFRET change (isotonic to hypotonic buffer) and
the expression ratio of A-CFP/E-YFP represented by the ratio of their measured fluo-
rescence intensities [a.u.] for 84 cells HeLa cells. (B) Normalized cFRET of a titration
of single HeLa cell expressing A-CFP/E-YFP with gradual decreasing osmolarities.(C)
Quantification of osmolarity titration experiments from 50 to 400 mOsm. In total, 68 cells
were measured for the titration curve, n = 7-21 depending on osmolarity.
Since the stoichiometry of VRACs formed by expressed subunits depends on sheer
abundance, as shown in Xenopus oocytes [80], it might influence the amplitude of
cFRET changes when the ratio of acceptors and donors is different in individual
cells. A comparison of cFRET changes upon activation and the expression ratio of
A-CFP/E-YFP of individual cells showed no correlation (Figure 3.7A), minimizing
the selection bias for cells as theoretically all cells that do express the fluorescently
tagged subunits in a detectable amount can be used for seFRET experiments. Next,
I tested whether the magnitude of activation can also be monitored with this sensor.
Indeed, cFRET reduced further, the smaller the osmolarity of the bath solution got
(Figure 3.7B). This change could be monitored in a single cell, opening possible
applications for cells with varying VRAC activity over time. The percentual decrease
of cFRET between cells was consistent and robust, with a sigmoid relation of cFRET
change and osmolarity (Figure 3.7C).
Having seen the sensitivity of the FRET sensor towards the magnitude of acti-
vation of VRACs, I next wanted to corroborate the overall applicability of it by
reproducing results of previously published electrophysiological experiments. It was
shown that the current amplitude is dependent on the cholesterol content of the
plasma membrane, with less cholesterol leading to larger currents [146]. To deplete
the plasma membrane of HeLa cells of cholesterol, I utilized methyl-β-cyclodextrin
(MbCD). The decrease of cholesterol levels was verified by staining treated and un-
treated cells with filipin, a fluorescent dye specifically binding to cholesterol (Figure
3.8A). Depletion of cholesterol did not alter the mean cFRET, but the cells showed a
significantly stronger decrease of cFRET between A-CFP/E-YFP upon hypotonic-
ity, compared to untreated cells (Figure 3.8B). This reflects a higher activity of
VRAC, ultimately leading to bigger currents, and is further proof that the FRET



































Figure 3.8: Depletion of cholesterol enhances VRAC activity
(A) Top panel: wide-field images of untreated, and MbCD treated, fixed Hela cells stained
with filipin. Scale bar, 20 µm. Bottom graph: Quantification of filipin fluorescence (n=5,
over 300 cells per condition). (B) Quantification of untreated and MbCD treated HeLa
cells expressing A-CFP/E-YFP challenged with hypotonicity (n=10 dishes with 46 cells).
The isotonic baseline is indicated by green dashed line. Data represent individual cells
(magenta diamonds) and mean ± s.e.m. Statistics: *p<0.05; **p<0.005; n.s., not signifi-
cant, Student’s t-test.
magnitude of channel activation.
Taken together cFRET of fluorescently tagged LRRC8 subunits can be used to
monitor VRAC activity in living cells. Being less invasive than voltage-clamping in
whole-cell configuration, this new technique enables tracking of VRAC activity in
new contexts.
3.2 Ionic strength changes do not activate VRACs on
endomembranes
Having FRET established as an optical sensor for VRAC activity, I next wanted to
explore the activation mechanism of these channels. The variety and seemingly con-
tradictive nature of published data concerning the activation mechanism of VRACs
encouraged the use of this new tool that hopefully circumvents biases introduced by
older methods. A study of VRACs in an artificial lipid bilayer environment could
show that these channels can be activated by iso-osmotic reduction of ionic strength
[79]. The underlying mechanism is believed to depend on electrostatic interactions
between the LRRDs of neighboring subunits in an individual channel [69–71]. Since
this would be a very elegant mechanism for VRAC activation but was only shown
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in an artificial in vitro environment, I investigated the influence of ionic strength in
living cells.
The ionic strength in living cells can be monitored with the FRET based ”RD-
sensor” [147]. It consists of CFP and YFP connected by two α-helices (Figure 3.9
A). An arginine in the one and an aspartic acid in the other helix create an electro-
static attraction which locates the two fluorophores in proximity close enough for
FRET to occur. The distance between the fluorophores relies thereby on the attrac-
tion of the charged amino acids, which are influenced by surrounding ions. More
ions, and therefore higher ionic strength, weaken the interaction between the two
helices and lead to the fluorophores moving apart and the FRET between them to
decrease. Fewer ions, on the other hand, lead to less interference of the electrostatic
attraction, moving the fluorophores closer together and therefore increase FRET.
Cells challenged by hypotonicity face a water influx created by the osmotic pressure
of their cytosolic osmolytes. With no net ion flux, the ionic strength in a swollen
cell will, therefore, decrease, which again is believed to activate VRAC. Indeed I
saw a robust decrease of ionic strength in HeLa cells expressing the RD-sensor upon
hypotonicity (Figure 3.9B). As expected, the ionic strength returns to its baseline
level when changing back to isotonic conditions. This change was homogenous over
the whole cell (Figure 3.9C). In most cells there was an accumulation of the RD-
sensor in the nucleus, making it discernable from the cytosol. With a mean FRET
ratio of 1.27 ± 0.06 the ionic strength in the nucleus of a cell is smaller compared
to the cytosol with a ratio of 1.26 ± 0.06. Nevertheless, the relative changes of the
FRET ratio upon hypotonic treatment were nearly identical, with a 7.9 % increase
in the cytosol and 7.6 % in the nucleus. Changes of ionic strength affect, therefore,
the whole cell and not only the plasma membrane. Concludingly, I tested the ac-
tivation of VRACs by hypotonicity on endomembranes since the ionic strength is
reduced there as well and should activate them if the hypothesis of ionic strength
solely activating VRACs is right. Firstly, I trapped expressed VRACs in the en-
doplasmic reticulum (ER) by application of brefeldin-A (BFA). HeLa cells treated
with BFA during transfection with fluorescently labeled VRAC subunits show clear
retention of the expressed proteins in the ER meshwork compared to the plasma
membrane localized untreated cells (Figure 3.9D). The exact mechanism and loca-
tion of VRAC formation by different subunits is not well understood. To verify
that VRACs are already assembled in the ER, I tested for the occurrence of intra-
complex FRET of A-CFP/E-YFP expressing cells treated with BFA by acceptor
photobleaching. CFP intensity of A-CFP/E-YFP complexes trapped in the ER did
increase significantly compared to unbleached cells (Figure 3.9E) leading to a mean
dFRET of 14.1 ± 8.8 %, which fits the dFRET of plasma membrane localized chan-





































































































Figure 3.9: Ionic strength reduction is not sufficient for VRAC activation in
the ER
(A) Scheme of the RD-ionic strength sensor. Increased ionic strength leads to reduced
FRET. Modified from [147]. (B) Changes of ionic strength measured in HeLa cells express-
ing the ratiometric RD sensor during hypotonic treatment. FRET intensity was divided
by Cerulean intensity and normalized to basal values, with increasing values corresponding
to decreasing ionic strength. Data represent mean of 10 cells ± s.d. (C) Ratio maps of
two representative cells in isotonic (green star in panel B) and hypotonic (magenta star
in panel B) buffer. Calibration bar left of ratio maps represents FRET/Cerulean ratios
and their respective color code in the LUT. Right: intensity profile along the white line
shown in the ratio maps. (D) Epifluorescence images of A-GFP and E-RFP in live cells
without (top row) and with (bottom row) 5 µg/ml brefeldin-A (BFA) treatment. Images
of BFA-treated cells were background-subtracted by rolling-ball algorithm (radius = 50
pixels) and contrast increased by an unsharp mask (sigma = 3, weight = 0.7). Scale bar,
20 μm. (E) Quantification of APB experiments of HeLa cells expressing A-CFP/E-YFP
or A-CFP/CD4-YFP treated with 5 µg/ml BFA. Data points (diamonds) represent the
percentual CFP intensity change of indicated subunit compositions in individuel cells. For
each subunit pair, the CFP change of bleached (black diamonds), unbleached cells (red




CFP intensity increase due to bleaching, ruling out crowding effects as the reason for
the observed dFRET of A-CFP/E-YFP complexes. So, I could show, that VRACs
are already formed by their subunits in the ER and that the ionic strength of a
cell changes over the whole cell volume upon extracellular hypotonicity. Challeng-
ing BFA-treated cells with hypotonicity did not decrease cFRET however (Figure
3.9F). During the maturation of a protein it can be post-translationally modified for
example by glycosylation. LRRC8A was shown to be glycosylated at N66 and N83
[30]. The collapse of the Golgi due to BFA treatment prohibits the modification
of glycosylations and might lead to the observed absence of cFRET change upon
hypotonicity. To rule this out I tagged a non-glycosylatable mutant of LRRC8A
(noGlyc) with CFP, having both glycosylation sites mutated to alanine [30]. Cells
co-expressing noGlyc-CFP/E-YFP showed the expected decrease of cFRET due to
hypotonic treatment, even though the glycosylation is missing on the LRRC8A sub-
units of the complexes.
VRACs trapped in the ER by BFA cannot be activated by hypotonicity, but BFA
itself does influence the signaling and overall health of cells and might, therefore,
be the reason for this inactivity. So, I next aimed to exploit the reverse dimeriza-
tion system to follow VRAC through the sectretory pathway [148]. This system
relies on the self-dimerizing domains of the FK506-binding protein (FM). These
dimerize with high affinity and lead to aggregation of fusion proteins, which are
retained in the ER. The interaction of FM domains can be substituted with the
small molecule ”D/D-solubilizer”, releasing fusion proteins out of the aggregates.
Released proteins will then travel in bulk from the ER to the Golgi complex and
finally to the plasma membrane (Figure 3.10A). First I tested a fusion protein of
green-fluorescent protein (GFP) and four FM domains (GFP-FM4), that contains
the signal sequence of human growth hormone for ER import [149]. When expressed,
GFP-FM4 is retained in the ER as clearly visible aggregates (Figure 3.12B). Upon
addition of D/D-solubilizer the aggregates disassemble and GFP-FM4 spreads over
the ER meshwork. After 53 minutes the proteins traveled to a juxtanuclear re-
gion, the Golgi apparatus. From there they were excreted to the extracellular space
within 89 minutes after D/D-solubilizer addition. The release by D/D-solubilizer
was carried out at room temperature and worked in all cells observed. To transfer
this system to VRAC I chose to fuse the FM tag to LRRC8A, being the obliga-
tory subunit and therefore contained in every channel formed. I inserted two FM
domains in the second extracellular loop of LRRC8A since other studies used this
position as well to insert for example HA-tags [30]. Expression of this construct
though led to CFP signal spread homogeneously over the ER volume, rather than
spot like aggregates as seen for GFP-FM4. The two inserted FM domains seem to
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Figure 3.10: Fluorescent fusion proteins can be tracked through the secretory
pathway by the reverse-dimerization system
(A) Scheme of the reverse-dimerization system. Proteins fused with FM tags multimer-
ize to aggregates that are retained in the ER. Upon D/D-solubilizer addition, the FM
multimers dissociate and traffick through the ER to the Golgi network and finally to the
plasma membrane. (B) A HeLa cell expressing GFP-FM4 at the indicated time points
after D/D-solubilizer addition. Scale bar, 20 µm. (C) Two HeLa cells expressing A-CFP-
FM2 and the Golgi marker protein GalNAc-T2-RFP at the indicated time points after
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Figure 3.11: Dissociated A-CFP-FM2 complexes colocalize with organelle
markers
Representative fluorescence images of HeLa cells co-expressing LRRC8A-CFP-FM2 (left,
cyan in merge) and organelle markers (middle) ER-YFP (top, yellow in merge),
GalNAcT2-RFP (middle, red in merge) and CD4-YFP (bottom, yellow in merge) at indi-
cated time points after addition of D/D solubilizer.
in the ER. So I next tried to fuse two FM domains to the C-terminus of the CFP tag
of LRRC8A (A-CFP-FM2). Expression of A-CFP-FM2 finally led to the expected
spot-like aggregates in the ER (Figure 3.10C).
Attempts to release VRACs out of the aggregates with D/D-solubilizer failed at
room temperature, with cells either dying, no change of aggregates or incubation
times of hours before release (data not shown). Incubation at 37 ◦C, however, led
to homogeneously spread A-CFP-FM2 signal in the ER meshwork after 10 minutes
and bulk travel of the channels to the Golgi after 80 minutes. 165 minutes after
addition of D/D-solubilizer channels were inserted in the plasma membrane (Figure
3.10C). To validate the subcellular localization at the respective time points I co-
expressed A-CFP-FM2 with organelle markers for ER, Golgi and plasma membrane.
Indeed, A-CFP-FM2 showed good co-localization with the respective organelle mark-
ers at the respective time points after D/D-solubilizer addition (Figure 3.11). Co-
expression of A-CFP-FM2 with E-YFP resulted in spot like aggregates as well, with
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co-localizing CFP and YFP signal (data not shown). The time course for the release
of A-CFP-FM2/E-YFP complexes was identical to that of A-CFP-FM2 homomers,
enabling the activity measurement of VRAC with FRET in different organelles. Un-
fortunately, it was not possible to measure all organelles in the same cell, since they
died either before or after the Golgi measurement. A possible reason might be the
combined cytotoxicity of the D/D-solubilizer treatment and light exposure during
seFRET measurement. So, I tested individual cells at the determined time points
after release. Again cFRET did not decrease upon hypotonicity for ER-localized
channels; neither did it for those that reached the Golgi apparatus (Figure 3.12).
As soon as VRACs were transported to the plasma membrane, cFRET did decrease
when cells were treated with hypotonic buffer, showing on the one hand the general
functionality of CFP-FM2 tagged subunits and on the other hand that the plasma
membrane localization is required for VRAC activation. However, the decrease of














0 100 200 300 400
time [s]
0 100 200 300 400
time [s]













































Figure 3.12: A-CFP/E-YFP formed channels are not activated by hypotonicity
on endomembranes
Top panels: cFRET measured in HeLa cells expressing A-CFP-FM2/E-YFP. VRACs lo-
calizing to the ER (n = 4, 10 cells), Golgi (n = 5, 26 cells) and plasma membrane (PM;
n = 5, 11 cells) were measured at 10, 80 and 165 min after addition of D/D solubilizer.
Data in time traces represent mean ± s.d. Bottom graph: average normalized cFRET in
of the first seven-time points in isotonic and last three time points in hypotonic buffer.
Data represent individual cells (ER, PM) or FOVs (Golgi) and mean ± s.e.m. Statistics:
***p<0.0005; n.s., not significant, Student’s t-test, comparing hypotonic with isotonic.
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3.3 VRAC activation by PMA can be shown with
FRET but is impeded by whole-cell voltage clamp
The established FRET sensor could already show that ionic strength is likely not
the activating stimulus of VRAC in living cells, so I next aimed at several signaling
pathways that were published to either activate or inactivate VRAC. During the last
decades, numerous workgroups published a plethora of different signaling molecules
and mechanisms that are supposed to be involved in VRAC activity, for some path-
ways having publications that claim them to be activating while others state the
opposite (reviewed in [9, 36]). Most of the acquired data suffer from the lack of
knowledge which protein family forms VRACs, thereby having no good negative
controls to discriminate detected osmolyte fluxes from other channels. Furthermore
it is now known that VRACs have different biophysical properties depending on
subunit composition and even varying activation mechanisms [30, 79, 117]. So, I
started to decipher the signaling pathway with the new subunit-specific tool.
With the reverse dimerization system, I could show that the plasma membrane
localization is needed to activate VRACs by hypotonicity in living cells. One fac-
tor present there is the actin cytoskeleton, with ambiguous data concerning VRAC
regulation [146, 150–152]. To assess the involvement of the actin cytoskeleton for
VRAC activation, I exploited the toxin latrunculin B (LatB), which prevents F-actin
assembly and leads to depolymerization of microfilaments. Treating HeLa cells for
one hour with LatB led to complete depolymerization of actin filaments (Figure
3.13A). Nevertheless did cFRET of A-CFP/E-YFP complexes decrease upon hypo-
tonicity similarly to untreated samples, ruling out a general necessity of the actin
cytoskeleton for VRAC activation (Figure 3.13B). There still might be a modulating
role of actin for VRAC activity (for many publications hint towards its involvement
in VRAC regulation, discussed in [153]), but I wanted to focus on the key regulatory
pathway.
Another potential activation pathway involves PKCs, again with publications
proposing a stimulating or inhibiting effect [134–140]. The protein kinase C family
consists of several paralogs with different tasks that they fulfill by phosphorylating
their specific substrates on a serine or threonine residue. PKCs are activated and
recruited to the plasma membrane by diacylglycerol (DAG), which is the product
of phospholipase C catalyzing the cleavage of phosphatidylinositol-4,5-bisphosphate
(PIP2) to DAG and inositol-1,4,5-triphosphate (IP3). Activation of PKCs is ex-
perimentally accomplished by the addition of phorbol esters, which serve as DAG
analogs, for example phorbol-12-myristate-13-acetate (PMA) or 1-oleoyl-2-acetyl-
sn-glycerol (OAG). First I tried to reproduce findings that suggested activation of
























Figure 3.13: VRAC activation is independent of the actin cytoskeleton
(A) Representative fluorescence images of control HeLa cells treated with 2 µM latrunculin
B (LatB) or not (untreated) that were fixed and stained with Alexa Fluor 546-phalloidin.
Image of untreated cells was deconvolved using the blind-algorithm package of LAS X.
Scale bar, 20 µm. (B) Quantification of normalized cFRET of HeLa cells expressing A-
CFP/E-YFP, treated with LatB and untreated challenged with hypotonicity (n=8 dishes
with 26 cells). Data represent individual cells (magenta diamonds) and mean ±s.e.m.
Statistics: n.s., not significant, Student’s t-test, comparing hypotonic with isotonic.
ment with this by showing decreasing cFRET upon application of OAG (data not
shown). The consecutive experiments suffered from varying quality of OAG batches,
with batches causing no cFRET change and some with a highly variable degree of
cFRET changes. So, I decided to test the effect of PMA, since both chemicals are
supposed to activate PKCs. Addition of 1 µM PMA led to a reproducible and robust
decrease of cFRET for A-CFP/A-YFP homomers and A-CFP/E-YFP heteromers
(Figure 3.14A). For homo- and heteromers cFRET decreased by up to 10 %. Cells
expressing CFP-18AA-YFP did not show any change of cFRET upon PMA addi-
tion (Figure 3.14B). I want to emphasize that VRACs formed solely by LRRC8A
subunits can be activated by PMA, hinting towards a general mechanism that might
be true for all VRACs irrespective of their subunit composition. For yet unknown
reasons, isosmotically activated VRACs were previously shown in many situations
to be closing when the bath solution is switched to hypertonic buffer [44, 154]. After
activation of A-CFP/E-YFP in HeLa cells by PMA there was no change of cFRET
when I applied 400 mOsm hypertonic buffer (data not shown), but application of 500
mOsm led to cFRET recovering to the initial value in isotonic buffer before PMA
addition (Figure 3.14C). The effect is therefore likely due to a real conformational
change of the channel subunits and not due to photophysical alterations of CFP or
YFP creating a false-positive result.
To validate that the cFRET decrease by PMA reflects the opening of VRACs
and that they conduct osmolytes, we performed patch-clamp fluorometry. Surpris-


















































































































Figure 3.14: VRACs in the plasma membrane are activated by the DAG ana-
log PMA
(A) Normalized cFRET of HeLa cells expressing A-CFP/A-YFP (11 cells), A-CFP/E-
YFP (12 cells), and HEK293 cells expressing A-CFP/A-YFP (12 cells). 1 µm PMA was
added at the time point indicated by black arrows. Data represent mean ± s.d. (B)
Normalized cFRET of HeLa cells expressing CFP-18AA-YFP (21 cells).1 µm PMA was
added at the time point indicated by black arrow. Data represent mean ± s.d. (C) Nor-
malized cFRET of HeLa cells expressing A-CFP/E-YFP (9 cells). After addition of PMA,
VRACs were inactivated with hypertonic solution (500 mOsm). Data represent mean
± s.d. (D) Quantification of a reverse-dimerization experiment in HeLa cells expressing
A-CFP-FM2/E-YFP. At 10 min (ER; n = 4 dishes with 5 cells), 80 min (Golgi; n = 5,
12 cells) or 165 min (PM; n = 5, 6 cells) after addition of D/D solubilizer, when VRACs
have reached the respective compartments, cFRET was measured before (untreated) and
after addition of 1 µM PMA. Data represent individual cells (diamonds) and mean ±
s.e.m. Statistics: *p<0.05; n.s., not significant, Student’s t-test, comparing before and
after PMA application.
decrease in the whole-cell configuration (Figure 3.15A). Patch-clamp fluorometry
experiments had to be performed in KO cells with all 5 LRRC8 genes depleted
(HEK 5x KO), as already discussed. A possible explanation for this contradiction
of activation by PMA in wildtype HEK293 and HEK 5x KO cells could be the dif-
ferent genetic background of the clonal expanded KO cell line compared to the more
heterogenous wildtype one. As well could the FRET sensor show artifacts that do
not relate to actual channel gating, but the artificial cFRET decrease should be
reproducible. I suspected rather the whole-cell configuration to impair cell signaling
and masking thereby the activating effect of PMA. In the previous experiments,
cells were dialyzed with the pipette solution for at least 10 minutes, diluting cel-
lular osmolytes including signaling molecules. Therefore, we tested the currents of
cells pre-incubated with PMA before membrane breakthrough and establishment of
whole-cell voltage clamp. With this method we measured a mean current of -406
± 306 pA in HEK 5x KO cells expressing A-CFP/E-YFP after PMA incubation,
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whereas untreated cells resulted in -148 ± 94 pA (Figure 3.15B left panel). To assess
the influence of background currents, created by measuring directly after membrane
breakthrough without time to test persisting gigaseal, we measured untransfected
HEK 5x KO cells treated with PMA as well, resulting in a mean current of -166 ± 66
pA (3.15B left panel). The measured currents showed a high variability for several
reasons. VRAC currents shown before were corrected for basal currents in isotonic
buffer by subtracting the mean current measured in isotonic buffer for all timepoints.
Furthermore, we waited after membrane breakthrough that the baseline, reflecting
stable giga seal and possible background currents, did not shift anymore. Lastly it
is a general recommendation for whole-cell voltage-clamp to wait up to five min-
utes before the measurement to dialyze the cytosol against the pipette solution, an
incubation skipped here on purpose due to it likely causing the seen false-negative
result. Besides the recording of currents at -80 mV, we recorded voltage step traces.
For untreated and PMA treated cells they showed the outward rectification and
inactivation at positive potentials characteristic for VRACs and were not present
in untransfected HEK 5x KO cells. Activation of VRAC by PMA is obvious by
the increase of currents at positive potentials. The observed current increase of A-
CFP/E-YFP channels by PMA contradicts the before acquired results in whole-cell
configuration, whereas it corroborates the predicted opening by cFRET experiments.
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Figure 3.15: Whole-cell configuration impedes PMA activation of VRACs
(A) Simultaneous measurements of whole-cell current at -80 mV (open circles) and nor-
malized cFRET values (solid circles) in A-CFP/E-YFP-expressing HEK5x KO cells with
addition of 1 µM PMA (indicated by arrow). Data represent mean of 3 cells ± s.d. Above,
representative current traces from voltage-step protocols at the depicted time points (a,
b, c).(B) Whole-cell currents at -80 mV of A-CFP/E-YFP-expressing (and untransfected
as control, n = 8 cells) HEK 5xKO cells (left) and current densities of wild-type HEK293
cells (right) with whole-cell configuration established after pre-incubation with indicated
buffers: isotonic buffer without (n = 9) or with 1 µM PMA (n = 8) (left), isotonic (n =
7) and hypotonic (n = 7) buffers without and isotonic buffer with 1 μM PMA (n = 8)
(right). Data represent individual cells (diamonds) and mean ± s.e.m. Above, represen-
tative current traces from voltage-step protocols for each condition.
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The subunits used for FRET experiments have to be tagged with a fluorescent
protein at their C-termini. Even though we and others previously [30, 80] could show
that they still conduct currents when cells are challenged by hypotonicity, the FP
tags still might influence the underlying signaling. So, we next measured endogenous
VRAC currents in wildtype HEK293 cells with the whole-cell patch after incuba-
tion method. As for A-CFP/E-YFP complexes in KO cells, endogenous VRACs of
HEK293 cells open upon PMA application and have a mean current density of -16.6
± 15.4 pA/pF compared to the current density provoked by hypotonic treatment
of -14.4 ± 10.5 pA/pF (Figure 3.15B right panel). The activation is observable in
negative, as well as positive clamp voltages compared to cells incubated in isotonic
buffer.
These experiments demonstrate the involvement of DAG in the signaling events
activating VRACs. Its analog PMA can evoke currents of A/A homomers, A/E
heteromers and of endogenous VRACs in HEK293 cells. We could also show that
the whole-cell configuration, used for decades to investigate VRAC characteristics,
can adulterate findings concerning the underlying signaling pathway.
3.4 DAG mediates activation of VRAC by PKD
rather than PKC
I could show that the DAG analog PMA activates VRACs isosmotically. PMA is a
known PKC activator [155, 156], so I next aimed at manipulating PKCs to see the
effect on VRAC activity. The PKC family consists of several members and their
physiological activation depends on the specific isozyme, with cofactors as Ca2+ for
the conventional subclass of PKCs, having in common the activation and localization
by plasma membranous DAG. I used the inhibitor Go¨6983 for its ability to affect a
broad spectrum of the PKC family, according to the suppliers, excluding only the
isoform PKCµ (better known as PKD).
Addition of Go¨6983 to HeLa cells expressing A-CFP/E-YFP led to an unexpected
increase of cFRET in isotonic and hypotonic buffers (Figure 3.16A). Since a decrease
of cFRET reflects channel opening, increasing cFRET likely resembles a deactivation
of already open VRACs. The steady increase even under isotonic conditions might
be caused by the increased basal activity seen for fluorescently labeled LRRC8 sub-
units in Xenopus oocytes [80]. Photophysical artifacts created by Go¨6983 leading
to the observed increase of cFRET can be excluded due to it not influencing cFRET
of CFP-18AA-YFP (Figure 3.16B). Furthermore, I observed the same ominous in-
crease for staurosporine and tamoxifen, drugs known to inhibit PKCs as well (data
not shown). To further investigate the effect of inhibiting PKCs on current and
44
Results

















 HEK 5x KO A-CFP/E-YFP, whole-cell patch 
FRET
0 200 400 1000 1400600 800 1200
time [s]
C





































FRET of cells in same FOV
without whole-cell patch
Iso + Gö Hypo+GöIso Hypo
0 200 400 1000 1400600 800 1200
time [s]
D














     HEK 5x KO A-CFP/E-YFP
whole-cell patch after incubation
   HEK 5x KO A-CFP/E-YFP







































































Figure 3.16: PKC signaling is dispensable for FP labeled VRAC activation by
hypotonicity
(A) Time traces (left) and quantification (right) of HeLa cells expressing A-CFP/E-YFP,
treated with 1 µM Go¨6983 and buffer switching to hypotonicity (7 cells). Left: data
represents mean ± s.d. Right: data represents mean of individual cells (squares) and
mean ± s.e.m (B) Time trace of HeLa cells expressing CFP-18AA-YFP treated with 1
µM Go¨6983. Data represent mean ± s.d. (C) Simultaneous measurements of whole-cell
currents (left) and normalized cFRET values (middle) during a buffer exchange experi-
ment with A-CFP/E-YFP-expressing HEK 5x KO cells. Isotonic and hypotonic buffers
without and with 1 µM Go¨6983, as indicated above. Right: normalized cFRET values
of an unclamped HEK 5xKO cell expressing A-CFP/E-YFP in the same FOV. Data rep-
resent mean of 3 cells ± s.d. (D) Normalized cFRET of a representative HEK 5xKO
cell expressing A-CFP/E-YFP pre-incubated with 1 µM Go¨6983 for 20 minutes and then
challenged with hypotonicity. (E) Whole-cell currents at -80 mV of HEK 5xKO cells
expressing A-CFP/E-YFP. Whole-cell configuration was established after at least 15 min-
utes incubation in isotonic (n=9), hypotonic (n=7), and hypotonic buffer containing 1 µM
Go¨6983 (n=5). Data represent individual cells (diamonds) and mean ± s.e.m.
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FRET of VRACs we performed patch-clamp fluorometry. Surprisingly, and seem-
ingly contradicting the FRET experiments, channels in Go¨6983 treated cells still
opened upon hypotonic treatment and were seemingly impaired in closing again in
isotonic buffer (Figure 3.16C). The FRET signal of patched cells again increased
after inhibitor addition, but to unexplainable high values. This effect was again
caused by the whole-cell configuration, as unpatched cells in the same field of view
showed the same FRET response as HeLa cells expressing A-CFP/E-YFP. When
switching from Go¨6983 containing isotonic medium to Go¨6983 containing hypotonic
medium there was a small decrease of cFRET detectable in unpatched cells (Figure
3.16C right panel). Differences in the perfusion system of the setups used for sole
microscopy or patch-clamp fluorometry experiments led to longer incubation times
for the latter. I suspected this time difference to be responsible for the observed
decrease in HEK 5x KO cells compared to HeLa cells. To test this we incubated
HEK 5x KO cells expressing A-CFP/E-YFP with Go¨6983 for 20 minutes before ap-
plication of hypotonic buffer and indeed those cells showed the expected decrease of
cFRET upon hypotonic treatment, concludingly the signaling is unaffected by PKC
inhibition (Figure 3.16D). The influence of whole-cell configuration seen for PMA
and Go¨6983 led to us testing the PKC inhibitor with the whole-cell after incubation
method again. Detected currents after membrane breakthrough were unaffected by
Go¨6983 compared to hypotonic pre-incubation (Figure 3.16E).
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Figure 3.17: PKC signalling is dispensable for endogenous VRACs in HEK293
and HeLa cells
Whole-cell currents of endogenous VRACs measured at -80 mV (A,B,C) (A) Representa-
tive time trace of a HEK293 cell challenged with isotonic and hypotonic buffer containing
1 µM Go¨6983.(B) Time trace of HeLa cells challenged with isotonic and hypotonic buffer
containing 1 µM Go¨6983 (n=2). Data represents mean ± s.d. (C) Time traces of HEK293
cells either untreated (left;n=2) or treated with 1 µM Go¨6983 (right;n=2) challenged with
hypotonic buffer. Pipette solution of 1 µM Go¨6983 treated cells contained as well 1 µM
Go¨6983. Data represents mean ± s.d.
Since the increasing effect of Go¨6983 on the FRET of fluorescently tagged VRACs
at short inbuation times seems to be unrelated to simultaneously recorded currents,
we validated the influence of Go¨6983 with untagged endogenous VRACs as well.
Currents of untranfected HEK293 and HeLa cells could be measured by whole-cell
voltage clamp upon hypotonicity in the presence of Go¨6983 (Figure 3.17A,B). To
rule out time-dependent inhibition of PKCs by the drug, we compared untreated and
HEK293 cells pre-incubated with Go¨6983 for 20 minutes. Current traces upon hy-
potonicity are indistinguishable between those cells (Figure 3.17C). Taken together
the broad spectrum PKC inhibitor Go¨6983 did not prevent the activation of VRACs
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formed by A-CFP/E-YFP or untagged endogenous ones upon hypotonicity, ruling
out a general necessity of PKC signaling for VRAC activation in the used model.
According to the shown data, PMA is activating VRAC via a different protein
family. Even though PMA is sold and used as a PKC activator, it is recruiting
and potentially activating every protein to the plasma membrane that contains a
C1 domain (discussed in [157], note the title: ”Eyes wide shut: protein kinase
C isozymes are not the only receptors for the phorbol ester tumor promoters.”).
This domain is an “unzipped” beta sheet that is coordinating the binding of C1-
containing proteins with DAG or its phorbol ester analogs [158]. Besides being
present in conventional and novel PKC family members, C1 domains can be found
in the protein kinase D family (PKD). There are several members of the PKD family,
namely PKD1,2 and 3. Interestingly PKD1 was initially defined as a member of the
PKC family and named PKCµ, already showing that this class of protein kinases
was confused for PKCs before. I want to emphasize that “PKCµ” is the PKC
isoform excluded by vendors to be targeted by Go¨6983. So, even though there is
some pharmacological cross-talk between PKDs and PKCs, the observed effects of
Go¨6983 are most likely only due to PKC inhibition. Since PKDs are recruited to the
plasma membrane by PMA as well, we investigated the effect of the PKD inhibitor
CRT 0066101 with patch-clamp fluorometry. After a 15 minutes pre-incubation
with CRT 0066101 the current of HEK 5x KO cells expressing A-CFP/E-YFP was
strongly reduced, and cFRET did not decrease upon hypotonicity (Figure 3.18A).
Instead, a mild increase was observed. In contrast to the strong increase caused
by Go¨6983 and the hypotonicity induced decrease of cFRET after 20 minutes of
incubation, in CRT 0066101 treated cells no cFRET decrease was observable after
this incubation time. Again, we wanted to rule out possible artificial effects of
the whole-cell configuration and compared cells with membrane breakthrough after
incubation in hypotonic buffer with or without CRT 0066101. Indeed, we could
detect reduced currents here as well (Figure 3.18B). The pharmacological evidence
hints towards VRAC activation by hypotonic induced increase of DAG levels, which
then recruits PKD.
3.5 Membrane localized VRACs are activated by
DAG but not ionic strength
With the new optical FRET sensor, I was able to show that ionic strength does not
affect VRACs on endomembranes. Furthermore, VRACs are affected by pharma-
cological manipulation of DAG and PKD signaling. To further validate that ionic
strength is not the activating factor in living cells and further strengthen the role of
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Figure 3.18: Inhibition of PKDs impairs VRAC currents and cFRET change
upon hypotonicity
Left: simultaneous measurements of whole-cell current at -80 mV (open circles) and nor-
malized cFRET values (solid circles) during buffer exchange experiment with A-CFP/E-
YFP-expressing HEK 5xKO cells, after 15 min pre-incubation with 5 µM CRT 0066101
in the presence of CRT 0066101. Data represent the mean of 5 cells ± s.d. Right: average
currents of the last five time points in hypotonicity with (data from left panel) and with-
out (data from Figure 3.7B) CRT 0066101; data represent individual cells (diamonds) and
mean ± s.e.m. (B) Whole-cell currents of HEK 5xKO cells expressing A-CFP/E-YFP
clamped at -80 mV after pre-incubation with indicated buffers: isotonic buffer (n = 9),
hypotonic buffer (n = 7), hypotonic buffer with 5 µM CRT 0066101 (n = 4) or 1 µM
Go¨6983 (n = 5). Data represent individual cells (diamonds) and mean ± s.e.m. Statistics:
*p<0.05; Student’s t-test.
DAG, I aimed at manipulating the DAG recycling after activation (scheme of under-
lying hypothesis shown in Figure 3.19). Hypotonicity leads via an unknown mech-
anism to an increase in DAG levels at the plasma membrane by activating PLCs.
There, DAG is recruiting and activating PKDs which again lead to the activation of
VRACs. Changing the medium back to isotonic conditions creates the need for cells
to reduce the concentration of the activating DAG in the plasma membrane. This
reduction is achieved by phosphorylation of DAG by DAGK, generating phosphatic
acid (PA) which cannot bind to C1-domains, ending the recruiting of PKDs.
To show that this pathway indeed controls VRAC activity in living cells, I used the
DAGK inhibitor dioctanoylglycol (DOG). HEK 5x KO cells expressing A-CFP/E-
YFP showed unaltered currents due to hypotonicity when treated with DOG com-
pared to untreated cells (not shown), but did not recover to baseline values as
did control cells (Figure 3.20B left panel). Endogenous VRACs of untransfected
HEK293 cells could be kept open in isotonic conditions after activation in the same
way (Figure 3.20B right panel). The cFRET of A-CFP/E-YFP expressing HeLa
cells did, in accordance with electrophysiology, not recover after activation when
incubated with DOG (Figure 3.20C left panel). With these experiments confirming
again the importance of DAG signaling for VRAC activity, I next looked at the ionic
strength of DOG treated HeLa cells with the RD-sensor. I could show that the ionic
strength is unaltered by DOG (Figure 3.20C right panel). It needs to be noted that













Figure 3.19: Scheme of the action of dioctanoylglycol
Scheme of persisting VRAC activity with inhibited DAGK by DOG. Top: in an untreated
cell, hypotonicity leads to DAG production that activates VRAC. Returning to isotonic
conditions stimulates DAGK to phosphorylate DAG to PA, ending the activating stimulus
for VRAC. Bottom: in DOG treated cells, DAGK is inhibited, so that after production
of DAG by hypotonicity it is not phosphorylated to PA, leading to a persisting activation
stimulus in isotonic conditions.
of PKDs [159]. The affinities of recombinant C1 twin domains towards DOG were
dependent on the PKD isozyme they were derived from. The domain of PKD3 had
the highest affinity compared to those of PKD1 (4-fold) or PKD2(8-fold). Applica-
tion of DOG in isotonic buffer led only to a mild, not significant decrease of cFRET
(Figure 3.20A). If DOG recruited involved PKD isoforms in the used conditions, I
would expect it to cause the same reduction of cFRET as did PMA. The effect of
DOG to render activated VRACs still open in isotonic conditions is therefore likely
due to it inhibiting DAGK and not recruiting e.g. PKD3. Concludingly DOG treat-
ment leads to activated VRACs at the plasma membrane under isotonic conditions
regardless of ionic strength changes evoked by osmolarity. The activation of VRACs
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Figure 3.20: DAG regulates VRAC activity rather than ionic strength
(A) Time traces of HeLa cells expressing A-CFP/E-YFP treated with DOG in isotonic
buffer. Data represent mean ± s.e.m. (B) Recovery of whole-cell currents in HEK 5x
KO cells expressing A-CFP/E-YFP (left) and wild-type HEK293 (right) at -80 mV to
basal levels after switching from extracellular hypotonicity to isotonicity in the absence or
presence of the DAG kinase inhibitor dioctanoylglycol (100 µM DOG). In HEK 5x KO,
n = 3 for untreated (from measurements in Figure 3.7B) and n = 3 for DOG-treated;
in wild-type HEK293, n = 3 for untreated and n = 4 for DOG-treated. Data represent
individual cells (diamonds) and mean ± s.e.m. (C) cFRET was measured for HeLa cells
expressing either VRACs containing A-CFP/E-YFP (left, n = 7 dishes with 9 cells) or
the RD sensor for ionic strength (right, n = 6, 23 cells) consecutively in isotonic buffer,
hypotonic buffer supplemented with 100 µM DOG and isotonic buffer with DOG. Data
represent average cFRET of the last five time points per condition of individual cells and




4.1 FRET as an optical sensor for VRAC activity in
living cells
In this thesis, I managed to establish LRRC8 subunits fluorescently tagged at their
C-termini as a FRET sensor for VRAC activity. Decades of research on ion and
osmolyte transport by VRACs created a data landscape as diverse as it is contradic-
tory and confusing. This situation was mostly caused by the missing identification
of the protein class forming VRACs, so researchers relied mostly on pharmacolog-
ical and biophysical characteristics to discriminate effects of VRACs from other
channels. Over the last years more and more of the supposed specific inhibitors
used for these pharmacological identifications were shown to affect several targets,
not seldom other channels [52, 112, 160]. The diverse nature of possible activation
mechanisms and functions of VRACs became explainable by the identification of
the LRRC8 protein family as the subunits forming VRACs. Different stoichiome-
tries of these subunits lead to channels with differing biophysical characteristics, for
example, inactivation kinetics and conducting preferences, and even different sig-
naling pathways leading to their activation [30, 43, 117]. The unawareness of the
fact that there is probably not the one VRAC but rather different VRACs depend-
ing on subunit composition and unspecificity of used drugs renders the conclusions
of existing data at least questionable. Whole-cell voltage-clamp experiments have
been the gold standard for research on VRACs, with an opening of the channel be-
ing detectable as current produced by the flow of charged species. For the subunit
dependence, electrophysiological experiments are either cumbersome in preparation,
requiring knock-out cell lines to study a specific subunit composition or suffer from
uncertainty which species is responsible for the seen effects. All this initially led to
the idea of a new method that overcomes these drawbacks of the established ones.
Monitoring the FRET between subunits with CFP and YFP tags at their C-termini
is a promising new approach.
I could show, that fluorescent proteins fused to the C-termini of LRRC8 pro-
teins are in FRET distance by acceptor photobleaching. Intracomplex-FRET could
be reliably detected using sensitized emission FRET (FRET) microscopy. Further-
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more, activation of VRACs by either hypotonicity or the DAG analog PMA led to
a significant change of cFRET. Showing a high variability in absolute cFRET val-
ues, the changes normalized to basal FRET levels were similar between cells with
varying cFRET. During the preparation of this thesis, four groups published inde-
pendently of each other cryo-EM structures of LRRC8A VRAC homomers [69–72].
Even though there is some debate concerning the overall channel symmetry (dis-
cussed in [161]), all structures have in common that the leucine-rich repeat domains
(LRRDs) are facing towards the pore axis with their C-termini. The occurrence of
FRET between fluorophores at that position is thereby in accordance with the pro-
posed position of the LRRDs by cryo-EM. FRET measurements in biological systems
only generate apparent FRET values, whereas the approximation of the distance be-
tween these fluorophores necessitates tedious calibrations and need to fulfill certain
criteria as random orientation and homogeneous distance between the fluorophores
[162]. Non-interacting donors and acceptors are problematic as well, with even more
intense work needed to estimate the fractions of each carefully [163]. The complex
nature of VRAC’s subunit stoichiometry renders it therefore impossible to estimate
the mean distance between the fluorophores at the C-termini of the subunits in the
used system. I can neither predict which fluorophores in a hexamer could interact,
creating a situation where the position of a given subunit in the hexamer and their
neighbors influences potential FRET to occur, nor is it possible to exactly determine
non-interacting LRRC8A subunits, since they can form homomers with no FRET
partner at all. The varying absolute cFRET values determined for A-CFP/E-YFP
channels underline this mentioned complexity. Accordingly, I focused on the relative
FRET changes of VRACs formed by CFP/YFP fused LRRC8 proteins and how to
exploit that, rather than concentrating on analysis of absolute cFRET values.
Of the four groups having solved the cryo-EM structure of VRAC, two groups
discussed a subpopulation of particles with an overall expanded channel architecture,
hypothesizing this to be an intermediate state to open channels [70, 72]. The LRRDs
are further apart in this subpopulation as well, increasing the distance between their
C-termini. It is tempting to hypothesize that our data is proving exactly that, with
cFRET of channels with activating stimuli applied decreasing, which could mean
that the distance between CFP and YFP is increased, whereas closing of channels
brings them back to their original distance and thereby to the same cFRET as before.
However, the FRET between fluorophores does not only rely on the distance but as
well on the orientation of their dipole moments. It is, therefore, possible that the
decreased cFRET I detected upon activation is not due to a loosening of the overall
architecture of the channel but rather an angular change of the flexible LRRDs. As
for the absolute cFRET values, the question if changes occur due to distance or
angle may be adressed in interesting future studies but are not of importance for
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the here discussed general use as an activity sensor.
I initially detected the decrease of cFRET upon channel activation by lowering
the extracellular osmolarity. I want to discuss why this indeed reflects channel gat-
ing. A major concern was that the volume change of the cells upon hypotonicity
leads to a decrease of cFRET by reducing membrane crowding. APB experiments
of cells expressing A-CFP homomers and the unrelated plasma membrane protein
CD4-YFP hinted at no occurrence of crowding effects at expression levels used in
this thesis, but do not completely rule it out. Hypotonic treatment of cells express-
ing the intra-complex FRET construct GluA2-6Y-10C did not lead to a decrease
of cFRET, even though these proteins form channels at the plasma membrane as
well and are therefore a suitable control that variations of the plasma membrane
surface caused by volume changes do not influence the FRET between proteins in
the same complex. Furthermore, I would expect a similar effect for cell shrinkage, if
there was a volume impact on FRET of LRRC8 subunits, but hypertonicity did not
increase cFRET. Another striking finding is the co-occurrence of gradual cFRET
decrease with current increase determined by patch-clamp fluorometry supporting
that cFRET changes reflect channel gating.
Application of hypotonic medium leads to a change of several variables in the cell,
for example concentration of ions and even pH fluctuations [164]. In this thesis I used
YFP as the acceptor of the FRET pair, even though it is known for its sensitivity
towards pH and halides [165]. Since VRAC conducts Cl−, this flux might quench
YFP residing at the LRRDs. For patch-clamp fluorometry I fused the brighter and
stable mutants mVenus and mCerluean3 to LRRC8A and E. Even though mVenus
is still sensitive to the named factors, it is affected to a lesser extent than native
YFP [166]. If the changes caused by hypoosmolarity would be responsible for the
cFRET decrease by effecting YFP, this should manifest itself in a smaller effect for
mVenus tagged constructs, but the cFRET decrease is indistinguishable between
YFP or mVenus paired VRACs. Lastly, I could activate VRACs isosmotically by
manipulating cellular signaling molecules in two different ways. The first is the
activation of VRACs under isotonic conditions by application of PMA, shown by
cFRET decrease and by patch-clamp experiments (discussed in section 4.5) and the
second the persisting activity of activated VRACs in isotonic medium with inhibited
recycling of DAG by DOG (discussed in section 4.3). Those experiments show
the sensitivity of the FRET sensor towards VRAC activity and not to biophysical
alterations of the fluorophores that could lead to false-positive results.
Even though the expression of different subunits varied highly between individual
cells, there was a clear trend towards a higher expression of LRRC8A compared to
LRRC8E. For aFRET being a good approximation to absolute cFRET if the donor
is in excess with no free acceptor, I chose LRRC8E to be tagged with the acceptor
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YFP for most experiments. In this case, the normalized decrease of cFRET be-
tween cells was independent of the expression ratio of A-CFP/E-YFP. This enables
an unbiased choice of cells to measure since there is no need to sort for specific
subunit ratios. In addition this shows a major advantage of the FRET sensor over
conventional methods: the specificity for subunits that are detected in potential
heterogeneous populations. For both fluorophore combinations of A/E complexes
(A-CFP/E-YFP and A-YFP/E-CFP), higher intensities in the channel detecting
LRRC8A were regularly observed. LRRC8A was, therefore, abundant at higher
levels than LRRC8E in the used conditions. Even though A-CFP is expressed at a
higher rate and will thereby form A-CFP homomers with no interacting acceptor,
they will not influence the cFRET of heteromeric channels and can be neglected.
The same is true for non-fluorescent endogenous channel populations. With the
FRET sensor, one can only detect channels that contain both A-CFP and E-YFP,
or any other tagged LRRC8 protein, and do not suffer from the influence of their
relative ratios to each other. Expecting no feedback between different subunit sto-
ichiometries, fluorescently labeled LRRC8 proteins can be readily expressed along
with endogenous species of the model system in use and still report only activity of
the specifically labeled VRACs.
Among the confusing results around VRACs is the finding that their overexpres-
sion does not lead to currents increased above wild type levels [30]. In a seeming
contradiction to that, I found that the relative decrease of cFRET upon hypotonic-
ity is not dependent on the absolute expression levels of A-CFP/E-YFP. Therefore
it seems that always the same percentage of channels open irrespective of how many
were expressed. In all experiments performed in this thesis, I found A-CFP to be
expressed at higher levels than E-YFP, even though they were cloned in the same
plasmid and are thereby under the control of the same promoter. It was shown
that overexpression of LRRC8A reduces currents of endogenous VRACs [29, 30].
Furthermore, the ratio of expressed LRRC8A to another subunit influences cur-
rent amplitude as well, with more A subunits leading to decreased currents and
less to increased ones [28]. Experiments concluding that more channels do not lead
to increased currents didn’t check for the ratio of expressed subunits. Therefore,
more VRAC heteromers may lead to increased currents, but there were only small
numbers of them in those experiments.
Another explanation could be that it is not possible to express VRACs over a
certain limit. The beforehand discussed variations of the expression ratio of A-
CFP/E-YFP are mostly due to varying A-CFP levels. Whereas 94 % of analyzed
cells had E-YFP intensities evenly distributed from 1 to 450 a.u., the same percent-
age of cells were distributed between 1 and 1400 a.u. for A-CFP. There seems to be
only a small window for E-YFP expression, hinting towards the regulation of their
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absolute levels. Cells might tightly regulate VRAC numbers post-transcriptionally,
what could explain that LRRC8 B and D are hard to express in the same cells
expressing, for example, A and E. Another possibility is that cells simply die if too
many functional VRACs reach the plasma membrane, leaving those cells for ob-
servation that have a low expression by chance. This theory is supported by high
cell death of HeLa cells with released A-CFP-FM2/E-YFP complexes that did not
occur for solely A-CFP-FM2 expressing cells. In this conditions, high numbers of
A-CFP/E-YFP channels could reach the plasma membrane that would have either
been suppressed by cellular control mechanisms or would have gone unnoticed by
me due to the cells dying when expressed without trapping the channels in the
ER. More evidence is needed to conclude what is the reason for the not increasing
current for seemingly more expressed VRACs. I can, however, see for the FRET
sensor system that in the small range of possible LRRC8E levels the percentage of
opening upon hypotonicity is not related to the overall expression. This would lead
to increased currents since more channels are open at the same time.
The FRET sensor is for the discussed reasons a reliable tool for VRAC activity.
Nevertheless, as for any method, experiments with fluorescently tagged LRRC8
proteins need the correct controls to account for possible false-negative or false-
positive results. A good example was my attempt to reproduce experiments that
investigate the effect of oxidation on different VRAC subunits [117]. It was shown
that currents of A/E complexes could be strongly potentiated by application of the
oxidative reagent chloramine-T. Pilot experiments with A-CFP/E-YFP expressing
cells seemed to confirm this by showing strongly reduced cFRET upon chloramine-T
addition (data not shown). Control experiments with the FRET constructs CFP-
18AA-YFP and GluA2-6Y-10C showed the same effect, due to YFP being sensitive
to oxidation and therefore affirm results of A-CFP/E-YFP complexes to be false-
positive. By carefully ruling out FRET changes due to photophysical alterations,
the FRET sensor can show in a sensitive and subunit-specific way the activity of
VRACs in living cells.
4.2 Possible modulation but not activation of VRAC
by ionic strength
The understanding of cellular mechanisms for volume sensing was once described as
“frustratingly incomplete” [22]. It is still under debate whether VRACs themselves
can sense volume changes by the accompanying intrinsic property alterations or if
there is a signaling cascade leading to activation of VRACs. Some researchers of the
VRAC field argue that ionic strength can directly activate VRACs, rendering them
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the sensor for volume increase by hypotonicity (reviewed in [167]). In this model
the volume increase is not sensed since it is an extensive thermodynamic parameter,
but rather the ionic strength as an intensive one. Especially experiments showing
that single VRACs in lipid droplet bilayer systems can be activated by isosmotically
lowered ionic strength hinted towards this model. On the other hand, there are
arguments against this theory, including activation of VRACs by injecting isosmotic
buffers into cells leading them to swell with unchanged ionic strength (reviewed
in [9]). In this theory, ionic strength is a modulating factor for VRAC activity,
controlling its volume set point and which osmolytes pass through.
With the new FRET sensor, I could provide evidence, that ionic strength is not
directly activating VRACs in living cells. This was shown in two different ways.
Firstly, I showed that VRACs could not be activated by reduced ionic strength
when they are trapped intracellularly. Since the ionic strength is reduced over the
whole cell volume, as shown by the RD-sensor, VRACs would be affected by that
reduction regardless of their localization. Strikingly, APB experiments hint towards
a completed channel formation in the ER, a general prerequisite for the assumption
that VRACs can be activated in the ER or Golgi. Neither did cFRET of A-CFP/E-
YFP complexes change upon hypotonicity when they were trapped in the ER by
BFA, nor in the ER or Golgi when using the reverse dimerization system. Both
methods together rule out possible negative influences of the other one, strengthen-
ing the conclusion that ionic strength does not open VRACs directly. Especially the
reverse dimerization system is a very elegant approach since it directly proves that
complexes of A-CFP-FM2/E-YFP can only be activated when they are delivered to
the plasma membrane. I hypothesize that this is due to mandatory interaction part-
ners that are localized at the plasma membrane. It could be argued that especially
in the ER the protein maturation might not be finished yet, with for example correct
glycosylation missing or still ongoing glycosylation in the Golgi. Experiments with
a non-glycosylatable mutant of LRRC8A showed that this subunit is still forming
activatable channels at the plasma membrane together with LRRC8E. The latter
subunit contains two predicted glycosylation sites as well, one in every extracellular
loop. Eventhough glycosylation of LRRC8A is not needed for activatable channels,
my data does not rule out a genral requirement for correct trimming of glycosyla-
tion of at least a subset of subunits within a complex, since noGlyc-CFP/E-YFP
complexes could still be correctly glycosylated on LRRC8E. For further validating
that the missing trimming of glycosylations in the Golgi is not the cause for com-
plexes trapped there are not activatable, studies with a non-glycosylatble mutant of
LRRC8E co-expresswed with the non-glycosylatable LRRC8A mutant are needed.
A strong argument against the interpretation that intracellular trapped channels are
not activatable by ionic strength is that there is another unknown factor in the mat-
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uration process that is only taking place directly before or at the plasma membrane,
rendering trapped VRACs insensitive to activating stimuli. Another argument is the
different lipid composition of endomembranes compared to the plasma membrane,
implying a specific composition that is needed for proper channel function (reviewed
in [168]). The reverse dimerization system opens up interesting possibilities for fu-
ture experiments, with potential interaction candidates that are believed to activate
VRACs at the plasma membrane being verifiable by their ability to activate VRACs
intracellularly as well.
The second line of evidence for ionic strength not directly activating VRACs is
the persisting activity of already activated channels with inhibited DAG recycling
in isotonic buffer. With the RD-sensor, I could show that the ionic strength re-
duction and recovery by osmolarity changes are unaffected by the DAGK inhibitor
DOG. Whereas the ionic strength decreases upon hypotonicity and increases again
in isotonic buffer, VRAC stays active after the activation. This clearly shows that
the activity is not coupled to the variations in ionic strength in a cellular context.
A seemingly striking argument against the theory that ionic strength does not
activate VRACs directly but that they rather need a plasma membrane related
co-factor is the fact that they were activatable in lipid bilayers and reconstituted
liposomes [70, 72, 79]. I was also reported that VRAC currents could be evoked
in not swollen cells with reduced intracellular ionic strength [115, 169]. All of the
mentioned experiments have in common that there was an immense change of ionic
strength necessary to evoke currents (reviewed in [9]). So even though it is possible
to open VRACs without a cellular signaling context, the conditions needed for that
are not comparable to physiological ones. The fact that VRACs in artificial lipid lay-
ers without co-factors can produce currents when the ionic strength is highly reduced
could be explained in several ways. The solved structures of LRRC8A homomers
led to the hypothesis that there might be interactions between charged amino acids
in the LRRDs of the subunits within one complex and that this interaction is trans-
mitting the ionic strength of the cytosol to the rest of the channel [69–71]. The
overall stability of proteins is highly affected by the properties of the surrounding
medium, for example, the ion content [170]. A drastic change of the ionic strength
might impair the natural flexibility of the LRRDs by supporting the named interac-
tions between the LRRDs of neighboring subunits, leading to a steric conformation
that reflects the open state under natural conditions. This steric rearrangement
could potentially be similar to that initiated by physiological interaction partners or
modifications of LRRC8 proteins in vivo upon activation, which concludingly might
involve fixation of the LRRDs in a defined position.
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4.3 Combining old and new- Revisiting signaling of
VRAC activation with the FRET sensor
A plethora of different signaling pathways and molecules have been proposed to be
involved in VRAC activation over the last decades (reviewed in [9, 36, 82]). With the
new FRET sensor, I revisited old hypotheses and explored from there the underlying
signaling of VRAC for A/E complexes in HeLa and HEK293 cells. I could show that
VRAC is activated by plasma membranous DAG, which leads to PKD activation
and ultimately to the opening of VRACs. This can be brought into accordance with
existing old data, forming a promising hypothesis for VRAC activation.
Apart from other suspected roles for VRAC in vivo, it does play a role in RVD
[29, 30]. This process takes place when cells swell due to an osmotic pressure-
driven water influx, caused by either an extracellular reduction of osmolarity or an
intracellular increase. It is unknown how cells determine their volume to react ac-
cordingly, but influences of macromolecular crowding, the concentration of ions and
mechanochemical alterations of the plasma membrane are involved in different ways
(excessively reviewed in [8]). Which of those lead to activation of VRAC though is
a matter of debate until today. I could show in this work that VRACs can be acti-
vated isosmotically by the DAG analog PMA. Isosmotic activation was observed for
heteromers formed by A-CFP/E-YFP, but as well for homomers of A-CFP/A-YFP.
The role of DAG for VRAC activation is further strengthened by the observation
that manipulation of DAGK affected VRAC under isotonic conditions when they
were activated by hypotonicity before. Especially the activation of A-CFP/A-YFP
homomers hints towards a general role of DAG, since at least the A subunit of
every heteromeric complex would probably be affected as well. The DAG depen-
dent activation mechanism proposed in this thesis can explain old data sets and
is confirmed by others. Production of DAG in living cells is usually accomplished
by the phosphoinositide pathway. Here, the phospholipid phosphatidylinositol 4,5-
bisphosphate (PIP2) is hydrolyzed by activated phospholipase C (PLC) to inositol
1,4,5-triphosphate (IP3) and diacylglycerol (DAG). Both products of the PLC re-
action then further act as second messengers. It was shown that membrane stretch,
which is a result of cell swelling, leads to PLC activation via an unknown mechanism
[171–174]. VRACs are known to be insensitive to membrane stretch, so they are
not the volume sensitive entity in respect of membrane stretch. Nevertheless, in
ventricular cells, it could be shown as well that membrane stretch leads to a Cl−
current with VRAC characteristics [175]. Inhibition of PLC by a specific inhibitor,
on the other hand, led to reduced currents in hypotonic buffer [140]. Concordantly
to increased PLC activity, stretch and hypotonicity were shown to lead to increased
cellular IP3 levels, eventhough the DAG levels were not measured directly their in-
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crease by the shown PLC activity appears logic [176]. The role of PLC is, therefore,
a verified part of VRAC activation by hypotonicity and it is safe to assume that
the DAG, which I show to be the next downstream partner in VRAC activation,
is produced by this enzyme class. DAG levels are in this scheme coupled to cell
swelling by indirect activation of PLC by membrane stretch.
Many experimental findings that suggest a regulative influence of compounds
or messenger molecules can be linked to this part of the activation mechanism
of VRACs. One example is the activation of VRACs by reactive oxygen species
[44, 117, 177, 178]. ROS were shown to activate PLCs in different tissues and cells
[179–182]. Further on it was shown that hypotonicity leads to elevated ROS pro-
duction in various cell types [183–185]. A fascinating finding was that PLC prefer-
entially hydrolyzes oxidized lipids [181]. Consequently, existing data points towards
the production of ROS by hypotonicity, which then activate PLCs to hydrolyze fi-
nally PIP2 and leading to the activation of VRACs. So how can one explain the
seemingly contradictory finding that A/C and A/D heteromers are inhibited by ox-
idation, whereas A/E heteromers are potentiated [117]? Two possible scenarios can
be concluded from my data and the existing ones. Firstly, A/E and A/A complexes
are controlled by the here proposed signaling pathway of DAG activating PKD but
A/C and A/D are activated differently. Since I did not test the activation of, e.g.,
A/D complexes by PMA, I cannot rule out that a different pathway controls them.
So, the ROS supported action of PLC by hypotonicity would only lead to VRACs
opening that contain A and E subunits. It is necessary to emphasize that it is not
known how channels composed of more than two different subunits are regulated
by oxidation, even though they are believed to be physiologically relevant [35, 80].
Secondly, and which I believe to be more likely, are all different stoichiometries of
VRAC activatable by PLC mediated DAG activation of PKD. The elegant sorting
mechanism of cells to decide which VRAC population, dependent on subunit stoi-
chiometry, is activated would then be a feedback of the upstream activation stimuli.
ROS, for example, could be produced by cells due to hypotonicity and would, if
the same stimulus activates PLC, theoretically lead to activation of all VRACs, ir-
respective of their subunit composition. The initially upstream signaling event of
ROS would now influence the downstream decision of which channel composition
is needed, by impairing currents of A/C and A/D channels [117], leaving A/E and
potentially A/B heteromers to be opened. In both cases, it would be mysterious,
how currents can be measured of either A/D or A/C expressing cells deficient in all
five LRRC8 genes when they are challenged with hypotonic medium [30]. Since hy-
potonicity leads to increased ROS levels, one could have expected low or no currents
due to the inhibiting effect of ROS on A/D and A/C channels. Only A/D rescue ex-
periments led to decreased maximum currents compared to wildtype, whereas A/C
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currents were unaltered [30]. As discussed in section 4.6, more work in consistent
cell models are needed to fully understand the subunit dependence of the activation
mechanism in this and various other respects.
Apart from the PLC family, the protein class of G-proteins can be brought into
accordance with DAG mediated VRAC activation. Several groups found evidence
for an involvement of this group of proteins for VRAC activation [131, 186–188]. The
group of G-proteins contains the heterotrimeric and the small monomeric G-protein
families. These are divided into different subclasses, with for example a plethora
of different α subunits for heterotrimeric G-proteins (reviewed in [189]). As diverse
as the nature of G-proteins is the data concerning their involvement in VRAC acti-
vation. It is tempting to hypothesize a possible role of G-proteins for VRAC since
for example G(q/11)-coupled receptors are believed to be sensors for mechanical
membrane stretch und would therefore logically appeal as upstream activators of
VRAC [190, 191]. Especially since they were shown to lead to PLC activation (re-
viewed in [192]). Another hint at a possible role for G-proteins in VRAC activation
is that they were shown to be involved in organic osmolyte flux upon hypotonicity
[193]. Since alone the PLC-β family comprises four isozymes that are differently
regulated by the Gq family, that again comprises several members, the exact mesh-
work which isozyme acts when is beyond the scope of the discussion of this thesis.
Physiological activation of PLC isozymes by G-proteins is likely to be even more
complex, suggested by the fact that there is some evidence that not heterotrimeric
G-proteins activate VRAC, but rather the small GTPase Rho, which again activates
the PLC- subgroup [187, 188, 192]. Activation of VRAC was also reported by S1P
[194]. S1P can activate a group of G-protein coupled receptors, the sphingosine-
1-phosphate signaling-receptor (S1PR) family (reviewed in [195]). Of the S1PR
family, the members S1PR2,3 and 4 were shown to activate PLCs, again converging
at the here proposed signaling pathway. Nevertheless, Burow et al. [194] proposed
S1PR1 to be responsible for VRAC mediated ATP release in RAW macrophages.
This family member was shown to be coupled to the α subunit Gi that activates the
tyrosine kinase Src, which again can activate PLC [196]. If the discrepancies which
G-protein exactly activates VRAC between different publications is due to technical
limitations of used methods or due to different cell models will hopefully be shown
in future work. The FRET sensor presented here enables this new, subunit-specific
measurement of VRAC activity and opens new possibilities to revisit older experi-
ments concerning the role of G-proteins in VRAC activation (as discussed in section
4.6).
The activation of PLC by several means striving towards VRAC is thereby backed
up with numerous pieces of evidence, supporting the here presented hypothesis that
VRAC activation is carried by the second messenger DAG. Excitingly, I can report
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here for the first time, to my knowledge, that in relation to VRAC activation DAG
is not the upstream signal for PKC, but rather for the PKD family. Using the broad
spectrum PKD inhibitor CRT 0066101, I could show that both the currents and
the FRET change are impaired upon PKD inhibition. The PKD family consists of
the three members PDK1, PKD2, and PKD3. When PKD1 was discovered, it was
firstly confused for another PKC isoform since it shares a homologous C1 domain
with them [197]. Shortly after their discovery, the catalytic domain of PKD1 was
found to share a higher homology with the Ca2+/calmodulin-dependent protein ki-
nase (CAMK) group than with the PKA, PKG and PKC group and were therefore
classified as an own kinase family [198] (reviewed in [199]). As for PKCs, the ac-
tivation of PKD involves the binding towards plasma membranous DAG by their
C1-domain. This binding is believed to unfold the catalytic domain, rendering two
serine residues available for phosphorylation that is carried out by PKCs, that are
recruited to the plasma membrane as well. The phosphorylation by PKCs is not a
general necessity though, and the complete activation mechanism is not understood
yet [200]. A new idea is that PKDs contain a self-dimerizing ubiquitin-like domain
at their N-termini, leading to autophosphorylation of the catalytic domains by DAG
bound and dimerized PKDs at the plasma membrane [201]. Being fully activated,
PKDs than phosphorylate their substrates either on the plasma membrane or disso-
ciate from DAG to further operate in the cytosol. I discussed already the interwoven
findings towards stimuli detected upon hypotonicity and PLC activation, intrigu-
ingly for most of them exists data that they lead to PKD activation as well. A good
example is activation of PKDs by ROS [202–204]. Especially the studies by Waldron
et al. [202, 203] hint towards a potential meshwork of mechanisms around VRAC
activation by DAG mediated PKD recruitment. They could show that treatment of
different cells with H2O2 lead to autophosphorylation of essential serine residues and
phosphorylation of the added PKD substrate syntide-2. This was mediated via PLC
and Src, the latter kinase already mentioned in the potential activation of VRACs
by S1P signaling and the S1PR1, which lead to PLC stimulation by Src through Gi.
It was shown that ROS triggers S1PR1 sensitization and enhances S1P signaling
in bovine aortic endothelial cells, pointing towards a potential mechanism of ROS
mediated VRAC activation involving S1PR1 ultimately leading to PLC activation
and PKD recruitment by the PLC product DAG [205]. The Src-mediated PKD
activation relies on PKCs phosphorylating essential PKD serine residues. Conclud-
ingly if this is indeed a potential activation mechanism for VRACs, it is not the one
underlying VRAC activation by hypotonicity in HeLa and HEK293 cells. This is
demonstrated very clearly by a study using the same PKC inhibitor Go¨6983, result-
ing in abolished PKD activation by ROS [202], that I used in this thesis to show
unaltered currents and FRET reduction upon hypotonicity. If this is due to cell
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type-specific signaling pathways or different activation pathways for specific subunit
compositions fulfilling diverse tasks remains to be shown.
As discussed in section 4.5, the role of PKCs for VRAC activation in the used
system of HeLa and HEK293 cells is not fully clear, but they are dispensable for
general activation of VRACs by hypotonicity. The activation of PKD without up-
stream PKC is supported by the mentioned new theory of self-dimerizing and trans-
autophosphorylating DAG bound PKDs [201]. Further on, it was shown that PKDs
can be activated in a PKC-independent manner, by the Gq family member Gα q
by GPCR signaling [206]. There are thousands of different GPCRs, which again
can bind to several isoforms of α, β and γ subunits (reviewed in [189]). I already
discussed the potential role of Gα q as a subunit known to be bound to GPCRs sus-
pected to sense mechanical deformation of the plasma membrane [190, 191]. Just
like VRACs, these G-proteins are ubiquitously expressed and would, therefore, be
available as a fundamental activation pathway. Together with the findings that those
lead to PLC and ultimately to PKC-independent PKD activation, which was shown
by me to activate VRAC, this might be a worth path to test for VRAC activation.
A very recent finding of our group now impressively links my finding of PKD acti-
vating VRACs to a before known physiological role of both. Chen et al. [207] could
show that knock-down or inhibition of VRACs leads to impaired mouse myoblast
differentiation. An earlier study already presented the same effect with knocked
down PKD2 [208]. For the here presented data, it seems possible that impaired
differentiation of mouse myoblasts by PKD2 knock-down is caused by the missing
activation of VRACs at early stages of differentiation. The PKD2 isoform was ac-
tivatable by S1P [208], again strengthening the here made assumptions of a role for
S1PRs in VRAC activation through PKD. Nevertheless, did the same study show a
role for PKCs, with the absence of PKD2 activation by application of Go¨6983 [208].
As before, future experiments will show if the PKC dependency is linked to PKD
phosphorylation in a pathway-dependent manner.
Having discussed multiple ways leading to the DAG-PKD mediated activation of
VRACs, I want to shorty discuss as well the found mechanism of deactivation by
DAGK. I demonstrated that VRACs could be rendered active in isotonic conditions
after hypotonic treatment by application of the DAGK inhibitor DOG. Recovery
to basal levels after switching from hypotonic to isotonic buffer was impaired for
currents measured by whole-cell patch-clamp for A-CFP/E-YFP and endogenous
VRACs in HEK293 cells and FRET in HeLa cells. Thereby I could show that the
conversion of DAG, which recruits PKD to the plasma membrane, by DAGK to PA
is likely a deactivating mechanism for osmolarity change-induced VRAC opening.
As for the other above-mentioned enzymes, there exist several isoforms of DAGK,
with different stimuli leading to their activation and needed cofactors (reviewed
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in [209]). Some of the isoforms are expressed in a tissue-specific manner, whereas
others, e.g. DAGKα and ζ, were found in all examined tissues [209]. So, as for
the activation, the deactivation of VRACs by consumption of DAG could adapt to
various stimuli and tasks by different DAGK isoforms. It is known, that VRACs
can be deactivated by application of extracellular hypertonicity [44, 154]. This
phenomenon was until now, if at all, explainable with the theory that ionic strength
directly activates VRACs by influencing their LRRDs. Supposed that lowered ionic
strength leads to a steric rearrangement that opens the channel, increased ionic
strength should then theoretically close it again. Now it is possible to explain this
with molecular signaling, by hypertonicity leading to activation of DAGK which
removes the activating stimuli DAG. Indeed could be shown for DAGKη that this
isoform is recruited to the plasma membrane by hyperosmolarity [210]. It will be
interesting to see, whether distinct DAGK isoforms serve as off switches for VRACs,
depending on the specific task and tissue.
4.4 LRRC8 proteins as potential PKD targets
The identification of PKDs as an essential part of the signaling leading to VRAC
activation naturally leads to the question of the substrate of this group of kinases.
Apart from known signaling cascades, that could further regulate VRAC localiza-
tion, expression, and sensitivity, the LRRC8 family forming VRACs could poten-
tially be directly phosphorylated by PKDs. It is still under debate whether or not
phosphorylation events are generally needed for VRAC activation (reviewed in [9]).
Nevertheless, LRRC8 A,B,C, and D were found in phospho-proteome screens with
only LRRC8 E having neither a predicted nor a shown phosphorylation accord-
ing to Uniprot [211–215]. Strikingly, all these sites are located in Il1 (see Figure
4.1). Il1 could be shown to have a crucial role for trafficking and probably activa-
tion as well, by chimeras of LRRC8A IL1 with D,C and E [216]. The chimeras of
D, C, and E with A IL1 were transported to the plasma membrane as homomers
[216], whereas native homomers apart from LRRC8A formed ones are known to be
stuck in the ER [30]. Different lengths of the IL1 domain inserted, showed that
only LRRC8C chimeras containing two residues of LRRC8A that were identified in
phospho-proteome screens, T200 and S202, trafficed to the plasma membrane and
conducted currents comparable to A/C heteromers. If this effect is due to phospho-
rylation or, e.g. protein-protein interactions at that loop remains to be shown.
Threonine 200 and Serine 202 of LRRC8A might, therefore, play a crucial role by
being phosphorylated, but they do not have a PKD consensus sequence. Comparing
found substrates of PKD1 and 2, the consensus sequence for these kinases turned































































Figure 4.1: Conservation of PKD motifs in the LRRC8 family
Upper left corner: PKD consensus motif. Rest: Schematic representation of LRRC8 sub-
units. Position numbers of amino acids refer to their position in human LRRC8 variants.
Phosphorylation sites found in phosphoproteome screens (underlined in green) and PKD
motifs (underlined in magenta) are indicated below each structure scheme with the re-
spective amino acid and its position shown (one-letter code). Right of every structure
scheme are the consensus histograms of all found PKD motifs of that subunit. Black bars
represent percentual conservation of that position in the sequence, magenta bars behind
black bars represent 100 % conservation . Size of letters reflects their percentual occur-
rence. The number of species analyzed per subunit was: A 34, B 29, C 31,D 27, and E 25
depending on identification of these genes in the chosen species. S217 of LRRC8A is the
only residue having a PKD motif, and that was found in phosphoproteome screens.
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consensus sequence found for PKD3, due to low numbers of known substrates. I used
the web-tool ScanProsite to search all five human LRRC8 members for the consensus
sequence of PKD1 and 2 [219]. Indeed there are serine and threonine residues
within PKD motifs in all five LRRC8 proteins (Figure 4.1). Interestingly, most of
them are located in the LRRD of the respective protein. Combining this possibility
with the hypothesis of ionic strength, that was thought to alter attraction forces
between neighboring subunits, it is tempting to hypothesize that phosphorylation of
neighboring subunits could lead to the same effect. Apart from the LRRD localized
consensus sequences, serine 217 of LRRC8A has the PKD motif as well. This amino
acid did not only show up in general phospho-proteome screens [211, 212, 215],
but it was also detected in a PKD1 specific screen in HEK293 cells [220]. I want to
emphasize, that even though chimeras of LRRC8C with parts of IL1 of LRRC8A not
containing S217 were transported to the plasma membrane and conducted ions, only
the homomeric C-IL1 chimera with a long stretch of IL1 containing S217 produced
currents larger than heteromeric A/C complexes [216].
The PKD motif is rather short and variable and could thereby be found by chance,
with ScanProsite predicting to find it in ”100 000 proteins around 138 000 times”. A
good way to further strengthen or weaken the possible role of the found amino acids
as phosphorylatable residues is to determine their conservation between different
species. Especially since I want to identify potential residues that are phosphory-
lated to activate VRACs. Potential regulative phosphorylations might evolve dif-
ferently between species, but crucial ones for activation usually do not. I compared
LRRC8A-E from up to 34 species, throughout the subphylum of vertebrates (see
Material and Methods for details), to determine the conservation of the potential
phosphorylation sites found by ScanProsite (Figure 4.1). Of all analyzed motifs,
only two are perfectly conserved in all inspected species, being S217 in LRRC8A
and S661 in LRRC8C (note that the only mutation in LRRC8A S217 is a homolo-
gous S217 to T217 in Felis catus). Combining the facts that LRRC8A S217 already
showed up in a PKD1 phospho-proteome screen, its inclusion in chimeras leading
to higher peak currents and the high conservation between various species renders
this residue a good potential candidate for future mutagenesis experiments to val-
idate its role in activation by phosphorylation by PKD (see section 4.6). Another
well-conserved PKD motif is at S239 in LRRC8D, with the serine and lysine or
arginine at position -3 being conserved in all species an only leucine at position -5
missing in 7 % of them. This residue again is in the IL1, so regardless of several mo-
tifs found in human LRRC8 LRRDs, they are not well conserved and are therefore
probably not involved in activation by PKD mediated phosphorylation. If there is a
dependency on phosphorylation, A/E complexes might be an interesting tool, since
LRRC8E has neither been identified in phospho-proteome screens nor could I find a
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conserved PKD motif. Activation by phosphorylation would thereby rely solely on
LRRC8A, assuming no other controlling mechanisms of LRRC8E.
Direct phosphorylation of VRACs for activation is a comprehensible model since
various other channels have been shown to be activated or deactivated by direct phos-
phorylation or dephosphorylation (reviewed in [221–223]). Several voltage-gated
sodium channels,e.g., are phosphorylated at their intracellular loops for activation
and deactivation [221]. Another example of a Cl− channel being regulated by phos-
phorylation is the cystic fibrosis transmembrane conductance regulator (CFTR)
channel (reviewed in [224]). CFTR has a regulatory domain (being formed by a
long intracellular loop) that is phosphorylated several times in order to activate the
channel [225, 226]. It will be exciting to see wether future work shows VRACs to
be part of this group of channels regulated by direct phosphorylation.
4.5 The whole-cell voltage-clamp bias and the
mysterious role of PKC
A striking finding of this thesis was the bias introduced by whole-cell voltage-clamp
configuration regarding VRAC activation by the phorbol ester PMA. Neither could
currents nor FRET changes be detected upon PMA addition with established whole-
cell configuration. Only by measuring the currents of cells incubated prior to es-
tablished whole-cell configuration with PMA a increase of ion flux compared to
untreated cells could be detected. After gigaseal formation, the plasma membrane
of a patched cell is ruptured by, e.g. strong suction, to access the cytosol and dialyze
it with the pipette solution. This enables tight control of variables per experiment,
by either adding or omitting compounds to the pipette solution and thereby the
cytosol. As well is the ion content of the cell under the control of the experimenter,
which allows for the investigation of the influence of specific ions to the overall
population of a certain channel type in a cell. The drawback of this method is cre-
ated by its advantage at the same time: the dilution of cytosolic contents. Cytosolic
molecules can be diluted this way by factors of thousands to millions, with published
methods trying to minimize this effect [227]. Dialysis of the cytosol can happen in
seconds to minutes, depending on cell size and pipette diameter [228, 229]. A dra-
matic dilution of signaling molecules can, but does not necessarily have to, impair
the signaling pathway containing this molecule. Since the whole cytosolic content
is diluted with the whole-cell configuration, all signaling pathways are influenced to
a not predictable extent this way. In the scenario presented by me in this thesis,
the activation of VRAC by recruiting PKDs to the plasma membrane by PMA was
completely abolished by the whole-cell configuration. Without the FRET sensor,
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one could have concluded that C1-domain-containing proteins are not involved in
the activation of VRACs. Exactly that has already happened in a publication, stat-
ing that VRAC is activated in a PKC independent manner by measuring currents
in the whole-cell configuration with added PMA [140]. As mentioned above, PMA
is often confused (and advertised by suppliers) as a pure PKC activator. Interest-
ingly, another phorbol ester, recruiting C1-domain-containing proteins to the plasma
membrane [230], OAG did evoke currents under isotonic conditions and established
whole-cell configuration [140]. This leads to the question whether OAG and PMA,
apart from recruiting C1-domain-containing proteins, have different secondary ef-
fects that bring about the activation of VRAC with whole-cell configuration for one
but not the other compound. A mere concentration-dependent effect is comprehen-
sible as well, with OAG being used with a concentration of 100 µM, whereas PMA
was used by Zholos et al. with 100 nM [140]. It is not predictable which compounds,
and experiments suffer from the same false-negative (and potentially false-positive
as well) effect of the whole-cell configuration, and I could clearly show its influence
for at least PMA and Go¨6983. Therefore, all performed experiments of the past
utilizing this method need to be revisited to rule out biases potentially beyond the
effects for those two drugs.
That establishing the whole-cell configuration abolishes the activating effect of
PMA on VRAC observed by FRET can be easily explained by the dilution of crucial
factors for the DAG-PKD signaling pathway. A less clear situation is found for the
PKC inhibitor Go¨6983. FRET of unpatched cells increased upon Go¨6983 addition.
An initial hypothesis was that this rise is due to the closing of channels constitutively
opened by being fluorescently tagged at their C-termini, as was shown in Xenopus
oocytes [80]. Longer incubation with Go¨6983 though led to an overall increased
cFRET value that nevertheless was similarly reduced upon hypotonicity to untreated
cells. Further on could we detect channel opening as current flow regardless of
Go¨6983 treatment. Since the baseline current in isotonic buffer was not decreased
upon Go¨6983 addition, the rise is not due to closing of opened channels. A general
photophysical alteration as seen for chloramine-T (discussed in section 4.1), leading
to this increase of cFRET, can be excluded by unaffected other FRET constructs, as
CFP-18AA-YFP. The effect is, therefore, VRAC specific and not related to channel
gating. Whereas the increase in unpatched cells was of an explainable degree, with
more acceptor and donor pairs in a more efficient orientation and distance, the
increase of cells in the whole-cell configuration was altered again in comparison to
unpatched cells, by being magnitudes higher. The dilution of the cytosol thereby
enhances the effect of Go¨6983, that leads to increased cFRET. In my experiments, I
sacrificed spatial resolution for temporal resolution and sensitivity, rendering visual
inspection of cells treated with Go¨6983 to no avail. It might be enlightening to see
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whether the PKC inhibitor leads to an altered distribution of VRACs at the plasma
membrane that could result in clustering and therefore increased crowding FRET.
I could show that VRAC still conducts ions by electrophysiology and that A-
CFP/E-YFP complexes show reduced cFRET independent of Go¨6983 treatment.
Concludingly PKCs are dispensable for VRAC activation in HeLa and HEK293
cells by hypotonicity for at least this VRAC subunit combination. Still, several
publications state a role of PKCs for VRAC activation. Unfortunately, they suffer
from several potential sources of error. For example, some used the PKC inhibitor
Go¨6976, which was shown to inhibit PKDs as well [134, 135, 195]. Others used
phorbol esters, for example phorbol 12,13-dibutyrate (PDBu) or the already dis-
cussed OAG to claim an activating effect of PKCs on VRAC, even though PKDs
are affected by the same compounds [140, 231]. So apart from the discussed bias
introduced by the whole-cell configuration, that leads to the conclusion that PKC
does not activate VRAC since PMA is unable to evoke currents, a general speci-
ficity problem of pharmacological approaches further complicates the interpretation
of old data sets. I want to emphasize the part of the work of Hermoso et al. [135]
that went beyond a drug-based approach since they also used HeLa cells and are
thereby easier to compare to my experiments than the plethora of data gathered in
various other model systems. They created stable HeLa cell lines expressing kinase-
dead variants of PKCα and ζ and compared their volume decrease after hypotonic
swelling [135]. Indeed did the cell line with the kinase-dead PKCα show impaired
RVD compared to control cells. Besides noting that the effect of Go¨6976 was higher
than that of kinase-dead PKCα, there are several explanations for this discovery
in compliance with my data. On the one hand, it would be plausible that subunit
composition influences the activation mechanism. HeLa cells were shown to express
LRRC8D to several magnitudes higher extend than LRRC8E [232]. The impairment
of hypotonicity induced cFRET change and current by inhibited PKDs, presented
in this thesis, was shown for A-CFP/E-YFP complexes. With wildtype HeLa cells
expressing LRRC8D most, the reduced RVD for HeLa cells lacking a functional
PKCα could be due to VRACs containing the D subunits to be either directly ac-
tivated by PKCs or rely on PKD variants that require phosphorylation by PKCs
to be active. On the other hand it is known that long-term changes of one PKC
isozyme level can lead to an accumulation of other isozymes of this family [233].
Intervening in the phospho-proteome homeostasis of cells may, therefore, cause up-
and downregulation of signaling pathways in general, that ultimately interfere with
VRAC activation, but do not necessarily suggest a causal role of PKCα.
Another layer of complexity, apart from functional diversity derived from subunit
stoichiometries, is added by the fact that VRACs do not only conduct ions (with
chloride being the most prominent). They were shown to conduct other organic os-
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molytes as well, as excitatory amino acids and taurine in a subunit dependent man-
ner. In rat astrocytes, it was shown, that PDBu affects potential VRAC mediated
aspartate release, but not swelling-activated chloride currents [231]. Concludingly
there might be different pathways for varying channel compositions or conducted
species. I can therefore not rule out a role for PKCs in some of the possible combi-
nations of species, tissue, subunit composition, and activating stimuli. Nevertheless,
the presented data of A/E and A/A channels, activated in HeLa and HEK293 cells
by the supposed DAG-PKD signaling pathway due to hypotonicity, creates a frame-
work for future understanding of more complex and defined models and the potential
involvement of PKCs in them.
4.6 Perspective and conclusion
The FRET sensor approach to detect VRAC activity is a very versatile tool, enabling
fascinating new experiments that were not possible before and can complement the
established field of electrophysiology and labeled osmolyte flux experiments. Since
one of the biggest advantages of my FRET method is the subunit specificity, it will be
of worth to label and test all other LRRC8 subunits together with LRRC8A. First pi-
lot experiments performed by me with A-CFP/D-YFP complexes were very promis-
ing, with A-CFP/D-YFP formed VRACs showing the same drop as A-CFP/A-YFP
and A-CFP/E-YFP ones (data not shown). For yet unknown reasons, LRRC8D is
hardly expressed in HeLa, and other, cells [30]. This led me to firstly concentrate
on LRRC8E for this thesis, nevertheless, expressing cells can be found and this is-
sue should be addressed in the future. All combinations of A and another LRRC8
paralog are known to conduct current upon activation by hypotonicity. I expect
therefore to see the same FRET drop as seen for A/A, A/D and A/E for the other
combinations as well in HeLa cells. The repetition of here shown experiments with
Go¨6983, PMA and CRT 0066101 could than answer, if all subunit combinations are
indeed controlled by the same signaling pathway in HeLa cells, or if for example,
A/D complexes are activated by PKC instead. If the same mechanism controls all
subunits, there is likely a stimulus and cell type dependence for VRAC activation.
The FRET sensor could then be used in the discussed rat astrocytes (see section
4.5) to test again for general or subunit dependent activation pathways.
Another major advantage of the FRET sensor is its ability to monitor VRAC
activity in living cells over a long period of time. I measured FRET in cells for up
to four hours (data not shown), and in this time frame FRET was stable over the
whole period of measurement, and I expect no big differences in longer experiments,
provided that there is no substantial change of VRAC activity. The aforementioned
results of our group that VRAC is necessary for myogenic differentiation could be
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further verified and narrowed down to the exact time point of VRAC engagement
in differentiation with the FRET sensor. For this and all other cells to be exam-
ined for VRAC functions, one could consider a knock-in approach as well. As a
start, subunits should be labeled with CFP and YFP that were shown to be highly
expressed in that type of cell. Later experiments could then focus on the other re-
maining subunits as well, highlighting again that the FRET sensor will always only
report the activity of channels containing the labeled subunits without interfering
with the others. Genetic engineering of endogenous LRRC8 proteins would lead to a
less artificial accumulation of specific subunits created by transient transfection but
might make high detection sensitivity of the camera in use necessary. Furthermore,
potential artifacts created by the increased activity of fluorescently labeled LRRC8
subunits in stable knock-in cell lines need to be explored.
As discussed for the varying effect of oxidation on A/C, A/D and A/E heteromers,
it is not known how channels formed by more than two subunits would combine the
effects seen for only two subunits containing channels. This question is hard to
address with classical methods, so again, the FRET sensor might be a useful tool
to answer it. With LRRC8A being the obligatory subunit for VRACs, expression of
LRRC8A together with two other subunits labeled with either CFP or YFP would
lead to channels that would only show FRET if all three subunits are combined in
one single channel. Without LRRC8A, potential VRACs formed by the other two
could not reach the plasma membrane [30]. Channels containing only A and either
the CFP or YFP labeled subunit would not contribute to FRET and are neglectable.
Detection of FRET would only be possible from channels containing all three sub-
units, enabling specific assessment of the activity of this complex class of VRACs.
If this approach is feasible, another step might be the establishment of a three-color
FRET system. These comprise two donors and an acceptor, with the excitation and
emission spectra of donor one and donor two matching for FRET to occur, so that
finally donor two can excite the acceptor as well [234, 235]. The seemingly close ori-
entation of the LRRDs in a single VRAC tempt me to think that a three-component
FRET cascade could work here. An exemplary fluorophore combination that was
shown to be efficiently transferring energy two the last acceptor, given a correct
protein orientation, is Turquiose2, YPet and Cherry [236]. Expressing unlabeled
LRRC8A together with three other subunits labeled with these fluorescent proteins
could enable detection of channels composed specifically by these four subunits. If
three color-FRET works with transiently transfected cells, this would enable the
exciting possibility to generate knock-in cells with three different subunits, apart
from LRRC8A, labeled with e.g. Turquiose2, YPet and Cherry to monitor nearly
all possible channel compositions. This approach would require a lot of work and
sophisticated imaging hardware, but I do believe that the potential laying in cell
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lines with trackable VRACs justifies that.
In section 4.4, I discussed LRRC8 proteins as potential targets of PKDs. Consider-
ing the troubling side effects of used drugs by me and others concerning PKC,PKD,
and DAG signaling, all results relying solely on pharmacological data have to be
verified more thoroughly to be certain about signaling pathways involved. The here
proposed PKD dependency of VRAC activation falls into this as well and should
be considered as a hint for future experiments. Especially considering the existence
of at least three different PKD isoforms with yet an only beginning understanding
of mechanisms of action and targets. As discussed, stable knock-down or knock-
out of PKC can have severe side effects, mimicking a direct involvement of PKCs,
whereas their absence impeded proper phospho-proteome homeostasis. Neverthe-
less, it would be a good first step to see if HeLa cells lacking specific PKD isozymes
still show the characteristic cFRET reduction upon hypotonicity. The next step
proposed by me could be the usage of the affinity-directed protein missile system
(AdPROM) [237, 238]. Cloning of AdPROM into an inducible vector system re-
sulted in a reduction of target proteins already after two hours and a clear depletion
after six hours of induction [237]. This time frame is crucially shorter than knock-
out approaches and commonly used knock-down ones using siRNA, the first taking
weeks to produce stable cell lines and the latter at least 24 hours up to 48 hours
[239]. Protein depletion in two to four hours would be a vast improvement in time
the cells suffer from depleted PKD signaling before assessing the influence of them
on VRAC activation.
Another future approach should address the discussed direct phosphorylation of
LRRC8 subunits by PKDs, complementing the aforementioned methods. The most
promising potential PKD target is S217 in LRRC8A (see section 4.4). Mutating this
residue to alanine would then result in a loss-of-function mutation if it is needed for
activation. Since the FRET sensor method can detect activation of VRAC homomers
solely formed by LRRC8A subunits, compared to the very little if at all detectable
currents in electrophysiology, a LRRC8AS217A mutant tagged with either CFP or
YFP and following co-expression could be readily tested in HeLa cells. Challenging
LRRC8AS217A-CFP/LRRC8AS217A-YFP expressing cells with hypotonicity will then
reveal if VRACs lacking this motif are still active. Since LRRC8E has no conserved
PKD motifs, nor was it ever detected in a phosphor-proteome screen, the next choice
would logically be to co-express AS217A-CFP/E-YFP and test again for activation
by cell swelling. If the hetero- and homomers are still activatable one could consider
mutating S553 in LRRC8A together with S217, since this residue is a likely candidate
as well. Successful silencing of channel activity by substitution of serine to alanine
could then be further verified by the typical mutation of the phosphorylatable residue
to glutamic acid or aspartic acid, which in some cases can mimic phosphoserines.
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If the discussed residues are phosphorylated to activate VRACs, mutation of them
to glutamic or aspartic acid could render the channel constitutively open. Here a
drawback of the FRET sensor can be seen, since until now it is only able to detect
channel activity as a relative change from a before measured baseline cFRET value.
Constitutively open channels can thereby not be distinguished from closed ones since
the internal reference of the closed state is missing. But if these channels would be
shown with electrophysiology to be constitutively opened, a FRET analysis still
would be of benefit. Until now it is not sure, whether opening of a channel leads
to the FPs at the LRRDs to move completely out of FRET distance or just into a
position with less efficient FRET. In the first case, overall detected cFRET would
be a mixture of closed channels still producing cFRET and opened channels not
contributing to this value anymore. Constitutively open channels should then lead to
very low or now cFRET at all. In the second case I expect a mildly reduced cFRET
over the cell population. This knowledge might prove useful for understanding the
structure-function relationship of VRACs and its detection by FRET.
To further investigate the potential phosphorylation of LRRC8 proteins by PKDs
I propose to perform peptide spot arrays of all paralogs, incubated with the different
recombinant PKD isozymes. Thereby either primary structure motifs that are in-
volved in interactions with PKDs or even phosphorylated residues, by incubation of
recombinant PKDs with radioactively labeled ATP, of the respective LRRC8 protein
family member could be revealed. Newfound motifs could then be further analyzed
by mutagenesis and conservation analysis.
All of the discussed future experiments deal with the downstream events after
PLC mediated DAG production. It is still not known how cells sense their volume
or accompanying intrinsic changes, especially since I could show that ionic strength,
which was a likely explanation for VRAC activation by cell swelling, is not directly
activating VRACs. So even more work needs to be done to identify the mechanisms
upstream of PLC activation. I already discussed many hints, that could be dealt with
in section 4.3. Emphasis should be paid towards G-proteins, especially G-protein
coupled receptors, as this diverse group of plasma membrane proteins prominently
converged in one or the other way on PLC and therefore possibly VRAC. A summary
of the potential activating and deactivating stimuli concluded from my data and
previously published ones is illustrated in figure 4.2
In conclusion, I managed to establish a useful new tool for exploring VRAC
activation mechanisms and its functions in living cells and organisms. The here
shown system did work robustly and reproducible with A/A homomers and A/E
heteromers. I am confident that the other subunits will prove as promising as the
already tested combinations did. Furthermore, I was able to directly show, combin-



















Figure 4.2: Hypothetical scheme of VRAC activation
Illustrated is the combination of published regulations (thin arrows) and regulating path-
ways shown in this thesis (fat arrows). Involved molecules are G-protein coupled receptors
(GPCR), reactive oxygen species (ROS), phospolipase C (PLC), phosphatidylinositol 4,5-
bisphosphate (PIP2), diacylglycerol (DAG), protein kinase D (PKD), phosphatic acid
(PA), and diacylglycerol kinase (DAGK). Activating effects are marked with a plus sign
and deactivating effects with a minus sign. The color of plus and minus refers to the
osmolarity which triggers the pathway (green for hypertonic, magenta for hypotonic). Hy-
potonicity leads to the stimulation of PLC by several potential pathways including GPCRs
and ROS. PLC hydrolyzes PIP2 to DAG (and IP3, the role of which in VRAC regulation
is unclear) which recruits and activates PKD. PKD acts either on VRACs themselves or
on different proteins leading to the opening of VRACs. Switching the extracellular solu-
tion from a hypotonic to a isotonic buffer (which is therefore hypertonic compared to the
hypotonic buffer) stimulates DAGK, which is then converting DAG to PA. This ends the
recruitment and stimulation of PKD and leads to the deactivation of VRACs.
strength is not directly activating VRACs in living cells and. Rather is DAG medi-
ated PKD activation a key regulator for A/E heteromers and it will be exciting to
see if this holds true for other subunit combinations as well. My work suggests that
the localization in the plasma membrane is needed for VRAC activation, following
investigations could, therefore, aim at the identification of the plasma membrane
specific co-factors leading to VRAC activation. The here presented work provides
completely new ways of accessing VRACs role in living cells that have not been
possible to this extent until now.
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5 Materials and Methods
5.1 Materials
Chemicals
All chemicals used in this thesis were purchased from Sigma-Aldrich, Merck or Roth,
if not stated otherwise.
Cell lines
Table 5.1: Cell lines
Name Source/Reference Additional information
HeLa RRID: CVCL 0030 Obtained from Leibniz
Forschungsinstitut DSMZ
HEK293 RRID: CVCL 0045 Obtained from Leibniz-
Forschungsinstitut DSMZ
HEK 5x KO [35] (PMID:28193731) Gift from T.J. Jentsch












Table 5.3: Drugs and chemicals
Name Supplier Product number
Brefeldin-A (BFA) Sigma-Aldrich B5936
D/D-solubilizer Clontech,TaKaRa 635054
Latrunculin B (LatB) Sigma-Aldrich 428020
Alexa Fluor 546-
phalloidin









CRT 0066101 Tocris,Bio-Techne 4975/10
Dioctanoylglycol (DOG) Tocris, Bio-Techne 0484
Identifiers of LRRC8 homologs
Table 5.4: UniProt IDs of LRRC8 subunits from different species used for homology
analysis
UniProt IDs
Species LRRC8A LRRC8B LRRC8C LRRC8D LRRC8E
Xenopus lae-
vis
Q6NU09 A0A1L8GMZ1 A0A1L8GMY5 A0A1L8GMW1 Q6NU09
Ornithorhynchus
anatinus
F7E9Z4 F7E7Y7 F6QUQ7 - -
Gopherus
agassizii
A0A452IMR6 - - A0A452IF87 -
Monodelphis
domestica
F7F2H1 F7G4V3 F7G4Z3 - F7CGX2
Myotis lucifu-
gus
G1PHG5 G1PZP4 G1PKY6 G1Q2B8 G1PNC3
Bos taurus A5PK13 E1BDX2 A5PK13 A4IFE5 F6PRJ0
Ovis aries W5PH89 W5Q1V8 W5Q1X3 W5PKY0 W5NY27
Eschrichtius
robustus
A0A2F0AUK3 A0A2F0BNQ8 A0A2F0BJ07 - A0A2F0B4N3
Dasypus
novemcinctus
C1FXV0 - - - -
Loxodonta
africana
G3TL97 G5E711 G3T1R0 G3TTR1 G3TW15
Rattus
norvegicus





Species LRRC8A LRRC8B LRRC8C LRRC8D LRRC8E
Mus musculus Q80WG5 Q5DU41 Q8R502 Q8BGR2 Q66JT1
Erinaceus eu-
ropaeus
A0A1S2ZZQ4 A0A1S3WDC4 A0A1S2ZUF3 A0A1S2ZUF7 A0A1S3ACI3
Homo sapiens Q8IWT6 Q6P9F7 Q8TDW0 Q7L1W4 Q6NSJ5
Equus cabal-
lus
F7BJ71 A0A3Q2H0I2 F7BE34 F6Z951 F7C6Z4
Felis catus M3W4V0 A0A337SKR1 M3X422 M3X2H7 M3WLN1
Iconisemion
striatum
A0A1A7X3D9 - - - A0A1A7YMV4
Danio rerio E9QIH3 - E7F333 Q08BM6 -
Salmo salar A0A1S3M3U0 A0A1S3KLJ4 A0A1S3L6H5 C0H928 -
Canis lupus
familiaris
E2RQD5 E2R9Z8 E2R9Z9 E2RA00 E2RNX3
Sus scrofa F1RR61 A0A287B5M3 F1S4E4 A0A286ZWM5 F1SA81
Anolis caroli-
nensis
H9G7Z5 G1KZ23 G1K985 G1KUQ0 G1KJG8
Ailuropoda
melanoleuca
D2H153 D2HJK7 D2HJK8 D2HJK9 D2HI92
Cavia porcel-
lus
H0V2C2 H0V7N0 A0A286XG73 H0VC12 H0V1Y0
Taeniopygia
guttata




I3LZR5 - I3MF01 I3M5K2 I3NB98
Chlorocebus
sabaeus
A0A0D9RPP4 A0A0D9S6T1 A0A0D9S6T0 A0A0D9SAE9 A0A0D9R756
Ficedula albi-
collis
U3JFD0 U3JG25 U3JG26 U3KKM5 -
Mustela puto-
rius furo
M3YNJ3 M3Y036 M3Y030 M3Y018 M3Y9F8
Pan paniscus A0A2R9CN78 A0A2R8ZS38 A0A2R9B1I8 - A0A2R9BKS4
Macaca mu-
latta
F7E1A8 A0A1D5QGF5 F7HLE0 F6TCH4 F7GRN6
Meleagris gal-
lopavo
G1MZK8 G1N8Q7 G1N8Q4 G1NR00 -
Mandrillus
leucophaeus
A0A2K5YFP4 A0A2K5YLW9 A0A2K5Y2I2 - A0A2K6A9Q8
Pongo abelii A0A2J8UJR0 H2N6T9 H2N6T8 A0A2J8R3A9 A0A2J8RD66
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Buffers for imaging and patch-clamping
All imaging buffers were prepared with sterile filtered stock solutions. Isotonic
imaging buffer (340 mOsm) contained (in mM): 150 NaCl, 6 KCl, 1 MgCl2, 1.5
CaCl2, 10 glucose,10 HEPES, pH 7.4 (adjusted with NaOH). For osmolarity titration
experiments, the concentration of NaCl was adjusted to (in mM): 105 (250 mOsm),
80 (200 mOsm), 55 (150 mOsm), 30 (100 mOsm), and 5 (50 mOsm). The buffer
with 250 mOsm was the standard hypotonic buffer used in all other experiments.
Hypertonic buffers were as isotonic buffer supplemented with 60 mM (for 400 mOsm)
or 160 mM (for 500 mOsm) mannitol.
Patch-clamp experiments were performed with an isotonic bath solution (320
mOsm) containing (in mM): 150 NaCl, 6 KCl, 1 MgCl2, 1.5 CaCl2, 10 glucose, and
10 HEPES, pH 7.4 (adjusted with NaOH). The pipette solution (290 mOsm), against
which the cytosol is dialyzed, contained (in mM):40 CsCl, 100 Cs-methanesulfonate,
1 MgCl2, 1.9 CaCl2, 5 EGTA, 4 Na2ATP, and 10 HEPES, pH 7.2 (adjusted with
CsOH). After preparation, the pipette solution was stored at -20 ◦C, and was thawed
and kept in ice for usage. Hypotonic bath solution (240 mOsm) contained (in mM):
105 NaCl, 6 CsCl, 1 MgCl2, 1.5 CaCl2, 10 glucose, 10 HEPES, pH 7.4 (adjusted
with NaOH). All solutions for patch-clamp experiments were sterile filtered after
preparation and their osmolarities were measured with a vapor pressure osmometer
(VAPRO 5600, Elitech).
Throughout this thesis, isotonic/hypotonic imaging buffer and isotonic/hypotonic





Name Source/Reference Additional informa-
tion
LRRC8A-GFP (A-GFP) [30] (PMID: 24790029) Gift from T.J. Jentsch
(MDC and FMP, Berlin,
Germany)






This thesis LRRC8A-coding se-
quence subcloned from
AN66A,N83A-GFP ([30];
gift from T.J. Jentsch,





LRRC8A-YFP (A-YFP) This thesis
LRRC8E-CFP (E-CFP) This thesis
LRRC8E-YFP (E-YFP) This thesis
LRRC8E-Venus (E-YFP) This thesis
LRRC8E-RFP (E-RFP) This thesis
CFP-18AA-YFP [145] (PMCID:
PMC2706461)
Gift from C.F. Kamin-
ski (University of Cam-
bridge, UK)
GluA2-6Y-10C [144] (PMID:27313205)
ionic strength sensor (RD
sensor)
[147] (PMID: 28853549) Gift from B. Poolman
and A.J. Boersma (Uni-
versity of Groningen, The
Netherlands)






Cell culture media and solutions
Table 5.6: Cell culture media and solutions












FuGENE 6 Promega E2691
Opti-MEM Gibco 31985070
5.2 Methods
5.2.1 Bacterial transformation and cloning
Heat-shock transformation and plasmid purification
Plasmids were transformed in chemically competent DH5α cells with a maximal
total mass of 100 ng in 1-5 µl. Bacteria aliquots were thawed on ice before usage
for 15 minutes. After addition of plasmids, DNA-bacteria mixtures were incubated
for 30 minutes on ice. Heat shock was performed by incubation of bacteria at
42 ◦C for 45 seconds, and a following incubation for two minutes on ice. Then
one ml of pre-warmed LB medium was added, and cells incubated for one hour at
37 ◦C before plating on either ampicillin or kanamycin containing LB-agar plates.
Grown colonies were picked and incubated in LB medium before DNA purification
(NucleoSpin Plasmid QuickPure, Macherey-Nagel). To control for the correct insert
sequence, plasmids were Sanger-sequenced (Microsynth Seqlab GmbH).
Cloning of CFP,YFP, and RFP fusion constructs
The coding sequences of human LRRC8A, LRRC8AN66A,N83A and LRRC8E were ex-
cised from LRRC8A-GFP, LRRC8AN66A,N83A-GFP, and LRRC8E-GFP constructs
[30] by a double digest with EcoRI and KpnI (New England Biolabs). The vectors
pECFP-N1 and pEYFP-N1 were digested as well with EcoRI and KpnI. Vector back-
bones and inserts were gel-purified (NucleoSpin Gel and PCR clean-up, Macherey
Nagel) after separation in a TAE based agarose gel prepared from UltraPure agarose
(Invitrogen). Purified inserts were ligated with vector backbones at a ratio of 3:1
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with T4-Ligase (New England Biolabs) for 10 minutes at room temperature. FRET
constructs had 12 amino acid long linker (LVPRARDPPVAT for LRRC8A and
AN66A,N83A, and WVPRARDPPVAT for LRRC8E) between the respective LRRC8
protein and the fluorescent protein.
CD4-YFP was created from CD4-GFP [240] by excising the coding sequence of
CD4 with EcoRI and SalI and cloning it into pEYFP-N3 using the same enzymes.
For expression of GalNAcT2-RFP, the stalk region of N-acetylgalactosaminyltransferase
2 (GalNAcT2) was subcloned from pGalNAcT2-GFP [241] into pmRFP-N1. Purifi-
cation and ligation were performed as described above.
The generation of A-CFP-FM2 was done by inserting the restriction sites for XbaI-
EcoRV-SpeI with the Q5 mutagenesis kit (New England Biolabs) 3’ of the above
described A-CFP construct. Mutagenesis was performed with Q58A forward and
Q58A reverse primers (see table 5.2) and the PCR program shown below according
to the suppliers manual. Two fused FM domains [148] were excised with XbaI and
SpeI and cloned into the restricted sites of the mutagenesis product. Purification
and ligation were performed as described above.





98 30 sec 1
98 10 sec
69 20 sec 25
72 3 min 30 sec
72 2 min 1
Cloning of mCerulean3 and Venus constructs
To replace CFP and YFP in LRRC8X-XFP expression constructs by its improved
derivatives mCerulean3 and Venus [242, 243], coding sequences of mCerluean3 and
Venus were amplified from the GluA2-6Y-10C construct (see table 5.5) using GFP
forward and GFP reverse primers (see table 5.2) and the PCR program shown
below. PCR amplicons had 5’ AgeI and 3’ NotI restriction sites inserted. CFP or
YFP were excised from LRRC8X-XFP expression constructs with AgeI and NotI
to be replaced by either mCerluean3 or Venus amplicons digested with the same
enzymes. Purification and ligation were performed as described above.
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98 30 sec 1
98 15 sec
69 30 sec 25
72 1 min
72 7 min 1
5.2.2 Cell culture
Cells used in this thesis (see table 5.1) were cultured in DMEM supplemented with
10 % FBS at 37 ◦C in 5 % CO2 and humidified air. For subcultures and transfection
cells were detached using Accutase according to the suppliers manual. Cells were
subcultured before reaching 80 % confluency and seeded at 30 %. Transfection
with plasmids (see table 5.5) was performed using FuGENE 6 according to the
suppliers manual. For microscopy and patch-clamp experiments, cells were seeded
in 35mm glass-bottom dishes (MatTek) or on 20 mm glass coverslips, coated with
poly-L-lysine 0.01 % solution (Sigma-Aldrich) for HEK293 and HEK 5x KO cells.
Plasmids were transfected at equimolar ratios. Cells were measured 24-48 hours
post-transfection.
5.2.3 Drug treatment
Drugs stored at -20 ◦C were allowed to reach room temperature for 20 minutes
before solvation. All here described drugs are listed in table 5.3. To trap expressed
proteins in the ER, 5 µg/ml BFA (pre-solved solution, 10 mg/ml) was added to
the transfection mix containing culture medium. Depolymerization of the actin
cytoskeleton was achieved by the addition of 2 µM LatB (dissolved in DMSO) to
the culture medium and 1 hour incubation at 37 ◦C in 5 % CO2. Depletion of the
cholesterol content of the plasma membrane was done by addition of 5 mM MbCD
(dissolved in DMEM by stirring for 30 min at room temperature and following
sterile filtration) to the culture medium and incubation for 1 hour at 37 ◦C in 5
% CO2.The following drugs were applied at the respective concentration at time
points indicated in Results: 1 µM PMA (dissolved in DMSO), 5 µM CRT 0066101
(dissolved in H2O), and 100 µM DOG (dissolved in DMSO).
5.2.4 FRET measurements
Acceptor photobleaching and seFRET experiments were performed on a high-speed
setup from Leica microsystems (Dmi6000B stage, 63x/1.4 oil objective, high-speed
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external Leica filter wheels with Leica FRET set filters (11522073), EL6000 light
source, DFC360 FX camera, controlled by Las AF). All experiments were performed
at room temperature.
Acceptor photobleaching
Cells were searched and focused using maximum gain and low illumination intensity
to avoid pre-bleaching of fluorophores. FOVs were chosen that contained two or more
cells sufficiently separated for one subset of cells being included in the illumination
path of the almost closed field diaphragm, whereas the other cells were outside
of the illumination path. The intensity of CFP and YFP was measured using the
respective excitation and emission filters before and after bleaching steps. Bleaching
was performed by closing the field diaphragm to only illuminate part of the cells in
the FOV with the Leica filter cube N2.1 (excitation 515-560 nm) for 2.5-5 minutes
per bleaching step. YFP intensity was monitored in Las AF after every step, and
cells were bleached until YFP intensity decreased below 10 % of its value before
bleaching. Evaluation of APB was done using FIJI [244] by measuring the intensity
of CFP and YFP in bleached and unbleached cells in hand-drawn regions of interest
(ROI).
seFRET
The cells were washed three times with isotonic buffer before the experiments. The
sensitized emission of FRET constructs was assessed by measuring in short succes-
sion the CFP channel (IDD), the YFP channel (IAA), and the FRET channel (IDA).
Images were acquired every 10 seconds or 20 seconds for VRACs released with the
reverse dimerization system to further minimize bleaching. Acquisition parameters
were constant for all channels (100ms exposure, gain 1, illumination intensity 2)
for correction factors to be constant as well. Spatial resolution was sacrificed for
temporal resolution and sensitivity by 8x8 binning. Out of the three acquired chan-
nels, cFRET maps were calculated with the PixFRET plugin [245] according to the
following equation [246]
cFRET =
IDA − IDD · β − IAA · γ
IAA
With β being the correction factor for donor bleed through and γ the correction
factor for acceptor cross excitation. Correction factors were determined with cells
expressing either only donor (A-CFP or cytosolic CFP) or only acceptor (A-YFP
or cytosolic YFP) constructs by the acquisition of IDD and IDA for donor only and
IAA and IDA for acceptor only samples. Calculation of correction factors was done
according to the fraction of intensity detected in IDA to absolute detected intensity
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IDD or IAA (β = I
DA
IDD
and γ = I
DA
IAA
). The mean of correction factors determined
on three different days of at least five samples per day was used for all performed
experiments (β = 0.614 and γ = 0.097).
Images were processed in PixFRET using a gaussian blur of 2 and threshold of
1. Since PixFRET does only process stacks of a single timepoint, a macro was
programmed that ordered stacks according to the input demands of PixFRET and
calculated automatically cFRET maps for all time points of an experiment. All cells
were evaluated that did show membrane-localized signals in all three channels with
hand-drawn ROIs. To minimize selection biases, high-intensity regions of cells, that
by morphology were channels residing in the Golgi, were only spared from ROIs if
they were oversaturated in one of the three channels. Measured absolute cFRET
values were normalized to the mean cFRET of the first timepoints in an experiment
in isotonic buffer.
Ratiometric FRET
The ionic strength in cells was measured using the FRET RD-sensor (see table 5.5).
Since acceptor and donor have a fixed stoichiometry in that sensor, the ratio of
IDA
IDD
is a reliable measure of the strength of occurring FRET. Therefore, images of
IDA and IDD channels were acquired every 10 seconds of RD-sensor expressing cells.
Images were subtracted of background and every pixel of the IDA image divided by
the respective pixel in the IDD channel to create a ratio map. Ratios were measured
from hand drawn ROIs and normalized to isotonic values of that individual cell
to account for ionic strength variations between cells and inhomogeneties in the
detection.
Patch-clamp fluorometry
For patch-clamp fluorometry experiments, either FRET and currents of A-CFP/E-
YFP expressing HEK 5x KO or of endogenous VRACs in HEK293 or HeLa cells
were measured. Thin wall borosilicate capillaries (Warner instruments, Hamden,
USA) were pulled on the P1000 micropipette puller (Sutter Instruments) and pol-
ished using a heat filament. Pulled pipettes had a resistance of 3-5 MΩ after filling
with the intracellular solution. Pipettes were spanned in an ISO-type holder (G23
Instruments) for minimized drifting. Experiments were performed on an Olympus
IX81 stage, equipped with a 40x/0.6 Olympus objective, and a Prime 95B CMOS
camera (Photometrics). Excitation of CFP and YFP was achieved by 445 and
514 nm diode lasers (iChrome MLE, Toptica Photonics) coupled to the stage via a
manual TIRF input. Laser angles were adjusted to pass the objective parallel to
the optical path for epifluorescence detection. Filter cubes in the turret contained
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only dichroic mirrors for either CFP or YFP. Emission light was split by a Cairn
OptoSplit-II, equipped with a T495Ipxr dichroic mirror and emission filters for CFP
(Em: 470/24) and YFP (Em: 520/40) and detected simultaneously on the same
camera chip.
The monitoring of sealing and capacitance correction was performed with an Ax-
opatch200B amplifier. Currents of cells were recorded using Axograph X (Axograph
Scientific) and an Instrutech ITC-18 D-A interface (HEKA Elektronik). For patch-
clamp fluorometric experiments, cells were chosen that where isolated from other
cells (to avoid chemical cross-talk via tight-junction channels) and expressed all flu-
orescent fusion proteins to a detectable degree. After the successful establishment
of the whole-cell configuration, cells were held at -30 mV. The protocol for a patch-
clamp fluorometry experiment consisted of 9 cycles with 500 ms steps to -80 mV
every 12 seconds. Cycle 10 consisted of a voltage step protocol, holding the potential
for 300 ms at -40, 0, 40, 80, and 100 mV in turn. This protocol was repeated for
the duration of the experiment. Before each voltage step to -80 mV, the emission of
CFP and YFP was simultaneously detected after sequential excitation with either
the 445 or 514 nm laser (exposure 100 ms, 2x2 binning).
Currents were analyzed with Axograph X. Outward flow of chloride was measured
at -80 mV, subtracted from basal currents at the holding potential, and currents at
-80 mV in isotonic buffer. Voltage-steps were recorded for monitoring if measured
currents were due to VRACs, by testing them for outward rectification and inacti-
vation at positive potentials. Fluorescence images were split into stacks matching
the input requirements for PixFRET and were treated as described above.
5.2.5 Reverse dimerization system
Cells expressing the GFP-FM4 construct were measured 24-48 h after transfection
using the Leica L5 filter cube (Ex: 480/40, DC: 505, Em: 527/30). Before imaging,
cells were washed three times with isotonic buffer and imaged in isotonic buffer.
After the acquisition of images before D/D-solubilizer addition, 500 nM of D/D-
solubilizer were added to the isotonic buffer and images acquired every 1-5 minutes
at room temperature.
To A-CFP-FM2 or A-CFP-FM2/E-YFP expressing cells the 500 nM D/D-solubilizer
was added directly to the growth medium and cells incubated at 37 ◦C and 5 % CO2.
Exemplary pictures of A-CFP-FM2 aggregates were acquired before D/D-solubilizer
addition. To perform a buffer switch experiment with VRACs localized in the re-
spective organelles, dishes were washed and imaged in D/D-solubilizer containing
isotonic buffer precisely 10 minutes after D/D-solubilizer addition for ER, after 80
minutes for Golgi, and after 165 minutes for plasma membrane (PM) measurements.
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FRET measurements were performed with the first cell showing colocalizing signals
in the CFP and YFP channel in the respective organelle (determined by visual in-
spection) as described above. For ER and PM localized complexes, cFRET was
measured with hand-drawn ROIs in the cFRET map. To measure cFRET of com-
plexes in the Golgi, a mask was generated with the CFP channel that was used
on the cFRET map. The mask was thresholded to contain only the high-intensity
juxtanuclear regions of all cells in the FOV. Cells showing signal at the plasma
membrane were excluded from the mask.
5.2.6 Qualitative and quantitative microscopy
Imaging of intracellular localization, organelle markers, actin cytoskeleton, and
cholesterol content was performed on a Leica Dmi8 (63x/1.4 oil objective, 20x/0.7
dry objective, EL6000 light source, Hamamatsu OcraFlash4.0 camera, controlled by
LasX). All experiments were performed at room temperature. Cholesterol content
determination was performed using the 20x/0.7 objective. All other images were
acquired using the 63x/1.4 oil objective. Coverslips were cleaned by sonication for
15 minutes in 70 % before sterilization and cell seeding.
Intracellular localization of A-GFP/E-RFP
HeLa cells treated and untreated with BFA, expressing A-GFP/E-RFP were grown
on glass-bottom dishes. For imaging, cells were washed three times with PBS and
imaged in isotonic buffer. Acquisition of A-GFP signals was performed using the
GFP filter cube (Ex: 480/40, DC: 505, Em:527/30) and E-RFP using the rhodamine
filter cube (Ex: 540/23, DC: 580, Em: 590 LP). Images were processed with FIJI.
For better visualization of the ER meshwork, images of BFA treated cells were
background-subtracted using a rolling ball algorithm (radius = 50 pixels), and the
contrast was enhanced by an unsharp mask (sigma = 3, weight = 0.7).
Co-localization of A-CFP-FM2 with organelle markers
HeLa cells were cotransfected with A-CFP-FM2 and either ER-YFP (ER), GalNAc-
T2-RFP (Golgi), or CD4-YFP (PM) on coverslips (5 mm diameter). 24 h after
transfection, aggregates were released with D/D-solubilizer for 10 (ER), 80 (Golgi),
or 165 minutes (PM). Cells were fixed after these times by washing three times with
PBS, fixation with 4 % paraformaldehyde (PFA) for 15 minutes at room temper-
ature, washing three times with PBS, neutralization with DMEM containing 10 %
FBS at 37 ◦C for 10 minutes and final washing three times with PBS before air
drying and mounting using Fluoromount-G (Southern Biotech). A-CFP-FM2 was
imaged using a CFP filter cube (Ex: 436/20, DC: 455, Em: 480/40) together with
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a YFP filter cube (Ex: 500/20, DC:515, Em: 535/30) for ER-YFP and CD4-YFP,
and a rhodamine filter cube for GalNAc-T2-RFP.
Actin cytoskeleton
To stain the actin cytoskeleton, HeLa cells treated and untreated with LatB were
PFA fixed as described above. After the final wash with PBS, cells were perme-
abilized with 0.1 % Triton-X100 in PBS containing 1 % BSA for 5 minutes, before
staining with Alexa Fluor 546-phalloidin (Thermo Fisher Scientific) diluted 1:1000
in PBS containing 1 % BSA for 1 h at room temperature. After staining, cells
were washed three times with PBS before mounting as described above. Cells were
imaged with a rhodamine filter cube. Images of untreated cells were deconvolved
using the blind algorithm of LasX with 15 iterations.
Cholesterol content determination
For determination of the cholesterol content of the plasma membrane, cells treated
and untreated with MbCD were fixed as described above. After the final wash with
PBS, cells were stained with 125 µg/ml filipin (dissolved in DMSO, diluted in PBS)
for 45 minutes at room temperature, before washing three times with PBS. Images
were acquired directly after staining using a DAPI filter cube (Ex: 360/40, DC:
400, Em: 425 LP). Images were segmented into signal and background by manual
thresholding and mean intensities of all cells in one FOV in the treshhold measured
as a data point.
5.2.7 Homology analysis of PKD motifs in LRRC8 proteins
To study the conservation of potential PKD motifs, I used the consensus motif
of PKD1 and 2 L/V/I-X-R/K-X-X-S/T [217, 218]. This motif was searched in
all human LRRC8 paralogs with the web-tool ScanProsite [219]. To test for the
conservation of these motifs in the vertebrate subphylum, 34 entries of LRRC8A
of different species were collected (summary of UniProt identifiers for all subunits
and species in table 5.4). The other paralog sequences were searched for that set
of species as well. Sequences of LRRC8 family members of all species were aligned
using Clustal Omega [247]. Alignments created with Clustal Omega were analyzed
using Jalview 2 [248] and conservation histograms for the predicted PKD motifs of




Data are represented as mean of individual cells ± standard deviation (s.d.) or mean
of n (number of independent experiments) ± standard error of the mean (s.e.m.) as
indicated. P values were determined by two-tailed Student’s t-test and are indicated




Protocol for seFRET experiments
This protocol refers to a Leica microscope using LasF and the FRET wizard package,
but it is general enough to be adapted to any widefield platform to perform seFRET
experiments with living cells. I recommend you to use a positive as well as a negative
control for your first experiments to learn what ”real” cFRET and what false positive
signals created by background or autofluorescence looks like. A good positive control
could be the CFP-18AA-YFP construct used in this thesis.
• Day 1 - Seeding
– Coat your glass-bottom dishes or coverslips with poly-L-lysine if you are
going to work with cells hardly attaching to glass (e.g., HEK293) as
follows:
∗ add 400 µl of 0.01 % poly-L-lysine solution to the 10 mm glass window
of a glass-bottom dish (or 10 mm coverslip) and incubate for 15
minutes at room temperature, scale volumes according to the glass
surface in use
∗ aspirate poly-L-lysine solution and wash intensively 3 times with H2O
or PBS 1
∗ air dry (under the clean bench) for 2 h
– Seed cells in 35 mm glass-bottom dishes at an appropriate density, for
HeLa and HEK293 seed roughly 0.3 · 106 cells per dish
– (Optional) For robust cell lines, as are HEK293 and HeLa, the transfec-
tion mix can be directly added after seeding, see day 2 for a description
of transfection and continue with day 3
• Day 2 - Transfection
– The following numbers refer to the transfection of a 35 mm dish, scale
up according to your numbers of dishes or dish size
1High concentrations of poly-L-lysine are very effective at killing cells, so don’t use too highly
concentrated solutions and wash intensively.
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– FuGENE is used at a ratio to DNA of 3:1 with a total DNA mass of 1 µg
– Prepare FuGENE 6 mix by adding 3 µl FuGENE to 145 µl pre-warmed
OptiMem
– Incubate for 5 minutes at room temperature
– Add DNA to a total amount of 1 µg, for two plasmids add 500 ng of each
– (Mandatory for first experiments) transfect acceptor and donor only sam-
ples as well to determine correction factors 2
– Vortex DNA-FuGENE mix for 10 seconds and incubate for 20 minutes
at room temperature
– Add 150 µl of your transfection mix dropwise to your cells
• Day 3 - FRET measurement
– Prepare imaging buffers and eventually drugs as described in the mate-
rials part
– Start microscopy platform and wash perfusion system first with H2O and
then with your imaging buffers
– Start LasF with the widefield tree option, switch to the FRET wizard
– The FRET wizard is an intuitive plugin for LasF that guides you through
an experiment, I will briefly describe some functions but for a detailed re-
port refer to: https://www.leica-microsystems.com/science-lab/fret-sensitized-
emission-wizard-widefield/
– Configure your experiment by creating three channels in the “setup”
panel, for better orientation and metadata generation name them mean-
ingfully (suggestion: Donor, FRET, Acceptor), filter sets should be as
follows:
∗ Filter cube for all three channels: FRE (FRET cube containing only
a dichroic mirror)
∗ Donor channel: Excitation filter: CFP; Emission filter: CFP
∗ FRET channel: Excitation filter: CFP; Emission filter: YFP
∗ Acceptor channel: Excitation filter: YFP; Emission filter: YFP
– Make sure that “Same exposure for all channels” is enabled, thereby a
change of any parameter in one channel will automatically be applied to
2Take care that both are expressed correctly, e.g., using E-YFP alone as an acceptor only sample
would lead to E-YFP being retained in the ER and consequently changed intensities you would
encounter in a regular experiment
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all channels of your experiment (a prerequisite for your correction factors
to be working)
– Now follows the most delicate step of the setup: determination of the
acquisition parameters
∗ Take a sample expressing the FRET pair under investigation
∗ Adjust light intensity, gain, and exposure for the first channel (e.g.,
Donor) in the first field of view until detected signals are in the mid
detector range of the camera3, make sure not to use long exposure
times (exceeding 300 ms) since seFRET of living cells relies on short
successive images of your sample
∗ Inspect your sample in different field of views to see how homoge-
nous the expression of your proteins and therefore how reliable your
acquisition parameters are
∗ Switch on the same sample to the second channel and check detected
intensity levels; if you encounter overexposed cells reduce exposure
time, gain or light intensity (keep in mind that this change affects all
your channels)
∗ If you changed the acquisition parameters, recheck the first channel
if you can still detect enough or too much signal
∗ Repeat detection test for the last channel
∗ In the end, you need parameters that lead to detectable signals in all
three channels, some trial and error is unavoidable in this step
∗ You can save your settings now to have them later fastly available
again
∗ In some cases, it might be wise to determine several acquisition pa-
rameters if your sample is very heterogeneous in signal intensity, but
keep in mind that you will need separate sets of correction factors
for these acquisition sets!
– Now switch from “setup” to “Corr. Images” and change the sample on
the microscope to a donor only sample
– Choose the “Donor” sample type and acquire several images of your cells
with the acquisition parameters you determined before, sample type de-
termines the names of acquired images and that LasF automatically uses
them for correction factor calculation
3I highly recommend to use the “Over/Under-exposed LUT”, since it is easier for your eyes to
discriminate the intensity distribution of your sample and if you have oversaturated pixels. You
find it at the upper left corner of the screen where your images are shown.
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– Choose the “Acceptor” sample type and do the same with an acceptor
only sample
– The “FRET” sample type would enable you to acquire images that are
named by LasF accordingly; it is not different from the other sample
types by any means, and you won’t probably need it
– (Optional) Switch from “Corr. Images” to “Corr. Factors” and follow
the instructions on the screen to determine the correction factors from
the donor and acceptor only samples you just acquired. Alternatively,
you can calculate them later by yourself using FIJI. It might be useful
to get a quick estimation of your factors so that you can follow a live
calculated cFRET map during image acquisition
– (Optional) If you already know your correction factors from other exper-
iments you can enter them here manually without the need for real donor
and acceptor only samples
– Now you are ready to go for your actual measurement:
∗ Load a FRET pair sample (your sample) on the microscope and
switch to “Evaluation”
∗ Leave “method 1” as your calculation method, it generates cFRET
maps normalized to overall acceptor signal (method 2 is for confocal
setups, method 3 for ratiometric FRET sensors)
∗ Activate “Acquisition mode” if you want to acquire time-lapse or
z-Stacks, otherwise the button “Run Experiment” only acquires a
single stack of one-time point
∗ Define and run your experiment, if you entered correction factors
before, the last window shows you a cFRET map of the current
frame
∗ To remove the background signal from that frame, draw a ROI in
any channel and hit “Accept” under “Background Subtractions”
∗ To follow cFRET (and the other channels) during your experiment,
switch the upper header to Graphs, draw a ROI around your cell and
the graphs update the signals of every frame 4
∗ after your measurement, save the .lif file (do NOT export tiff, you
loose thereby the metadata of your experiment!) and go on with the
evaluation using FIJI
4The FRET wizard uses the background information of a single frame for your whole stack. Since
these values can vary highly during your experiment do not take time-lapse graphs too serious.
Rather trust on those you calculate with FIJI.
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• Evaluation
– Having your images acquired, you need to set up your FIJI for calculating
cFRET maps
– I used the plugin PixFRET5, which is quite useful for calculating single
maps for one time point; to process time-lapse or z-stacks, you need a
macro that adds this. If you need it, write me a message on www.researchgate.net
(there is only one other Benjamin Ko¨nig until now, I am the one with
green hair) or an E-mail at bennik2@freenet.de, and I send it to you.
– For PixFRET to work you need to create single stacks for every time
point in the following order: FRET, Donor, Acceptor
– Enter your correction factors in the tabs “Donor model” and “acceptor
model”, if you don’t have them yet you can calculate them as follows:
∗ Remove background from all donor and acceptor only samples
∗ For a donor only sample measure the intensity of a cell in the FRET
channel and divide this value by the intensity of the same ROI in the
donor channel. This percentage is your donor bleed through β
∗ For an acceptor only sample measure the intensity of a cell in the
FRET channel and divide this value by the intensity of the same ROI
in the acceptor channel. This is the percentage of cross-excitation γ
– To avoid artificial cFRET spikes at the boundaries of cells use the gaus-
sian filter option in PixFRET. The default value of 2 usually works fine.
– In PixFRET you can choose between different normalization methods.
Which to choose depends on your sample and your question. I recommend
to read this paper [145] if you are unsure which one would be the best
for your application
– Now draw a ROI in your FRET stack (in the order FRET, Donor, Ac-
ceptor) to determine background values and hit “Get” in the background
section, then draw a ROI around your signal and hit “compute FRET”6
– This is your cFRET map from which you can get the cFRET value
5It appears that a company tries to commercialize protocols and plugins, including PixFRET.
So it is possible that you will not find a download link for PixFRET without paying for it. In
this case: write me as described above. It is possible to write a code that does the same as
PixFRET




[1] Clay M. Armstrong. The na/k pump, cl ion, and osmotic stabilization of cells. Proceedings
of the National Academy of Sciences of the United States of America, 100(10):6257–6262,
2003.
[2] Alexander Leaf. Maintenance of concentration gradients and regulation of cell volume. An-
nals of the New York Academy of Sciences, 72(12):396–404, 1959.
[3] D. C. Tosteson and J. F. Hoffman. Regulation of cell volume by active cation transport in
high and low potassium sheep red cells. J Gen Physiol, 44:169–94, 1960.
[4] M. Wickson-Ginzburg and A. K. Solomon. Electrolyte metabolism in hela cells. The Journal
of general physiology, 46(6):1303–1315, 1963.
[5] S. H. Khan, N. Ahmad, F. Ahmad, and R. Kumar. Naturally occurring organic osmolytes:
from cell physiology to disease prevention. IUBMB Life, 62(12):891–5, 2010.
[6] C. W. Bourque. Central mechanisms of osmosensation and systemic osmoregulation. Nat
Rev Neurosci, 9(7):519–31, 2008.
[7] F. Lang, G. L. Busch, M. Ritter, H. Volkl, S. Waldegger, E. Gulbins, and D. Haussinger.
Functional significance of cell volume regulatory mechanisms. Physiol Rev, 78(1):247–306,
1998.
[8] E. K. Hoffmann, I. H. Lambert, and S. F. Pedersen. Physiology of cell volume regulation in
vertebrates. Physiol Rev, 89(1):193–277, 2009.
[9] Kevin Strange, Toshiki Yamada, and Jerod S. Denton. A 30-year journey from volume-
regulated anion currents to molecular structure of the lrrc8 channel. The Journal of General
Physiology, 151(2):100–117, 2019.
[10] J C Parker, P B Dunham, and A P Minton. Effects of ionic strength on the regulation of na/h
exchange and k-cl cotransport in dog red blood cells. The Journal of General Physiology,
105(6):677–699, 1995.
[11] He´le`ne Guizouarn and Rene´ Motais. Swelling activation of transport pathways in erythro-
cytes: effects of cl, ionic strength, and volume changes. American Journal of Physiology-Cell
Physiology, 276(1):C210–C220, 1999.
[12] R. Motais, H. Guizouarn, and F. Garcia-Romeu. Red cell volume regulation: the pivotal




[13] C. A. Hubner, V. Stein, I. Hermans-Borgmeyer, T. Meyer, K. Ballanyi, and T. J. Jentsch.
Disruption of kcc2 reveals an essential role of k-cl cotransport already in early synaptic
inhibition. Neuron, 30(2):515–24, 2001.
[14] A. Mercado, V. Broumand, K. Zandi-Nejad, A. H. Enck, and D. B. Mount. A c-terminal
domain in kcc2 confers constitutive k+-cl- cotransport. J Biol Chem, 281(2):1016–26, 2006.
[15] J. E. Capo-Aponte, P. Iserovich, and P. S. Reinach. Characterization of regulatory vol-
ume behavior by fluorescence quenching in human corneal epithelial cells. J Membr Biol,
207(1):11–22, 2005.
[16] Kenneth B. E. Gagnon, Roger England, and Eric Delpire. Volume sensitivity of cation-cl
cotransporters is modulated by the interaction of two kinases: Ste20-related proline-alanine-
rich kinase and wnk4. American Journal of Physiology-Cell Physiology, 290(1):C134–C142,
2006.
[17] A. Mercado, L. Song, N. Vazquez, D. B. Mount, and G. Gamba. Functional comparison of
the k+-cl- cotransporters kcc1 and kcc4. J Biol Chem, 275(39):30326–34, 2000.
[18] D. B. Mount, A. Mercado, L. Song, J. Xu, Jr. George, A. L., E. Delpire, and G. Gamba.
Cloning and characterization of kcc3 and kcc4, new members of the cation-chloride cotrans-
porter gene family. J Biol Chem, 274(23):16355–62, 1999.
[19] Joanne E. Race, Fadi N. Makhlouf, Paul J. Logue, Frederick H. Wilson, Philip B. Dunham,
and Eli J. Holtzman. Molecular cloning and functional characterization of kcc3, a new k-cl
cotransporter. American Journal of Physiology-Cell Physiology, 277(6):C1210–C1219, 1999.
[20] Kevin Strange, Thomas D. Singer, Rebecca Morrison, and Eric Delpire. Dependence of
kcc2 k-cl cotransporter activity on a conserved carboxy terminus tyrosine residue. American
Journal of Physiology-Cell Physiology, 279(3):C860–C867, 2000.
[21] M. B. Rust, S. L. Alper, Y. Rudhard, B. E. Shmukler, R. Vicente, C. Brugnara, M. Trudel,
T. J. Jentsch, and C. A. Hubner. Disruption of erythroid k-cl cotransporters alters ery-
throcyte volume and partially rescues erythrocyte dehydration in sad mice. J Clin Invest,
117(6):1708–17, 2007.
[22] T. J. Jentsch. Vracs and other ion channels and transporters in the regulation of cell volume
and beyond. Nat Rev Mol Cell Biol, 17(5):293–307, 2016.
[23] H. C. Hartzell, Z. Qu, K. Yu, Q. Xiao, and L. T. Chien. Molecular physiology of bestrophins:
multifunctional membrane proteins linked to best disease and other retinopathies. Physiol
Rev, 88(2):639–72, 2008.
[24] N. Pedemonte and L. J. Galietta. Structure and function of tmem16 proteins (anoctamins).
Physiol Rev, 94(2):419–59, 2014.
[25] M. D. Cahalan and R. S. Lewis. Role of potassium and chloride channels in volume regulation
by t lymphocytes. Soc Gen Physiol Ser, 43:281–301, 1988.
[26] A. Hazama and Y. Okada. Ca2+ sensitivity of volume-regulatory k+ and cl- channels in
cultured human epithelial cells. J Physiol, 402:687–702, 1988.
98
References
[27] Bernd Nilius, Jan Sehrer, Felix Viana, Christine De Greef, Luc Raeymaekers, Jan Eggermont,
and Guy Droogmans. Volume-activated cl- currents in different mammalian non-excitable
cell types. Pflu¨gers Archiv, 428(3):364–371, 1994.
[28] Toshiki Yamada, Robert Wondergem, Rebecca Morrison, Viravuth P. Yin, and Kevin
Strange. Leucine-rich repeat containing protein lrrc8a is essential for swelling-activated cl
currents and embryonic development in zebrafish. Physiological Reports, 4(19):e12940, 2016.
[29] Z. Qiu, A. E. Dubin, J. Mathur, B. Tu, K. Reddy, L. J. Miraglia, J. Reinhardt, A. P.
Orth, and A. Patapoutian. Swell1, a plasma membrane protein, is an essential component
of volume-regulated anion channel. Cell, 157(2):447–458, 2014.
[30] F. K. Voss, F. Ullrich, J. Munch, K. Lazarow, D. Lutter, N. Mah, M. A. Andrade-Navarro,
J. P. von Kries, T. Stauber, and T. J. Jentsch. Identification of lrrc8 heteromers as an
essential component of the volume-regulated anion channel vrac. Science, 344(6184):634–8,
2014.
[31] Jennifer C. Lueck, Dmytro Puchkov, Florian Ullrich, and Thomas J. Jentsch. Lrrc8/vrac
anion channels are required for late stages of spermatid development in mice. Journal of
Biological Chemistry, 293(30):11796–11808, 2018.
[32] F. Formaggio, E. Saracino, M. G. Mola, S. B. Rao, M. Amiry-Moghaddam, M. Muc-
cini, R. Zamboni, G. P. Nicchia, M. Caprini, and V. Benfenati. Lrrc8a is essential for
swelling-activated chloride current and for regulatory volume decrease in astrocytes. Faseb
j, 33(1):101–113, 2019.
[33] C. Kang, L. Xie, S. K. Gunasekar, A. Mishra, Y. Zhang, S. Pai, Y. Gao, A. Kumar, A. W.
Norris, S. B. Stephens, and R. Sah. Swell1 is a glucose sensor regulating beta-cell excitability
and systemic glycaemia. Nat Commun, 9(1):367, 2018.
[34] Mar´ıa C. Hyzinski-Garc´ıa, Alena Rudkouskaya, and Alexander A. Mongin. Lrrc8a protein
is indispensable for swelling-activated and atp-induced release of excitatory amino acids in
rat astrocytes. The Journal of physiology, 592(22):4855–4862, 2014.
[35] D. Lutter, F. Ullrich, J. C. Lueck, S. Kempa, and T. J. Jentsch. Selective transport of
neurotransmitters and modulators by distinct volume-regulated lrrc8 anion channels. J Cell
Sci, 130(6):1122–1133, 2017.
[36] L. Chen, B. Konig, T. Liu, S. Pervaiz, Y. S. Razzaque, and T. Stauber. More than just
a pressure relief valve: physiological roles of volume-regulated lrrc8 anion channels. Biol
Chem, 2019.
[37] Carl D. Bortner, Francis M. Hughes, and John A. Cidlowski. A primary role for k+ and na+
efflux in the activation of apoptosis. Journal of Biological Chemistry, 272(51):32436–32442,
1997.
[38] C. D. Bortner and J. A. Cidlowski. A necessary role for cell shrinkage in apoptosis. Biochem
Pharmacol, 56(12):1549–59, 1998.




[40] T. Shimizu, H. Ohtake, T. Fujii, Y. Tabuchi, and H. Sakai. Volume-sensitive outwardly rec-
tifying cl(-) channels contribute to butyrate-triggered apoptosis of murine colonic epithelial
mce301 cells. J Physiol Sci, 65(2):151–7, 2015.
[41] Yuesheng Xia, Yan Liu, Tong Xia, Xing Li, Cong Huo, Xin Jia, Lin Wang, Rong Xu, Ning
Wang, Mingming Zhang, Hong Li, and Xiaoming Wang. Activation of volume-sensitive cl-
channel mediates autophagy-related cell death in myocardial ischaemia/reperfusion injury.
Oncotarget, 7(26):39345–39362, 2016.
[42] K. Kumagai, F. Toyoda, C. A. Staunton, T. Maeda, N. Okumura, H. Matsuura, Y. Matsusue,
S. Imai, and R. Barrett-Jolley. Activation of a chondrocyte volume-sensitive cl(-) conductance
prior to macroscopic cartilage lesion formation in the rabbit knee anterior cruciate ligament
transection osteoarthritis model. Osteoarthritis Cartilage, 24(10):1786–1794, 2016.
[43] R. Planells-Cases, D. Lutter, C. Guyader, N. M. Gerhards, F. Ullrich, D. A. Elger, A. Ku-
cukosmanoglu, G. Xu, F. K. Voss, S. M. Reincke, T. Stauber, V. A. Blomen, D. J. Vis, L. F.
Wessels, T. R. Brummelkamp, P. Borst, S. Rottenberg, and T. J. Jentsch. Subunit com-
position of vrac channels determines substrate specificity and cellular resistance to pt-based
anti-cancer drugs. Embo j, 34(24):2993–3008, 2015.
[44] T. Shimizu, T. Numata, and Y. Okada. A role of reactive oxygen species in apoptotic
activation of volume-sensitive cl(-) channel. Proc Natl Acad Sci U S A, 101(17):6770–3,
2004.
[45] L. Sirianant, P. Wanitchakool, J. Ousingsawat, R. Benedetto, A. Zormpa, I. Cabrita,
R. Schreiber, and K. Kunzelmann. Non-essential contribution of lrrc8a to volume regulation.
Pflugers Arch, 468(5):805–16, 2016.
[46] F. Lang, E. Shumilina, M. Ritter, E. Gulbins, A. Vereninov, and S. M. Huber. Ion channels
and cell volume in regulation of cell proliferation and apoptotic cell death. Contrib Nephrol,
152:142–160, 2006.
[47] W. Liang, L. Huang, D. Zhao, J. Z. He, P. Sharma, J. Liu, A. O. Gramolini, M. E. Ward, H. C.
Cho, and P. H. Backx. Swelling-activated cl- currents and intracellular clc-3 are involved in
proliferation of human pulmonary artery smooth muscle cells. J Hypertens, 32(2):318–30,
2014.
[48] B. Nilius, J. Eggermont, T. Voets, G. Buyse, V. Manolopoulos, and G. Droogmans. Proper-
ties of volume-regulated anion channels in mammalian cells. Prog Biophys Mol Biol, 68(1):69–
119, 1997.
[49] T. Voets, G. Szucs, G. Droogmans, and B. Nilius. Blockers of volume-activated cl- currents
inhibit endothelial cell proliferation. Pflugers Arch, 431(1):132–4, 1995.
[50] Jerzy M. Dziekan, Han Yu, Dan Chen, Lingyun Dai, Grennady Wirjanata, Andreas Larsson,
Nayana Prabhu, Radoslaw M. Sobota, Zbynek Bozdech, and Pa¨r Nordlund. Identifying
purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay.
Science Translational Medicine, 11(473):eaau3174, 2019.
[51] T. A. Bogush, B. B. Polezhaev, I. A. Mamichev, E. A. Bogush, B. E. Polotsky, S. A. Tju-
landin, and A. B. Ryabov. Tamoxifen never ceases to amaze: New findings on non-estrogen
receptor molecular targets and mediated effects. Cancer Invest, 36(4):211–220, 2018.
100
References
[52] Nicole H. Bowens, Preeti Dohare, Yu-Hung Kuo, and Alexander A. Mongin. Dcpib, the
proposed selective blocker of volume-regulated anion channels, inhibits several glutamate
transport pathways in glial cells. Molecular pharmacology, 83(1):22–32, 2013.
[53] T. Liu and T. Stauber. The volume-regulated anion channel lrrc8/vrac is dispensable for
cell proliferation and migration. Int J Mol Sci, 20(11), 2019.
[54] A. Schwab, A. Fabian, P. J. Hanley, and C. Stock. Role of ion channels and transporters in
cell migration. Physiol Rev, 92(4):1865–913, 2012.
[55] R. Wong, W. Chen, X. Zhong, J. T. Rutka, Z. P. Feng, and H. S. Sun. Swelling-induced
chloride current in glioblastoma proliferation, migration, and invasion. J Cell Physiol,
233(1):363–370, 2018.
[56] Haifeng Zhang, Zhiqin Deng, Dongxia Zhang, Huarong Li, Lei Zhang, Jin Niu, Wanhong
Zuo, Rao Fu, Lihong Fan, Jiang-Hong Ye, and Junjun She. High expression of leucine-rich
repeat-containing 8a is indicative of a worse outcome of colon cancer patients by enhancing
cancer cell growth and metastasis. Oncology reports, 40(3):1275–1286, 2018.
[57] T. Akita and Y. Okada. Characteristics and roles of the volume-sensitive outwardly rectifying
(vsor) anion channel in the central nervous system. Neuroscience, 275:211–31, 2014.
[58] Alexander A. Mongin. Volume-regulated anion channel–a frenemy within the brain. Pflugers
Archiv : European journal of physiology, 468(3):421–441, 2016.
[59] A. L. Schober, C. S. Wilson, and A. A. Mongin. Molecular composition and heterogeneity
of the lrrc8-containing swelling-activated osmolyte channels in primary rat astrocytes. J
Physiol, 595(22):6939–6951, 2017.
[60] J. Yang, M. D. C. Vitery, J. Chen, J. Osei-Owusu, J. Chu, and Z. Qiu. Glutamate-releasing
swell1 channel in astrocytes modulates synaptic transmission and promotes brain damage in
stroke. Neuron, 102(4):813–827.e6, 2019.
[61] N. J. Allen and C. Eroglu. Cell biology of astrocyte-synapse interactions. Neuron, 96(3):697–
708, 2017.
[62] N. B. Hamilton and D. Attwell. Do astrocytes really exocytose neurotransmitters? Nat Rev
Neurosci, 11(4):227–38, 2010.
[63] L. Kumar, J. Chou, C. S. Yee, A. Borzutzky, E. H. Vollmann, U. H. von Andrian, S. Y. Park,
G. Hollander, J. P. Manis, P. L. Poliani, and R. S. Geha. Leucine-rich repeat containing 8a
(lrrc8a) is essential for t lymphocyte development and function. J Exp Med, 211(5):929–42,
2014.
[64] A. Lalouette, A. Lablack, J. L. Guenet, X. Montagutelli, and D. Segretain. Male sterility
caused by sperm cell-specific structural abnormalities in ebouriffe, a new mutation of the
house mouse. Biol Reprod, 55(2):355–63, 1996.
[65] C. D. Platt, J. Chou, P. Houlihan, Y. R. Badran, L. Kumar, W. Bainter, P. L. Poliani, C. J.
Perez, S. Y. R. Dent, D. E. Clapham, F. Benavides, and R. S. Geha. Leucine-rich repeat
containing 8a (lrrc8a)-dependent volume-regulated anion channel activity is dispensable for
t-cell development and function. J Allergy Clin Immunol, 140(6):1651–1659.e1, 2017.
101
References
[66] H. E. Miley, E. A. Sheader, P. D. Brown, and L. Best. Glucose-induced swelling in rat
pancreatic beta-cells. The Journal of physiology, 504 ( Pt 1)(Pt 1):191–198, 1997.
[67] L. Best, P. D. Brown, A. Sener, and W. J. Malaisse. Electrical activity in pancreatic islet
cells: The vrac hypothesis. Islets, 2(2):59–64, 2010.
[68] Till Stuhlmann, Rosa Planells-Cases, and Thomas J. Jentsch. Lrrc8/vrac anion channels
enhance β-cell glucose sensing and insulin secretion. Nature Communications, 9(1):1974,
2018.
[69] D. Deneka, M. Sawicka, A. K. M. Lam, C. Paulino, and R. Dutzler. Structure of a volume-
regulated anion channel of the lrrc8 family. Nature, 558(7709):254–259, 2018.
[70] G. Kasuya, T. Nakane, T. Yokoyama, Y. Jia, M. Inoue, K. Watanabe, R. Nakamura,
T. Nishizawa, T. Kusakizako, A. Tsutsumi, H. Yanagisawa, N. Dohmae, M. Hattori, H. Ichijo,
Z. Yan, M. Kikkawa, M. Shirouzu, R. Ishitani, and O. Nureki. Cryo-em structures of the
human volume-regulated anion channel lrrc8. Nat Struct Mol Biol, 25(9):797–804, 2018.
[71] Jennifer M. Kefauver, Kei Saotome, Adrienne E. Dubin, Jesper Pallesen, Christopher A.
Cottrell, Stuart M. Cahalan, Zhaozhu Qiu, Gunhee Hong, Christopher S. Crowley, Tess
Whitwam, Wen-Hsin Lee, Andrew B. Ward, and Ardem Patapoutian. Structure of the
human volume regulated anion channel. eLife, 7:e38461, 2018.
[72] David M. Kern, SeCheol Oh, Richard K. Hite, and Stephen G. Brohawn. Cryo-em struc-
tures of the dcpib-inhibited volume-regulated anion channel lrrc8a in lipid nanodiscs. eLife,
8:e42636, 2019.
[73] F. Abascal and R. Zardoya. Lrrc8 proteins share a common ancestor with pannexins, and
may form hexameric channels involved in cell-cell communication. Bioessays, 34(7):551–60,
2012.
[74] Benjamin Ko¨nig and Tobias Stauber. Biophysics and structure-function relationships of
lrrc8-formed volume-regulated anion channels. Biophysical Journal, 116(7):1185–1193, 2019.
[75] Julio F. Cordero-Morales and Valeria Va´squez. How lipids contribute to ion channel function,
a fat perspective on direct and indirect interactions. Current Opinion in Structural Biology,
51:92–98, 2018.
[76] Atsunori Oshima, Kazutoshi Tani, and Yoshinori Fujiyoshi. Atomic structure of the innexin-6
gap junction channel determined by cryo-em. Nature Communications, 7(1):13681, 2016.
[77] S. Maeda, S. Nakagawa, M. Suga, E. Yamashita, A. Oshima, Y. Fujiyoshi, and T. Tsukihara.
Structure of the connexin 26 gap junction channel at 3.5 a resolution. Nature, 458(7238):597–
602, 2009.
[78] Pingzheng Zhou, Maya M Polovitskaya, and Thomas J. Jentsch. Lrrc8 amino-termini in-
fluence pore properties and gating of volume-regulated vrac anion channels. Journal of
Biological Chemistry, 2018.
[79] R. Syeda, Z. Qiu, A. E. Dubin, S. E. Murthy, M. N. Florendo, D. E. Mason, J. Mathur, S. M.
Cahalan, E. C. Peters, M. Montal, and A. Patapoutian. Lrrc8 proteins form volume-regulated
anion channels that sense ionic strength. Cell, 164(3):499–511, 2016.
102
References
[80] H. Gaitan-Penas, A. Gradogna, L. Laparra-Cuervo, C. Solsona, V. Fernandez-Duenas,
A. Barrallo-Gimeno, F. Ciruela, M. Lakadamyali, M. Pusch, and R. Estevez. Investigation of
lrrc8-mediated volume-regulated anion currents in xenopus oocytes. Biophys J, 111(7):1429–
1443, 2016.
[81] Tingting Yang, Qun Liu, Brian Kloss, Renato Bruni, Ravi C. Kalathur, Youzhong Guo, Edda
Kloppmann, Burkhard Rost, Henry M. Colecraft, and Wayne A. Hendrickson. Structure and
selectivity in bestrophin ion channels. Science (New York, N.Y.), 346(6207):355–359, 2014.
[82] Y. Okada. Volume expansion-sensing outward-rectifier cl- channel: fresh start to the molec-
ular identity and volume sensor. Am J Physiol, 273(3 Pt 1):C755–89, 1997.
[83] Jianqiang Bao, Carlos J. Perez, Jeesun Kim, Huan Zhang, Caitlin J. Murphy, Tewfik Hamidi,
Jean Jaubert, Craig D. Platt, Janet Chou, Meichun Deng, Meng-Hua Zhou, Yuying Huang,
He´ctor Gaita´n-Pen˜as, Jean-Louis Gue´net, Kevin Lin, Yue Lu, Taiping Chen, Mark T. Bed-
ford, Sharon Yr Dent, John H. Richburg, Rau´l Este´vez, Hui-Lin Pan, Raif S. Geha, Qinghua
Shi, and Fernando Benavides. Deficient lrrc8a-dependent volume-regulated anion channel
activity is associated with male infertility in mice. JCI insight, 3(16):e99767, 2018.
[84] Human genomics. the genotype-tissue expression (gtex) pilot analysis: multitissue gene reg-
ulation in humans. Science, 348(6235):648–60, 2015.
[85] P. S. Jackson and K. Strange. Volume-sensitive anion channels mediate swelling-activated
inositol and taurine efflux. American Journal of Physiology-Cell Physiology, 265(6):C1489–
C1500, 1993.
[86] P. S. Jackson, K. Churchwell, N. Ballatori, J. L. Boyer, and K. Strange. Swelling-activated
anion conductance in skate hepatocytes: regulation by cell cl- and atp. Am J Physiol, 270(1
Pt 1):C57–66, 1996.
[87] V. G. Manolopoulos, T. Voets, P. E. Declercq, G. Droogmans, and B. Nilius. Swelling-
activated efflux of taurine and other organic osmolytes in endothelial cells. American Journal
of Physiology-Cell Physiology, 273(1):C214–C222, 1997.
[88] S. H. Boese, F. Wehner, and R. K. Kinne. Taurine permeation through swelling-activated
anion conductance in rat imcd cells in primary culture. Am J Physiol, 271(3 Pt 2):F498–507,
1996.
[89] O. P. Hamill, A. Marty, E. Neher, B. Sakmann, and F. J. Sigworth. Improved patch-clamp
techniques for high-resolution current recording from cells and cell-free membrane patches.
Pflu¨gers Archiv, 391(2):85–100, 1981.
[90] A. Huxley. From overshoot to voltage clamp. Trends Neurosci, 25(11):553–8, 2002.
[91] Erwin Neher and Bert Sakmann. The patch clamp technique. Scientific American, 266(3):44–
51, 1992.
[92] P. S. Jackson and K. Strange. Characterization of the voltage-dependent properties of a
volume-sensitive anion conductance. J Gen Physiol, 105(5):661–76, 1995.
[93] T. Voets, G. Droogmans, and B. Nilius. Modulation of voltage-dependent properties of a
swelling-activated cl- current. J Gen Physiol, 110(3):313–25, 1997.
103
References
[94] Victor G. Romanenko, George H. Rothblat, and Irena Levitan. Sensitivity of volume-
regulated anion current to cholesterol structural analogues. The Journal of general phys-
iology, 123(1):77–87, 2004.
[95] P. S. Jackson and K. Strange. Single-channel properties of a volume-sensitive anion conduc-
tance. current activation occurs by abrupt switching of closed channels to an open state. The
Journal of general physiology, 105(5):643–660, 1995.
[96] J. E. Linley. Perforated whole-cell patch-clamp recording. Methods Mol Biol, 998:149–57,
2013.
[97] L. Best and P. D. Brown. Studies of the mechanism of activation of the volume-regulated
anion channel in rat pancreatic beta-cells. J Membr Biol, 230(2):83–91, 2009.
[98] L. Best and A. P. Yates. Electrophysiological effects of osmotic cell shrinkage in rat pancreatic
beta-cells. Islets, 2(5):303–7, 2010.
[99] M. Jakab, M. Grundbichler, J. Benicky, A. Ravasio, S. Chwatal, S. Schmidt, V. Strbak,
J. Fu¨rst, M. Paulmichl, and M. Ritter. Glucose induces anion conductance and cytosol-
to-membrane transposition of icln in ins-1e rat insulinoma cells. Cellular Physiology and
Biochemistry, 18(1-3):21–34, 2006.
[100] Y. E. Han, J. Kwon, J. Won, H. An, M. W. Jang, J. Woo, J. S. Lee, M. G. Park, B. E. Yoon,
S. E. Lee, E. M. Hwang, J. Y. Jung, H. Park, S. J. Oh, and C. J. Lee. Tweety-homolog
(ttyh) family encodes the pore-forming subunits of the swelling-dependent volume-regulated
anion channel (vracswell) in the brain. Exp Neurobiol, 28(2):183–215, 2019.
[101] M. C. Hyzinski-Garcia, M. Y. Vincent, R. E. Haskew-Layton, P. Dohare, Jr. Keller, R. W.,
and A. A. Mongin. Hypo-osmotic swelling modifies glutamate-glutamine cycle in the cerebral
cortex and in astrocyte cultures. J Neurochem, 118(1):140–52, 2011.
[102] S. Broer. Adaptation of plasma membrane amino acid transport mechanisms to physiological
demands. Pflugers Arch, 444(4):457–66, 2002.
[103] Henry A. Polach. Evaluation and status of liquid scintillation counting for radiocarbon
dating. Radiocarbon, 29(1):1–11, 1987.
[104] C. S. Wilson, M. D. Bach, Z. Ashkavand, K. R. Norman, N. Martino, A. P. Adam, and
A. A. Mongin. Metabolic constraints of swelling-activated glutamate release in astrocytes
and their implication for ischemic tissue damage. J Neurochem, 2019.
[105] H. K. Kimelberg, S. K. Goderie, S. Higman, S. Pang, and R. A. Waniewski. Swelling-
induced release of glutamate, aspartate, and taurine from astrocyte cultures. J Neurosci,
10(5):1583–91, 1990.
[106] D. L. Martin, V. Madelian, B. Seligmann, and W. Shain. The role of osmotic pressure and
membrane potential in k(+)-stimulated taurine release from cultured astrocytes and lrm55
cells. J Neurosci, 10(2):571–7, 1990.
[107] L. J. Galietta, P. M. Haggie, and A. S. Verkman. Green fluorescent protein-based halide
indicators with improved chloride and iodide affinities. FEBS Lett, 499(3):220–4, 2001.
104
References
[108] A. Ghosh, N. Khandelwal, A. Kumar, and A. K. Bera. Leucine-rich repeat-containing 8b
protein is associated with the endoplasmic reticulum ca(2+) leak in hek293 cells. J Cell Sci,
130(22):3818–3828, 2017.
[109] Michael A. Model. Methods for cell volume measurement. Cytometry Part A, 93(3):281–296,
2018.
[110] Else K. Hoffmann, Lars Ole Simonsen, and Ian H. Lambert. Volume-induced increase of k+
and cl- permeabilities in ehrlich ascites tumor cells. role of internal ca2+. The Journal of
Membrane Biology, 78(3):211–222, 1984.
[111] Janina Trothe, Dirk Ritzmann, Victoria Lang, Paul Scholz, U¨mit Pul, Roland Kaufmann,
Claudia Buerger, and Torsten Ertongur-Fauth. Hypotonic stress response of human ker-
atinocytes involves lrrc8a as component of volume-regulated anion channels. Experimental
Dermatology, 27(12):1352–1360, 2018.
[112] Jonas Friard, Michel Tauc, Marc Cougnon, Vincent Compan, Christophe Duranton, and
Isabelle Rubera. Comparative effects of chloride channel inhibitors on lrrc8/vrac-mediated
chloride conductance. Frontiers in Pharmacology, 8(328), 2017.
[113] W. E. Crowe, J. Altamirano, L. Huerto, and F. J. Alvarez-Leefmans. Volume changes in single
n1e-115 neuroblastoma cells measured with a fluorescent probe. Neuroscience, 69(1):283–96,
1995.
[114] Steffen Hamann, Jens Folke Kiilgaard, Thomas Litman, Francisco J. Alvarez-Leefmans,
Benny R. Winther, and Thomas Zeuthen. Measurement of cell volume changes by fluo-
rescence self-quenching. Journal of Fluorescence, 12(2):139–145, 2002.
[115] Carolyn L. Cannon, Srisaila Basavappa, and Kevin Strange. Intracellular ionic strength
regulates the volume sensitivity of a swelling-activated anion channel. American Journal of
Physiology-Cell Physiology, 275(2):C416–C422, 1998.
[116] Tamara Bond, Srisaila Basavappa, Michael Christensen, and Kevin Strange. Atp dependence
of the i¡sub¿cl, swell¡/sub¿ channel varies with rate of cell swelling. Evidence for Two Modes
of Channel Activation, 113(3):441–456, 1999.
[117] Antonella Gradogna, Paola Gavazzo, Anna Boccaccio, and Michael Pusch. Subunit-
dependent oxidative stress sensitivity of lrrc8 volume-regulated anion channels. The Journal
of Physiology, 595(21):6719–6733, 2017.
[118] A. A. Mongin and S. N. Orlov. Mechanisms of cell volume regulation and possible nature of
the cell volume sensor. Pathophysiology, 8(2):77–88, 2001.
[119] T. Voets, G. Droogmans, G. Raskin, J. Eggermont, and B. Nilius. Reduced intracellular ionic
strength as the initial trigger for activation of endothelial volume-regulated anion channels.
Proc Natl Acad Sci U S A, 96(9):5298–303, 1999.
[120] R. Z. Sabirov, J. Prenen, T. Tomita, G. Droogmans, and B. Nilius. Reduction of ionic




[121] J. Zhang and M. Lieberman. Chloride conductance is activated by membrane distention of
cultured chick heart cells. Cardiovasc Res, 32(1):168–79, 1996.
[122] L. Best and P. D. Brown. Studies of the mechanism of activation of the volume-regulated
anion channel in rat pancreatic beta-cells. J Membr Biol, 230(2):83–91, 2009.
[123] P. S. Jackson, R. Morrison, and K. Strange. The volume-sensitive organic osmolyte-anion
channel vsoac is regulated by nonhydrolytic atp binding. Am J Physiol, 267(5 Pt 1):C1203–9,
1994.
[124] H. E. Miley, P. D. Brown, and L. Best. Regulation of a volume-sensitive anion channel in
rat pancreatic beta-cells by intracellular adenine nucleotides. J Physiol, 515 ( Pt 2):413–7,
1999.
[125] S. Oiki, M. Kubo, and Y. Okada. Mg2+ and atp-dependence of volume-sensitive cl- channels
in human epithelial cells. Jpn J Physiol, 44 Suppl 2:S77–9, 1994.
[126] A. J. Patel, I. Lauritzen, M. Lazdunski, and E. Honore. Disruption of mitochondrial res-
piration inhibits volume-regulated anion channels and provokes neuronal cell swelling. J
Neurosci, 18(9):3117–23, 1998.
[127] A. Bryan-Sisneros, V. Sabanov, S. M. Thoroed, and P. Doroshenko. Dual role of atp in
supporting volume-regulated chloride channels in mouse fibroblasts. Biochimica et Biophysica
Acta (BBA) - Biomembranes, 1468(1):63–72, 2000.
[128] D. W. Hilgemann. Cytoplasmic atp-dependent regulation of ion transporters and channels:
mechanisms and messengers. Annu Rev Physiol, 59:193–220, 1997.
[129] S. Sorota. Tyrosine protein kinase inhibitors prevent activation of cardiac swelling-induced
chloride current. Pflugers Arch, 431(2):178–85, 1995.
[130] V. Crepel, W. Panenka, M. E. Kelly, and B. A. MacVicar. Mitogen-activated protein and
tyrosine kinases in the activation of astrocyte volume-activated chloride current. J Neurosci,
18(4):1196–206, 1998.
[131] T. Voets, V. Manolopoulos, J. Eggermont, C. Ellory, G. Droogmans, and B. Nilius. Reg-
ulation of a swelling-activated chloride current in bovine endothelium by protein tyrosine
phosphorylation and g proteins. J Physiol, 506 ( Pt 2):341–52, 1998.
[132] P. Doroshenko. Pervanadate inhibits volume-sensitive chloride current in bovine chromaffin
cells. Pflugers Arch, 435(2):303–9, 1998.
[133] S. M. Thoroed, A. Bryan-Sisneros, and P. Doroshenko. Protein phosphotyrosine phosphatase
inhibitors suppress regulatory volume decrease and the volume-sensitive cl- conductance in
mouse fibroblasts. Pflugers Arch, 438(2):133–40, 1999.
[134] A. Rudkouskaya, A. Chernoguz, R. E. Haskew-Layton, and A. A. Mongin. Two conventional
protein kinase c isoforms, alpha and beta i, are involved in the atp-induced activation of




[135] M. Hermoso, P. Olivero, R. Torres, A. Riveros, A. F. Quest, and A. Stutzin. Cell volume
regulation in response to hypotonicity is impaired in hela cells expressing a protein kinase
calpha mutant lacking kinase activity. J Biol Chem, 279(17):17681–9, 2004.
[136] I. Ben Soussia, F. Mies, R. Naeije, and V. Shlyonsky. Melatonin down-regulates volume-
sensitive chloride channels in fibroblasts. Pflugers Arch, 464(3):273–85, 2012.
[137] L. Catacuzzeno, A. Michelucci, L. Sforna, F. Aiello, M. Sciaccaluga, B. Fioretti, E. Castigli,
and F. Franciolini. Identification of key signaling molecules involved in the activation of the
swelling-activated chloride current in human glioblastoma cells. J Membr Biol, 247(1):45–55,
2014.
[138] Gregory M. Dick, Karri K. Bradley, Burton Horowitz, Joseph R. Hume, and Kenton M.
Sanders. Functional and molecular identification of a novel chloride conductance in canine
colonic smooth muscle. American Journal of Physiology-Cell Physiology, 275(4):C940–C950,
1998.
[139] Sophia F. von Weikersthal, Margery A. Barrand, and Stephen B. Hladky. Functional and
molecular characterization of a volume-sensitive chloride current in rat brain endothelial
cells. The Journal of Physiology, 516(1):75–84, 1999.
[140] Alexander Zholos, Benjamin Beck, Vadym Sydorenko, Lo¨ıc Lemonnier, Pascal Bordat, Na-
talia Prevarskaya, and Roman Skryma. Ca(2+)- and volume-sensitive chloride currents are
differentially regulated by agonists and store-operated ca2+ entry. The Journal of general
physiology, 125(2):197–211, 2005.
[141] Katia Hiersemenzel, Euan Brown, and Rory Duncan. Imaging large cohorts of single ion
channels and their activity. Frontiers in Endocrinology, 4(114), 2013.
[142] Ekaterina A. Bykova, Xiao-Dong Zhang, Tsung-Yu Chen, and Jie Zheng. Large movement
in the c terminus of clc-0 chloride channel during slow gating. Nature Structural &Amp;
Molecular Biology, 13:1115, 2006.
[143] T. Y. Chen. Structure and function of clc channels. Annu Rev Physiol, 67:809–39, 2005.
[144] Linda G. Zachariassen, Ljudmila Katchan, Anna G. Jensen, Darryl S. Pickering, Andrew
J. R. Plested, and Anders S. Kristensen. Structural rearrangement of the intracellular do-
mains during ampa receptor activation. Proceedings of the National Academy of Sciences,
113(27):E3950–E3959, 2016.
[145] A. D. Elder, A. Domin, G. S. Kaminski Schierle, C. Lindon, J. Pines, A. Esposito, and
C. F. Kaminski. A quantitative protocol for dynamic measurements of protein interactions
by fo¨rster resonance energy transfer-sensitized fluorescence emission. Journal of the Royal
Society Interface, 6(Suppl 1):S59–S81, 2009.
[146] I. Levitan, C. Almonte, P. Mollard, and S. S. Garber. Modulation of a volume-regulated
chloride current by f-actin. The Journal of Membrane Biology, 147(3):283–294, 1995.




[148] C. T. Rollins, V. M. Rivera, D. N. Woolfson, T. Keenan, M. Hatada, S. E. Adams, L. J.
Andrade, D. Yaeger, M. R. van Schravendijk, D. A. Holt, M. Gilman, and T. Clackson. A
ligand-reversible dimerization system for controlling protein-protein interactions. Proc Natl
Acad Sci U S A, 97(13):7096–101, 2000.
[149] V. M. Rivera, X. Wang, S. Wardwell, N. L. Courage, A. Volchuk, T. Keenan, D. A. Holt,
M. Gilman, L. Orci, Jr. Cerasoli, F., J. E. Rothman, and T. Clackson. Regulation of
protein secretion through controlled aggregation in the endoplasmic reticulum. Science,
287(5454):826–30, 2000.
[150] S. Morishima, T. Shimizu, H. Kida, and Y. Okada. Volume expansion sensitivity of swelling-
activated cl(-) channel in human epithelial cells. Jpn J Physiol, 50(2):277–80, 2000.
[151] E. M. Schwiebert, J. W. Mills, and B. A. Stanton. Actin-based cytoskeleton regulates a
chloride channel and cell volume in a renal cortical collecting duct cell line. J Biol Chem,
269(10):7081–9, 1994.
[152] T. K. Klausen, C. Hougaard, E. K. Hoffmann, and S. F. Pedersen. Cholesterol modulates the
volume-regulated anion current in ehrlich-lettre ascites cells via effects on rho and f-actin.
Am J Physiol Cell Physiol, 291(4):C757–71, 2006.
[153] M. Caramia, L. Sforna, F. Franciolini, and L. Catacuzzeno. The volume-regulated anion
channel in glioblastoma. Cancers (Basel), 11(3), 2019.
[154] J. Mao, L. Wang, A. Fan, J. Wang, B. Xu, T. J. C. Jacob, and L. Chen. Blockage of volume-
activated chloride channels inhibits migration of nasopharyngeal carcinoma cells. Cellular
Physiology and Biochemistry, 19(5-6):249–258, 2007.
[155] P. J. Robinson. Differential stimulation of protein kinase c activity by phorbol ester or cal-
cium/phosphatidylserine in vitro and in intact synaptosomes. J Biol Chem, 267(30):21637–
44, 1992.
[156] E. Tahara, H. Kadara, L. Lacroix, D. Lotan, and R. Lotan. Activation of protein kinase c
by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through klf6
induction. Cancer Biol Ther, 8(9):801–7, 2009.
[157] M. G. Kazanietz. Eyes wide shut: protein kinase c isozymes are not the only receptors for
the phorbol ester tumor promoters. Mol Carcinog, 28(1):5–11, 2000.
[158] Gongyi Zhang, Marcelo G. Kazanietz, Peter M. Blumberg, and James H. Hurley. Crystal
structure of the cys2 activator-binding domain of protein kinase cδ in complex with phorbol
ester. Cell, 81(6):917–924, 1995.
[159] Jun Chen, Fan Deng, Jun Li, and Q. Jane Wang. Selective binding of phorbol esters and
diacylglycerol by individual c1 domains of the pkd family. Biochemical Journal, 411(2):333–
342, 2008.
[160] Valentina Benfenati, Marco Caprini, Grazia Paola Nicchia, Andrea Rossi, Melania Dovizio,
Chiara Cervetto, Mario Nobile, and Stefano Ferroni. Carbenoxolone inhibits volume-
regulated anion conductance in cultured rat cortical astroglia. Channels, 3(5):323–336, 2009.
108
References
[161] Benjamin Ko¨nig and Tobias Stauber. Biophysics and structure-function relationships of
lrrc8-formed volume-regulated anion channels. Biophysical Journal, 116(7):1185–1193, 2019.
[162] Steven S. Vogel, B. Wieb van der Meer, and Paul S. Blank. Estimating the distance separating
fluorescent protein fret pairs. Methods (San Diego, Calif.), 66(2):131–138, 2014.
[163] A. Hoppe, K. Christensen, and J. A. Swanson. Fluorescence resonance energy transfer-based
stoichiometry in living cells. Biophys J, 83(6):3652–64, 2002.
[164] S. Muallem, B. X. Zhang, P. A. Loessberg, and R. A. Star. Simultaneous recording of
cell volume changes and intracellular ph or ca2+ concentration in single osteosarcoma cells
umr-106-01. J Biol Chem, 267(25):17658–64, 1992.
[165] Rebekka M. Wachter and S. James Remington. Sensitivity of the yellow variant of green
fluorescent protein to halides and nitrate. Current Biology, 9(17):R628–R629, 1999.
[166] G. J. Kremers, J. Goedhart, E. B. van Munster, and Jr. Gadella, T. W. Cyan and yellow
super fluorescent proteins with improved brightness, protein folding, and fret forster radius.
Biochemistry, 45(21):6570–80, 2006.
[167] S. F. Pedersen, T. K. Klausen, and B. Nilius. The identification of a volume-regulated anion
channel: an amazing odyssey. Acta Physiologica, 213(4):868–881, 2015.
[168] Doralicia Casares, Pablo V. Escriba´, and Catalina Ana Rossello´. Membrane lipid composi-
tion: Effect on membrane and organelle structure, function and compartmentalization and
therapeutic avenues. International journal of molecular sciences, 20(9):2167, 2019.
[169] B. Nilius, J. Prenen, T. Voets, J. Eggermont, and G. Droogmans. Activation of volume-
regulated chloride currents by reduction of intracellular ionic strength in bovine endothelial
cells. J Physiol, 506 ( Pt 2):353–61, 1998.
[170] Paolo Arosio, Baptiste Jaquet, Hua Wu, and Massimo Morbidelli. On the role of salt type
and concentration on the stability behavior of a monoclonal antibody solution. Biophysical
Chemistry, 168-169:19–27, 2012.
[171] A. L. Moore, M. W. Roe, R. F. Melnick, and S. D. Lidofsky. Calcium mobilization evoked
by hepatocellular swelling is linked to activation of phospholipase cgamma. J Biol Chem,
277(37):34030–5, 2002.
[172] C. Ruwhof, J. T. van Wamel, L. A. Noordzij, S. Aydin, J. C. Harper, and A. van der Laarse.
Mechanical stress stimulates phospholipase c activity and intracellular calcium ion levels in
neonatal rat cardiomyocytes. Cell Calcium, 29(2):73–83, 2001.
[173] J. H. Nam, H. S. Lee, Y. H. Nguyen, T. M. Kang, S. W. Lee, H. Y. Kim, S. J. Kim,
Y. E. Earm, and S. J. Kim. Mechanosensitive activation of k+ channel via phospholipase
c-induced depletion of phosphatidylinositol 4,5-bisphosphate in b lymphocytes. J Physiol,
582(Pt 3):977–90, 2007.
[174] M. Fujii, M. Ohtsubo, T. Ogawa, H. Kamata, H. Hirata, and H. Yagisawa. Real-time visu-
alization of ph domain-dependent translocation of phospholipase c-delta1 in renal epithelial




[175] D. M. Browe and C. M. Baumgarten. Stretch of beta 1 integrin activates an outwardly
rectifying chloride current via fak and src in rabbit ventricular myocytes. J Gen Physiol,
122(6):689–702, 2003.
[176] J. A. Felix, M. L. Woodruff, and E. R. Dirksen. Stretch increases inositol 1,4,5-trisphosphate
concentration in airway epithelial cells. Am J Respir Cell Mol Biol, 14(3):296–301, 1996.
[177] W. Deng, L. Baki, and C. M. Baumgarten. Endothelin signalling regulates volume-sensitive
cl- current via nadph oxidase and mitochondrial reactive oxygen species. Cardiovasc Res,
88(1):93–100, 2010.
[178] D. M. Browe and C. M. Baumgarten. Angiotensin ii (at1) receptors and nadph oxidase
regulate cl- current elicited by beta1 integrin stretch in rabbit ventricular myocytes. J Gen
Physiol, 124(3):273–87, 2004.
[179] X. T. Wang, K. D. McCullough, X. J. Wang, G. Carpenter, and N. J. Holbrook. Oxidative
stress-induced phospholipase c-gamma 1 activation enhances cell survival. J Biol Chem,
276(30):28364–71, 2001.
[180] Xiao-Chun Bai, Fan Deng, An-Ling Liu, Zhi-Peng Zou, Yu Wang, Zhi-Yong Ke, Qun-Sheng
Ji, and Shen-Qiu Luo. Phospholipase c-gamma1 is required for cell survival in oxidative
stress by protein kinase c. The Biochemical journal, 363(Pt 2):395–401, 2002.
[181] A. M. Domijan, S. Kovac, and A. Y. Abramov. Lipid peroxidation is essential for phospho-
lipase c activity and the inositol-trisphosphate-related ca(2)(+) signal. J Cell Sci, 127(Pt
1):21–6, 2014.
[182] Joan-Marc Servitja, Roser Masgrau, Rau´l Pardo, Elisabet Sarri, and Fernando Picatoste.
Effects of oxidative stress on phospholipid signaling in rat cultured astrocytes and brain
slices. Journal of Neurochemistry, 75(2):788–794, 2000.
[183] I. H. Lambert. Reactive oxygen species regulate swelling-induced taurine efflux in nih3t3
mouse fibroblasts. J Membr Biol, 192(1):19–32, 2003.
[184] R. Crutzen, V. Shlyonsky, K. Louchami, M. Virreira, E. Hupkens, A. Boom, A. Sener, W. J.
Malaisse, and R. Beauwens. Does nad(p)h oxidase-derived h2o2 participate in hypotonicity-
induced insulin release by activating vrac in beta-cells? Pflugers Arch, 463(2):377–90, 2012.
[185] J. B. Holm, R. Grygorczyk, and I. H. Lambert. Volume-sensitive release of organic osmolytes
in the human lung epithelial cell line a549: role of the 5-lipoxygenase. Am J Physiol Cell
Physiol, 305(1):C48–60, 2013.
[186] P. Doroshenko and E. Neher. Volume-sensitive chloride conductance in bovine chromaffin
cell membrane. J Physiol, 449:197–218, 1992.
[187] A. Y. Estevez, T. Bond, and K. Strange. Regulation of i(cl,swell) in neuroblastoma cells by
g protein signaling pathways. Am J Physiol Cell Physiol, 281(1):C89–98, 2001.
[188] Bernd Nilius, Thomas Voets, Jean Prenen, Holger Barth, Klaus Aktories, Kozo Kaibuchi,
Guy Droogmans, and Jan Eggermont. Role of rho and rho kinase in the activation of volume-




[189] Viktoriya Syrovatkina, Kamela O. Alegre, Raja Dey, and Xin-Yun Huang. Regulation, sig-
naling, and physiological functions of g-proteins. Journal of molecular biology, 428(19):3850–
3868, 2016.
[190] M. Mederos y Schnitzler, U. Storch, S. Meibers, P. Nurwakagari, A. Breit, K. Essin, M. Gol-
lasch, and T. Gudermann. Gq-coupled receptors as mechanosensors mediating myogenic
vasoconstriction. Embo j, 27(23):3092–103, 2008.
[191] G. L. Waldo, T. K. Ricks, S. N. Hicks, M. L. Cheever, T. Kawano, K. Tsuboi, X. Wang,
C. Montell, T. Kozasa, J. Sondek, and T. K. Harden. Kinetic scaffolding mediated by a
phospholipase c-beta and gq signaling complex. Science, 330(6006):974–80, 2010.
[192] T. Kendall Harden, Gary L. Waldo, Stephanie N. Hicks, and John Sondek. Mechanism
of activation and inactivation of gq/phospholipase c-β signaling nodes. Chemical reviews,
111(10):6120–6129, 2011.
[193] B. Ruhfus, H. Tinel, and R. K. Kinne. Role of g-proteins in the regulation of organic
osmolyte efflux from isolated rat renal inner medullary collecting duct cells. Pflugers Arch,
433(1-2):35–41, 1996.
[194] P. Burow, M. Klapperstuck, and F. Markwardt. Activation of atp secretion via volume-
regulated anion channels by sphingosine-1-phosphate in raw macrophages. Pflugers Arch,
467(6):1215–26, 2015.
[195] G. J. Duan, J. Zhu, C. Y. Xu, J. Y. Wan, L. Zhang, X. D. Ge, L. M. Liu, and Y. S. Liu.
Protective effect of go6976, a pkd inhibitor, on lps/d: -galn-induced acute liver injury in
mice. Inflamm Res, 60(4):357–66, 2011.
[196] Nicholas C. Zachos, Luke J. Lee, Olga Kovbasnjuk, Xuhang Li, and Mark Donowitz. Plc-γ
directly binds activated c-src, which is necessary for carbachol-mediated inhibition of nhe3
activity in caco-2/bbe cells. American journal of physiology. Cell physiology, 305(3):C266–
C275, 2013.
[197] F. J. Johannes, J. Prestle, S. Eis, P. Oberhagemann, and K. Pfizenmaier. Pkcu is a novel,
atypical member of the protein kinase c family. J Biol Chem, 269(8):6140–8, 1994.
[198] A. M. Valverde, J. Sinnett-Smith, J. Van Lint, and E. Rozengurt. Molecular cloning and
characterization of protein kinase d: a target for diacylglycerol and phorbol esters with a
distinctive catalytic domain. Proc Natl Acad Sci U S A, 91(18):8572–6, 1994.
[199] E. Rozengurt, O. Rey, and R. T. Waldron. Protein kinase d signaling. J Biol Chem,
280(14):13205–8, 2005.
[200] M. Cobbaut and J. Van Lint. Function and regulation of protein kinase d in oxidative stress:
A tale of isoforms. Oxid Med Cell Longev, 2018:2138502, 2018.
[201] Daniel J Elsner, Katharina M Siess, Thomas Gossenreiter, Markus Hartl, and Thomas A
Leonard. A ubiquitin-like dimerization domain controls protein kinase d dimerization and
activation by trans-autophosphorylation. Journal of Biological Chemistry, 2019.
111
References
[202] L. Paolucci, J. Sinnett-Smith, and E. Rozengurt. Lysophosphatidic acid rapidly induces
protein kinase d activation through a pertussis toxin-sensitive pathway. Am J Physiol Cell
Physiol, 278(1):C33–9, 2000.
[203] R. T. Waldron, O. Rey, E. Zhukova, and E. Rozengurt. Oxidative stress induces protein ki-
nase c-mediated activation loop phosphorylation and nuclear redistribution of protein kinase
d. J Biol Chem, 279(26):27482–93, 2004.
[204] P. Storz and A. Toker. Protein kinase d mediates a stress-induced nf-kappab activation and
survival pathway. Embo j, 22(1):109–20, 2003.
[205] J. Igarashi, M. Miyoshi, T. Hashimoto, Y. Kubota, and H. Kosaka. Hydrogen peroxide
induces s1p1 receptors and sensitizes vascular endothelial cells to sphingosine 1-phosphate,
a platelet-derived lipid mediator. Am J Physiol Cell Physiol, 292(2):C740–8, 2007.
[206] Richard T. Waldron, Giulio Innamorati, M. Eugenia Torres-Marquez, James Sinnett-Smith,
and Enrique Rozengurt. Differential pkc-dependent and -independent pkd activation by g
protein α subunits of the gq family: selective stimulation of pkd ser autophosphorylation by
gαq. Cellular signalling, 24(4):914–921, 2012.
[207] Lingye Chen, Thorsten M. Becker, Ursula Koch, and Tobias Stauber. The lrrc8/vrac anion
channel facilitates myogenic differentiation of murine myoblasts by promoting membrane
hyperpolarization. Journal of Biological Chemistry, 2019.
[208] Alexander Kleger, Christiane Loebnitz, Ganesh Pusapati, Milena Armacki, Martin Mu¨ller,
Stefan Tu¨mpel, Anett Illing, Daniel Hartmann, Cornelia Brunner, Stefan Liebau, Karl
L Rudolph, Guido Adler, and Thomas Seufferlein. Protein kinase d2 is an essential reg-
ulator of murine myoblast differentiation. PloS one, 6:e14599, 2011.
[209] Yulia V. Shulga, Matthew K. Topham, and Richard M. Epand. Regulation and functions of
diacylglycerol kinases. Chemical Reviews, 111(10):6186–6208, 2011.
[210] Aiko Kume, Koki Kawase, Suguru Komenoi, Takako Usuki, Ena Takeshita, Hiromichi Sakai,
and Fumio Sakane. The pleckstrin homology domain of diacylglycerol kinase η strongly
and selectively binds to phosphatidylinositol 4,5-bisphosphate. The Journal of biological
chemistry, 291(15):8150–8161, 2016.
[211] J. V. Olsen, B. Blagoev, F. Gnad, B. Macek, C. Kumar, P. Mortensen, and M. Mann. Global,
in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell, 127(3):635–
48, 2006.
[212] H. Zhou, S. Di Palma, C. Preisinger, M. Peng, A. N. Polat, A. J. Heck, and S. Mohammed.
Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Pro-
teome Res, 12(1):260–71, 2013.
[213] N. Dephoure, C. Zhou, J. Villen, S. A. Beausoleil, C. E. Bakalarski, S. J. Elledge, and
S. P. Gygi. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A,
105(31):10762–7, 2008.
[214] J. V. Olsen, M. Vermeulen, A. Santamaria, C. Kumar, M. L. Miller, L. J. Jensen, F. Gnad,
J. Cox, T. S. Jensen, E. A. Nigg, S. Brunak, and M. Mann. Quantitative phosphoproteomics
112
References
reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal, 3(104):ra3,
2010.
[215] K. T. Rigbolt, T. A. Prokhorova, V. Akimov, J. Henningsen, P. T. Johansen, I. Kratch-
marova, M. Kassem, M. Mann, J. V. Olsen, and B. Blagoev. System-wide temporal charac-
terization of the proteome and phosphoproteome of human embryonic stem cell differentia-
tion. Sci Signal, 4(164):rs3, 2011.
[216] Toshiki Yamada and Kevin Strange. Intracellular and extracellular loops of lrrc8 are es-
sential for volume-regulated anion channel function. The Journal of General Physiology,
150(7):1003–1015, 2018.
[217] Kiyotaka Nishikawa, Alex Toker, Franz-Josef Johannes, Zhou Songyang, and Lewis C. Cant-
ley. Determination of the specific substrate sequence motifs of protein kinase c isozymes.
Journal of Biological Chemistry, 272(2):952–960, 1997.
[218] Tim Eiseler, Angelika Hausser, Line De Kimpe, Johan Van Lint, and Klaus Pfizenmaier.
Protein kinase d controls actin polymerization and cell motility through phosphorylation of
cortactin. The Journal of biological chemistry, 285(24):18672–18683, 2010.
[219] E. de Castro, C. J. Sigrist, A. Gattiker, V. Bulliard, P. S. Langendijk-Genevaux, E. Gasteiger,
A. Bairoch, and N. Hulo. Scanprosite: detection of prosite signature matches and prorule-
associated functional and structural residues in proteins. Nucleic Acids Res, 34(Web Server
issue):W362–5, 2006.
[220] Mirita Franz-Wachtel, Stephan A. Eisler, Karsten Krug, Silke Wahl, Alejandro Carpy, Al-
fred Nordheim, Klaus Pfizenmaier, Angelika Hausser, and Boris Macek. Global detection
of protein kinase d-dependent phosphorylation events in nocodazole-treated human cells.
Molecular & Cellular Proteomics, 11(5):160–170, 2012.
[221] Todd Scheuer. Regulation of sodium channel activity by phosphorylation. Seminars in cell
& developmental biology, 22(2):160–165, 2011.
[222] M. J. Davis, X. Wu, T. R. Nurkiewicz, J. Kawasaki, P. Gui, M. A. Hill, and E. Wilson.
Regulation of ion channels by protein tyrosine phosphorylation. Am J Physiol Heart Circ
Physiol, 281(5):H1835–62, 2001.
[223] II Ismailov and D. J. Benos. Effects of phosphorylation on ion channel function. Kidney Int,
48(4):1167–79, 1995.
[224] DAVID N. SHEPPARD and MICHAEL J. WELSH. Structure and function of the cftr
chloride channel. Physiological Reviews, 79(1):S23–S45, 1999.
[225] M. C. Winter and M. J. Welsh. Stimulation of cftr activity by its phosphorylated r domain.
Nature, 389(6648):294–6, 1997.
[226] M. M. Reddy and P. M. Quinton. camp-independent phosphorylation activation of cftr by
g proteins in native human sweat duct. Am J Physiol Cell Physiol, 280(3):C604–13, 2001.
[227] S. Inayat, L. H. Pinto, and J. B. Troy. Minimizing cytosol dilution in whole-cell patch-clamp
experiments. IEEE Transactions on Biomedical Engineering, 60(7):2042–2051, 2013.
113
References
[228] Michael Pusch and Erwin Neher. Rates of diffusional exchange between small cells and a
measuring patch pipette. Pflu¨gers Archiv, 411(2):204–211, 1988.
[229] Iraj Laffafian and M. B. Hallett. Lipid-assisted microinjection: Introducing material into the
cytosol and membranes of small cells. Biophysical Journal, 75(5):2558–2563, 1998.
[230] K. Irie, A. Nakahara, Y. Nakagawa, H. Ohigashi, M. Shindo, H. Fukuda, H. Konishi,
U. Kikkawa, K. Kashiwagi, and N. Saito. Establishment of a binding assay for protein
kinase c isozymes using synthetic c1 peptides and development of new medicinal leads with
protein kinase c isozyme and c1 domain selectivity. Pharmacol Ther, 93(2-3):271–81, 2002.
[231] Iskandar F. Abdullaev, Alena Rudkouskaya, Gary P. Schools, Harold K. Kimelberg, and
Alexander A. Mongin. Pharmacological comparison of swelling-activated excitatory amino
acid release and cl- currents in cultured rat astrocytes. The Journal of physiology, 572(Pt
3):677–689, 2006.
[232] T. Okada, M. R. Islam, N. A. Tsiferova, Y. Okada, and R. Z. Sabirov. Specific and essential
but not sufficient roles of lrrc8a in the activity of volume-sensitive outwardly rectifying anion
channel (vsor). Channels (Austin), pages 1–12, 2016.
[233] Adrian R. Black and Jennifer D. Black. Protein kinase c signaling and cell cycle regulation.
Frontiers in immunology, 3:423–423, 2013.
[234] E. Galperin, V. V. Verkhusha, and A. Sorkin. Three-chromophore fret microscopy to analyze
multiprotein interactions in living cells. Nat Methods, 1(3):209–17, 2004.
[235] A. D. Hoppe, B. L. Scott, T. P. Welliver, S. W. Straight, and J. A. Swanson. N-way fret
microscopy of multiple protein-protein interactions in live cells. PLoS One, 8(6):e64760,
2013.
[236] Brandon L. Scott and Adam D. Hoppe. Optimizing fluorescent protein trios for 3-way fret
imaging of protein interactions in living cells. Scientific Reports, 5:10270, 2015.
[237] L. J. Fulcher, T. Macartney, P. Bozatzi, A. Hornberger, A. Rojas-Fernandez, and G. P.
Sapkota. An affinity-directed protein missile system for targeted proteolysis. Open Biol,
6(10), 2016.
[238] Luke J. Fulcher, Luke D. Hutchinson, Thomas J. Macartney, Craig Turnbull, and Gopal P.
Sapkota. Targeting endogenous proteins for degradation through the affinity-directed protein
missile system. Open biology, 7(5):170066, 2017.
[239] Derek W. Bartlett and Mark E. Davis. Insights into the kinetics of sirna-mediated gene silenc-
ing from live-cell and live-animal bioluminescent imaging. Nucleic acids research, 34(1):322–
333, 2006.
[240] L. Leisle, C. F. Ludwig, F. A. Wagner, T. J. Jentsch, and T. Stauber. Clc-7 is a slowly
voltage-gated 2cl(-)/1h(+)-exchanger and requires ostm1 for transport activity. Embo j,
30(11):2140–52, 2011.
[241] N. Le Bot, C. Antony, J. White, E. Karsenti, and I. Vernos. Role of xklp3, a subunit of the
xenopus kinesin ii heterotrimeric complex, in membrane transport between the endoplasmic
reticulum and the golgi apparatus. J Cell Biol, 143(6):1559–73, 1998.
114
References
[242] M. L. Markwardt, G. J. Kremers, C. A. Kraft, K. Ray, P. J. Cranfill, K. A. Wilson, R. N. Day,
R. M. Wachter, M. W. Davidson, and M. A. Rizzo. An improved cerulean fluorescent protein
with enhanced brightness and reduced reversible photoswitching. PLoS One, 6(3):e17896,
2011.
[243] T. Nagai, K. Ibata, E. S. Park, M. Kubota, K. Mikoshiba, and A. Miyawaki. A variant of
yellow fluorescent protein with fast and efficient maturation for cell-biological applications.
Nat Biotechnol, 20(1):87–90, 2002.
[244] J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch,
C. Rueden, S. Saalfeld, B. Schmid, J. Y. Tinevez, D. J. White, V. Hartenstein, K. Eliceiri,
P. Tomancak, and A. Cardona. Fiji: an open-source platform for biological-image analysis.
Nat Methods, 9(7):676–82, 2012.
[245] J. N. Feige, D. Sage, W. Wahli, B. Desvergne, and L. Gelman. Pixfret, an imagej plug-in for
fret calculation that can accommodate variations in spectral bleed-throughs. Microsc Res
Tech, 68(1):51–8, 2005.
[246] X. Jiang and A. Sorkin. Coordinated traffic of grb2 and ras during epidermal growth factor
receptor endocytosis visualized in living cells. Mol Biol Cell, 13(5):1522–35, 2002.
[247] Fabian Sievers, Andreas Wilm, David Dineen, Toby J. Gibson, Kevin Karplus, Weizhong Li,
Rodrigo Lopez, Hamish McWilliam, Michael Remmert, Johannes So¨ding, Julie D. Thomp-
son, and Desmond G. Higgins. Fast, scalable generation of high-quality protein multiple
sequence alignments using clustal omega. Molecular systems biology, 7:539–539, 2011.
[248] Andrew M. Waterhouse, James B. Procter, David M. A. Martin, Miche`le Clamp, and Ge-
offrey J. Barton. Jalview version 2—a multiple sequence alignment editor and analysis
workbench. Bioinformatics, 25(9):1189–1191, 2009.
115
